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 “Your self identity is 
something that you 
cannot rid yourselves 
of, no matter how old 
you are or what you 
do. Be it a retired 
person or a home-
maker; we all want to 
get to those days 
when we would 
introduce ourselves 
to the world with an 
identity that can be 
called as our own” 
                                                                                                        
 
 
 
 
 
 
 
 
Dedicated to my 
beloved father, who 
instilled in me this 
need to have self 
identity; you will 
always remain in my 
heart supporting and 
encouraging me 
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ABSTRACT 
Background: Iodine is a key nutrient in neurodevelopment, and the 
fetus is entirely dependent on the iodine intake of the mother to 
fulfill this important requirement for proper brain function. While 
this is clearly known, it is uncertain if maternal iodine nutrition 
should be monitored separately against what is in current practice in 
public health programs to control iodine deficiency. Also, it is 
unclear whether it is beneficial to supplement pregnant women with 
iodine in mild-to-moderately iodine deficient and also iodine 
sufficient areas. Finally, the role of thyroid dysfunction in depression 
during pregnancy is uncertain. 
Objectives: 1) to determine whether iodine supplementation to 
pregnant women improves maternal and newborn thyroid function, 
pregnancy outcome, birth weight, infant growth and cognitive 
performance; 2) to assess iodine intake and potential determinants of 
intake, in pregnant women and their children who were sharing all 
meals; 3) to measure thyroid status during pregnancy and assess 
potential determinants of maternal thyroid function including iodine 
status, thyroid autoimmunity, body weight and anemia; 4) to assess 
the association of maternal depression, and thyroid function during 
pregnancy. 
 
Methods: 1) In a randomized placebo controlled trial (RCT), the 
MITCH (Maternal Iodine Supplementation and its Effects on Thyroid 
function and CHild Development) study, pregnant women, 
gestational age ≤14 weeks, in Bangalore, India, were randomized to 
receive either a daily supplement of 200 µg oral iodine or placebo 
from enrolment until delivery. Women were followed through delivery, 
and then with postnatal follow-up of their infants at 6 weeks, 1 and 2 
year. Early neonatal development was assessed using the Neonatal 
Behavioral Assessment Scale (NBAS) at 6 weeks of age; 
neurocognitive assessment was done using the Bayley Scales of 
Infant Development (BSID III) at 1 and 2 years, and BRIEF-P 
(Behavior Rating Inventory of Executive Function) at 2 years; 2) A 
cross-sectional study comparing iodine status of pregnant women 
and their children, who were sharing all meals in Bangalore, India; 3) 
A cross-sectional study among 334 pregnant women ≤14 weeks of 
gestation, in Bangalore, India, who were screened for the RCT; 4) 
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Secondary analysis of the longitudinal data on 318 pregnant women 
in the RCT. 
 
Results: 1) In the RCT, there were no significant differences between 
groups in maternal thyroid function tests or thyroid volume during 
gestation. The prevalence of thyroid dysfunction or anti-TPO 
antibodies did not differ significantly during gestation and 
postpartum. Postpartum, there were no significant differences 
between the maternal and infant groups in thyroid function, birth 
outcomes or UIC. Neonates whose mothers received iodine 
supplementation during pregnancy had better orientation scores at 6 
weeks of age and lower scores of inhibition suggesting better 
executive function at 2 years of age although neurocognitive 
development on the BSID III were not significantly different between 
groups; 2) In the pilot study, a) median UIC in pregnant women was 
172 µg/L, b) the median UIC was >150 µg/L in all trimesters and c) 
thyroid size was not significantly different across trimesters;  the 
median UIC in children was 220µg/L, indicating ‘more than 
adequate’ iodine intake at this age. Median UIC was significantly 
higher in children than in their mothers (p=0.008). 3) In the cross-
sectional study, 21% women were vegetarian, 19% were anemic and 
23% were overweight or obese. Iodized salt was used by 98% of 
women and they were iodine sufficient, median UIC was 184.2 µg/L 
and all had normal thyroid volume. However, 18% of women had 
thyroid insufficiency: 3.7% had overt hypothyroidism (83% with 
positive TPO-Ab), 9.2% had subclinical hypothyroidism and 5.2% had 
hypothyroxinemia. Women consuming vegetarian diets did not have 
significantly lower iodine intakes or higher risk of hypothyroidism 
than those consuming mixed diets, but overweight/obesity and 
anemia predicted thyroid insufficiency; 4) In the longitudinal study, 
there was no significant difference in depressive symptoms between 
the iodine intervention and placebo groups. Women with depressive 
symptoms had significantly lower serum TSH compared to women 
without depressive symptoms in the first trimester. Pregnant women 
with prenatal depressive symptoms had a significantly higher 
number of medical symptoms.  
 
Conclusion: 1) Iodine supplementation in mildly iodine deficient and 
in iodine sufficient pregnant women was well-accepted and safe and 
did not increase the risk of excess iodine intake, hyper- or 
hypothyroidism, or thyroid autoimmunity. Though there were no 
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significant effects of iodine supplementation on neonatal and 
maternal thyroid function and birth outcomes, there were modest 
effects on neurocognitive development of children as assessed by 
executive function of children at 2 years. Thus, additional follow-up 
of these children for neurocognitive testing at a later age when 
development and cognitive testing is more reliable would provide 
valuable add on information; 2) The iodized salt program in 
Bangalore, India was providing adequate iodine to women 
throughout pregnancy, at the expense of higher iodine intake in their 
children, suggesting that the current WHO/UNICEF/ICCIDD cut-off 
for median UIC in children indicating more-than-adequate intake 
may need to be reconsidered; 3) Despite iodine sufficiency, many 
pregnant women had thyroid insufficiency predicted by low 
hemoglobin and higher BMI. The prevalence of overt hypothyroidism 
was >5-fold higher than reported in other iodine-sufficient 
populations of pregnant women, thus, screening of maternal thyroid 
function should be considered in antenatal care at hospitals in 
Bangalore, India; 4) Although iodine supplementation did not affect 
maternal depression, we highlighted the need for systemic screening 
for prenatal depression during antenatal visits as it is an 
independent risk factor for later development of clinical depression. 
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   INTRODUCTION 
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Background 
 
In 2007, WHO recommended that pregnant women should consume 
250 µg iodine daily and in 2011, the American Thyroid Association 
(ATA) suggested that the strategies to implement this 
recommendation might differ between countries. While iodine 
supplementation during pregnancy is clearly beneficial in severely 
iodine deficient areas, it was unclear whether pregnant women in 
mild-to-moderately iodine deficient and also iodine sufficient areas 
should receive supplementation. Countries with successful USI 
programmes tend not to depend so much on extra iodine 
supplementation to their pregnant population, while most of the 
other countries work with the advice of professional societies like the 
American and European thyroid association and endocrine societies 
where the onus of such advice rests on the clinical wisdom of the 
consulting gynecologists. Recently, Thailand became the first country 
in the world to have introduced maternal iodine supplementation as 
policy in their national program. However, there is no consensus on 
what aspects of safety should be evaluated during the course of such 
supplementation.  
 
Among all the other effects that iodine nutrition incurs on the general 
metabolism and homeostasis, its effect on brain development is the 
most pertinent and widely studied. However a recent systematic 
review of randomized controlled trials of iodine highlighted a lack of 
quality evidence of the effect of prenatal or periconceptional iodine 
supplementation on growth and cognitive function of children (1). We 
therefore set up a multicentre randomized controlled trial of iodine 
supplementation in pregnant women to determine whether the daily 
oral administration of iodine (200 µg) to pregnant women in areas of 
mild-to-moderate iodine deficiency improves maternal and newborn 
thyroid function, pregnancy outcome, birth weight, infant growth and 
cognitive performance. The studies belonging to this thesis were 
conducted at the Indian arm of the trial in Bangalore, one of the 
districts in the Indian state of Karnataka. The other arm of the trial 
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was conducted at Thailand, in a region with mild to moderate iodine 
deficiency. 
 
Pregnancy, nutrition, and brain development 
 
Pregnancy is a pivotal life event which marks the beginning of a life 
deeply ingrained to the maternal environment. The formation of the 
most complex organ of the highly organized human system, the 
brain, starts very early in pregnancy. Approximately 22 days after 
conception, the neural plate begins to fold inward, forming the neural 
tube, which eventually becomes the brain and the spinal cord (2). 
Seven weeks after conception, cell division begins within the neural 
tube, creating nerve cells (neurons) and glial cells (cells that support 
neurons). After a neuron is created, it migrates to its place in the 
brain, where it then grows axons and dendrites projecting out from 
its cell body. These branching projections make connections with 
other cells, called synapses, through which nerve signals travel from 
one cell to another. These neurodevelopmental processes begin 
during gestation and continue throughout infancy (3). Nutrition is 
especially important during pregnancy and infancy, which are crucial 
periods in brain development, laying the foundation for the 
development of cognitive, motor, and socio-emotional skills 
throughout childhood and adulthood (3). There is evidence for the 
effect of specific nutrient deficiencies during early development on 
five key neuronal processes viz neuron proliferation; axon and 
dendrite growth; synapse formation, pruning, and function; 
myelination, and neuron apoptosis (programmed cell death). Most of 
the neural  processes linked to these nutrients (protein-energy 
malnutrition, fatty acids, iron, iodine and thyroid hormones, zinc, 
choline, B-vitamins) have been studied in human as well as animal 
studies while other nutrients, such as copper, which is also 
important for some of these neurodevelopmental processes, have not 
been rigorously studied in human populations (3). Severe iodine 
deficiency, which causes both maternal and fetal hypothyroidism, is, 
worldwide, the most common cause of mental retardation (4-6). More 
recent evidence suggests that even mild reductions in maternal 
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thyroid hormone levels in early pregnancy are associated with 
reduced IQ in offspring (7, 8). Iodine, being an essential component 
of the thyroid hormones, is undisputedly the most important 
nutrient studied for its role in proper brain function. 
 
Brain development and thyroid hormones 
 
Iodine plays a central role in thyroid physiology, being both a major 
constituent of thyroid hormones and a regulator of thyroid gland 
function (14). The biologically active hormone interacting with 
nuclear thyroid receptors (3,5,3'-triiodo-L-thyronine or T3), is 
synthesized by the deiodination of its precursor thyroxine (T4). It also 
regulates its own steady-state level by exerting negative feedback 
regulation on thyrotropin-releasing hormone (TRH) and thyroid-
stimulating hormone secretion, and by regulating deiodinases in liver 
and brain (9). The brain is an important target of thyroid hormone 
not only during development but also in adult animals. Brain growth 
is characterized by two periods of maximal growth velocity (10). In 
the first phase (between the third and fifth months of gestation), the 
supply of thyroid hormones to the growing foetus is almost 
exclusively of maternal origin while during the second phase (from 
the third trimester onwards up to the second and third years 
postnatally), the supply of thyroid hormones to the foetus is 
essentially of foetal origin (11, 12). Thyroid hormone deficiency 
during the fetal and postnatal periods in humans may cause 
irreversible mental retardation and neurological deficits (13). Thyroid 
hormone deficiency occurring early in pregnancy shows problems in 
visual attention, visual processing and gross motor skills in the 
offspring. If it occurs later in pregnancy children are at additional 
risk of subnormal visual and visuospatial skills as well as slower 
response speeds and fine motor deficits (14). Fig 1 shows the 
timeline of human thyroid system and brain development from 
conception to birth (15). 
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Superimposing the development of the thyroid system onto the 
chronology of brain development, it is evident that thyroid hormone 
may influence brain structure and function during the earliest stages 
of development in humans and rodents (15). Most critical for brain 
development is the fact that T3 is produced by the fetus from 
maternal T4 and this is the only source of T4 for the fetus during the 
first trimester of pregnancy (5, 12, 14, 16, 17). During this critical 
period, fundamental processes occur in the development of the fetal 
central nervous system. In particular, the cerebral vesicles, from 
which the cerebral cortex develops, become recognizable in the 
developing central nervous system by embryonic day 35 and the 
neocortical development begins by embryonic day 46 (18). The 
concentration of T3 nuclear receptors is low at the beginning of 
neocortical development but it progressively increases 10-fold by the 
16th week of gestation (19), in parallel to neuroblast proliferation and 
neuronal migration (18). This makes the human brain especially 
vulnerable during development to deficiencies of iodine and thyroid 
hormones, not only because of their action through nuclear receptors 
(19, 20), but also for their possible non-genomic effects that might 
take place even earlier.  
 
Maternal depression and thyroid function during 
pregnancy 
 
Maternal depression is considered a risk factor for the socio-
emotional and cognitive development of children and stress factors 
such as negative life events, poor marital relationship, lack of social 
support, and personal and family psychopathology have been 
associated with depression. Stress or anxiety during pregnancy, are 
risk factors for premature birth and growth restrictions within the 
womb, both of which are risk factors for behavioural problems in the 
child. Stress/anxiety during pregnancy doubles the risk of a range of 
emotional, behavioural and cognitive problems (21). Several recent 
reviews suggest a higher prevalence of depression during pregnancy 
in women from developing countries compared to pregnant women 
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from the West (22, 23).  While in the past the focus has been on post 
partum depression (24), more recently there have been a 
considerable research interest in antenatal depression and its causal 
factors and outcomes (25).  Subjects with thyroid insufficiency seem 
especially susceptible to the development of depression (26). Some 
studies have found that antenatal thyroid dysfunction is associated 
with postnatal depression and that presence of thyroid antibodies 
are related to depressive mood (27, 28) both during pregnancy and 
the postnatal period. A recent review found that the evidence base of 
associations of TSH and thyroid hormone levels was good for 
cardiovascular, metabolic, bone, and pregnancy outcomes; however, 
there is paucity of high-quality data for neurological and 
psychological outcomes (29). In addition, findings from few studies 
that have looked at the association between thyroid function during 
pregnancy and pre natal depression are largely inconsistent. 
 
Iodine, thyroid and pregnancy 
  
Maintaining a pregnant woman in a euthyroid state is a challenge for 
the thyroid gland during gestation. During pregnancy, there is an 
increased demand for thyroid hormone and decreased iodine 
availability due to iodine transfer to the fetus and intensified iodine 
urinary losses induced by the increased renal glomerular filtration 
(30, 31). Physiological adaptations take place when iodine intake is 
sufficient and when there is no underlying thyroid pathology: the 
increase in estrogens induces an increase in thyroxine (T4)-binding 
globulin, which alters the ratio between free and bound thyroid 
hormones; the increase in human chorionic gonadotropin hormone, 
which has thyrotrophic activity, induces a slight increase in free 
thyroxine (FT4) with a peak at the end of the first trimester, and this 
causes a transient decrease in thyrotropin (TSH) through negative 
feedback on pituitary thyrotrophs (30, 32-34); the placental 
deiodinase III alters metabolism, distribution, and availability of T4 
for the mother and for the fetus in the second half of gestation (34, 
35). TSH rises over the second and third trimesters, moderately in 
areas where iodine is sufficient and more markedly in iodine deficient 
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areas (36, 37). Where iodine intake is adequate, the TSH levels are 
only slightly higher in the second and third trimesters than 1 year 
after delivery (38). However, it has been variously reported that the 
highest TSH level was in the second trimester (39), that the TSH level 
was similar during pregnancy and after delivery (40), and that the 
TSH level remained the same throughout pregnancy (41). As for 
levels of fT4 and fT3, the free thyroid hormones, the highest levels 
occur in the first trimester, and gradually decrease over the 
remainder of the pregnancy (36, 38, 41,42). In iodine-deficient areas 
the decrease is sharper (37). In a study performed in borderline 
iodine deficiency, fT4 and fT3 levels were significantly lower during 
pregnancy than 12 months after delivery (43). However, except TSH 
for which trimester specific cut-offs are available for pregnancy, other 
thyroid parameters have to fall back on the manufacturer’s 
recommended non-pregnant range for defining cut-offs which are 
method specific and creates additional difficulties for comparison of 
studies.  
 
Thyroid dysfunction in pregnancy 
 
Thyroid dysfunction is the most frequent endocrine disorder in 
pregnant women. Overt hypothyroidism and even subclinical 
hypothyroidism increases the risk of obstetric complications: 
miscarriage, fetal death, gestational hypertension, preterm birth, and 
low birth weight (44-48). Thyroid autoantibodies in pregnancy are 
associated with recurrent miscarriage (49) and with maternal 
morbidity later in life (50). When iodine intake is mildly to moderately 
deficient, there may not be enough T4 available to the fetus, and this 
may not be recognized because TSH does not necessarily increase 
because of stable or slightly increased triiodothyronine (T3) levels 
(34). Severe iodine deficiency can result in overt hypothyroxinemia, 
goiter, and the spectrum of iodine deficiency disorders (33). 
 
The prevalence of overt and subclinical hypothyroidism in pregnancy 
is estimated at 0.3-0.5% and 2-3% respectively (51). Endemic iodine 
deficiency is the most common cause of hypothyroidism seen in 
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pregnant women worldwide. In areas of iodine sufficiency, the 
prevalence of overt and subclinical hypothyroidism during pregnancy 
is 0.2-0.4% and 3-5%, respectively, but varies by trimester of 
pregnancy and the diagnostic criteria (particularly the TSH upper 
limit) used for classification (52). Over 90% of thyroid disorders in 
pregnancy are thought to be of autoimmune etiology (53) and chronic 
autoimmune thyroiditis is the main cause of hypothyroidism during 
pregnancy in iodine-sufficient regions (54). Other causes include 
post-surgical, post-radioiodine ablation and hypothyroidism 
secondary to pituitary disease which, although rare, can include 
lymphocytic hypophysitis occurring during pregnancy or postpartum 
(55). Thyroid dysfunction and antibodies during pregnancy seem to 
predict later thyroid disease warranting routine assay of thyroid 
hormones and especially antibodies during pregnancy (50). India, 
because of its large population, high birth rate and iodine deficient 
soils, has until recently had a large number of infants potentially 
exposed to in utero iodine deficiency (56) ; recent studies highlight 
the presence of iodine insufficiency among Indian women (57). Two 
additional variables that may affect the maternal thyroid axis and 
contribute to thyroid insufficiency during pregnancy are iron 
deficiency anemia (58) and overweight/obesity (59-63) and both are 
common among women in urban areas of India (64-66). Better 
understanding of the pattern and prevalence of maternal thyroid 
dysfunction and associated risk factors could improve screening and 
treatment in the Indian population. Improved detection of maternal 
hypothyroidism may be particularly valuable in the first trimester, 
because thyroid function should be normalized as quickly as 
possible, early in gestation (67). 
 
Iodine metabolism  
 
Dietary iodine is absorbed efficiently in the gastrointestinal tract. 
Iodine in organic form is converted mostly to iodide before 
absorption. Plasma iodide exchanges rapidly with iodide in red blood 
cells and with both rapid and slow extracellular compartments. The 
thyroid gland concentrates iodide (I-) against an electrochemical 
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gradient by a carrier-mediated mechanism driven by ATP. Besides 
the thyroid, other organs that concentrate iodide include the salivary 
glands, gastric mucosa, choroid plexus, mammary glands, and the 
placenta, but only in the thyroid does TSH regulate the process. The 
enteric phase consists of iodide secreted into saliva and gastric juice, 
which moves into the small intestine for reabsorption. The kidneys 
account for about two thirds of the iodide cleared from the plasma 
and more than 90% of iodide excreted from the body. Sweat and 
breast milk account for variable fractions of iodide loss. However, the 
fecal route contributes only about 1 % of total body iodide clearance 
(68). Fig.2 shows iodine pathway in the thyroid cell (69). The 
follicular cell in situ displays functional and structural polarity; the 
iodide transporter resides in the basolateral plasma membrane, 
which also contains ATPases and various channels and receptors, 
including the TSH receptor. At the apical surface, thyroglobulin, 
thyroid peroxidase, hydrogen peroxide, and iodide all come together. 
Oxidation and organification occur at or near this cell-colloid 
interface.  
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Figure 2: Iodine pathway in the thyroid cell. Iodine (I-) is transported into the thyrocyte by 
the sodium/iodide symporter (NIS) at the basal membrane and migrates to the apical 
membrane. I- is oxidized by the enzymes thyroperoxidase (TPO) and hydrogen peroxidase 
(H2O2) and attached to tyrosyl residues in thyroglobulin (Tg) to produce the hormone 
precursors iodotyrosine (MIT) and di-idotyrosine (DIT). Residues then couple to from 
thyroxine (T4) and tri-iodothyronine (T3) within the Tg molecule in the follicular lumen. Tg 
enters the cell by endocytosis and is digested. T4 and T3 are released into the circulation, 
and iodine on MIT and DIT is recycled with the throcyte. Reproduced with permission from 
Zimmermann et al. (69). 
 
Hormone secretion involves, first, pinocytosis of colloid-containing 
iodinated thyroglobulin, then fusion of colloid droplets with 
lysosomes, followed by proteolysis, which liberates free 
monoiodotyrosine (MIT), diiodotyrosine (DIT), T4, and T3. 
Iodotyrosine dehalogenase regenerates iodide from MIT and DIT for 
reuse within the thyroid or release into the blood, accounting for the 
iodide leak in the chronic state of iodine excess and in certain 
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thyroid disorders. Type I iodothyronine deiodinase converts some of 
the free T4 into T3. Both hormones are released into the circulation 
by a process that is not well understood. The thyroid also releases 
thyroglobulin, of which some is iodinated and some uniodinated 
newly synthesized protein. All of the steps in TH biosynthesis, from 
oxidation and organification of iodide to the secretion of T4 and T3 
into the circulation, are stimulated by TSH and inhibited by excess 
iodine (68). Iodine comprises 65 and 59% of the weights of T4 and 
T3, respectively. In the thyroid, mature thyroglobulin (Tg), containing 
0.1 to 1.0% of its weight as iodine, is stored extracellularly in the 
luminal colloid of the thyroid follicle (70, 71). 
 
Assessment of iodine status 
 
Iodine intake is a key determinant of iodine status but is difficult to 
assess. FFQs (used to assess the type, quantity, and frequency of 
foods and supplements consumed) exist, but food composition tables 
for iodine are not readily available (72). UI excretion is an accurate 
indicator of dietary iodine intake as >90% of ingested iodine is 
excreted in the urine and UI is highly sensitive to recent changes in 
iodine intake. For population estimates, daily iodine intake can be 
extrapolated from UI by assuming 90% of ingested iodine is found in 
urine and a 24-h urine volume of 1.5 L (73). Using this estimation, a 
UI of approx 140 µg/L would correspond to a daily intake of 200 µg 
iodine (74). During pregnancy this extrapolation may be less valid 
due to an increase in renal iodine clearance (75). 
WHO/UNICEF/ICCIDD has set the criteria of UIC assessment in 
school age children to be used to define the prevalence of iodine 
deficiency in populations. The population UIC cutoff values 
expressed as µg/L for school-age children are: <20 (severe 
deficiency), 20–49 (moderate deficiency), 50–99 (mild deficiency), 
100–199 (optimum), 200–299 (risk of iodine-induced 
hypothyroidism), and ≥300 (risk of adverse health). The 
corresponding values for pregnancy are: <150 (insufficient), 150–249 
(adequate), 250–499 (more than adequate), and ≥ 500 (in excess of 
amount to control deficiency) (72). Adequate iodine intake in school 
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children does not necessarily indicate iodine adequacy in pregnant 
women, and pregnant women should be directly monitored in 
countries with iodized salt programs. Recent evidence suggests that 
using the median UIC value from a population of school-age children 
as surrogate for other population groups might put pregnant women 
at risk of iodine deficiency.  
 
What are the consequences of not getting enough 
iodine during pregnancy? 
 
Delay in restoring euthyroid status in the developing neonate can 
lead to irreversible neurodevelopmental morbidity, which may be 
prevented by prompt thyroid hormone supplementation (76). Even 
with optimal replacement therapy, however, there are often residual 
and subtle neurodevelopmental sequelae persisting into childhood 
(77). At least 200 million children aged under 5 years fail to reach 
their potential in cognitive and socio-emotional development because 
of several causes, iodine deficiency being one of the most important 
factors (78). Maternal malnutrition during gestation impairs 
embryonic and fetal growth and development, resulting in deleterious 
outcomes, including iodine deficiency disorders (IDD) (79); the 
severity of IDD depending on the intakes. Cretinism, dwarfism, 
abortions, stillbirths, deaf mutism, spastic diplegia, squint are some 
of the common manifestations. In children, severe iodine deficiency 
may lead to mental retardation however mild-to-moderate iodine 
deficiency may also affect the language and hearing development. 
Children born in iodine deficient areas are at risk of neurological 
disorders and mental retardation because of the combined effects of 
maternal, fetal, and neonatal hypothyroxinaemia (80). The 
Copenhagen Consensus Conference 2008 ranked elimination of IDD 
as no. 3 in the 10 most cost effective development challenges in our 
world. 
 
In 1994, a meta-analysis of 18 studies of children and adolescents 
concluded that IQ scores averaged 13.5 points lower with iodine 
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deficiency (81). In severely iodine deficient rural areas of Bangladesh, 
children with low T4 levels performed less well than those with 
normal levels, in tests of reading, spelling and general cognitive 
ability, after controlling for a number of other factors that affected 
performance (82). A comparison of learning ability and motivation 
was carried out among 100 children, aged 9 to 15 years, in severely 
and mildly iodine deficient communities in Uttar Pradesh, India (83). 
It was found that the children from the severely iodine deficient 
villages were slow learners and also scored significantly lower on the 
achievement motivation scale as compared with children from mildly 
iodine deficient villages. Even lesser degrees of iodine deficiency, 
which affect many more individuals, can impair mental and motor 
function. In Papua New Guinea in 1976, the rate of fetal loss in late 
pregnancy or postnatal death in pregnant women with very low 
serum T4 concentrations was twice that of those with higher 
concentrations (84), perhaps because thyroid hormones have a 
strong modulating effect on the immune system. However there is no 
data on mortality or cognition from the mild to moderate iodine 
deficient and iodine sufficient regions. Longitudinal studies 
measuring TSH levels and levels of both free thyroid hormones in 
pregnant and non-pregnant women from areas where iodine intake is 
adequate are scarce, usually include a small number of participants, 
and they seldom include data on UIC (85). 
 
What are the consequences of getting too much 
iodine during pregnancy? 
 
Most people who are iodine sufficient are remarkably tolerant to high 
dietary intakes of iodine, and intakes up to 1000 µg/d are well 
tolerated by healthy adults (73). There are concerns that more than 
adequate iodine intake could increase thyroid autoimmunity in 
adults (86) but findings are equivocal. There is no clear evidence to 
define “how much more iodine may become too much iodine” during 
pregnancy. A recommendation was adopted to indicate that there is 
no proven further benefit in providing pregnant women with more 
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than twice the daily RNI (recommended nutritional intake) (87). The 
safe upper limit in pregnancy is uncertain because the fetal thyroid 
is vulnerable to iodine excess (88). The fetal thyroid gland is 
exquisitely sensitive to the inhibitory effects of high iodine 
concentrations, and a recent study showed that inhibitory effects of 
high iodine loads could lead to opposite variations in maternal and 
neonatal thyroid function, i.e. with facilitation of thyroid function in 
the mother but aggravation in the neonate (89). Congenital 
hypothyroidism in newborns has been reported in mothers who had 
an excessive dietary intake of iodine during pregnancy (90, 91). 
Routine iodine supplementation in pregnancy may not be without 
risk (1). A recent study reported that iodine supplementation ≥150 
µg/d in pregnancy was associated with poorer mental and 
psychomotor achievements of infants (92).  However, the view that 
iodine supplements at the dose recommended for pregnancy (150–
200 µg/d) are safe stems from the fact that these doses are well 
below the recommended upper intake limit of 600–1100 µg/d (73, 
93). 
 
What are the results from iodine supplementation 
during pregnancy? 
 
It has been shown that iodine supplementation during pregnancy 
may result in a substantial reduction in foetal and neonatal deaths. 
In the Democratic Republic of Congo, injection of iodized oil in the 
second half of pregnancy reduced perinatal and infant mortality and 
improved birth weight (94). A randomized, placebo-controlled trial of 
oral iodized oil (100 mg iodine) in West Java, Indonesia, at about 6 
weeks of age, on infant mortality up to 6 months of age showed a 
72% reduction in risk of mortality in the iodized oil group during the 
first 2 months, and a delay in the mean time to death: 48 days 
compared to 17 days (95). A meta-analysis of studies conducted in 
China in 2005 showed that the average IQ loss from severe iodine 
deficiency was 12.5 IQ points in children and they recovered 8.7 IQ 
points with iodine supplementation or IS  before and during 
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pregnancy (96). Controlled trials in which mothers were injected with 
iodine or placebo before or during pregnancy in areas where iodine 
deficiency was prevalent showed benefits on infant cognitive 
development in the Democratic Republic of Congo (97) and motor 
ability at age 10-11 years in Papua New Guinea (98). In an iodine 
deficient region in China, 4-7 year old children whose mothers were 
given iodine during pregnancy performed better on a psychomotor 
test than those who were supplemented beginning at 2 years of age 
(99). A Spanish trial found improved scores on both gross and fine 
motor coordination at 18 months if the supplements were given in 
early compared to late pregnancy (100). A recent review evaluated 
the efficacy and safety of iodine supplementation during pregnancy 
or the periconceptional period on the development and growth of 
children. Secondary outcomes included pregnancy outcome and 
thyroid function (1). The review highlighted that iodine 
supplementation during pregnancy or the periconceptional period in 
regions of severe iodine deficiency reduced risk of cretinism, but 
there were no improvements in childhood intelligence, development, 
growth, or pregnancy outcomes, although there was an improvement 
in some motor functions. None of the RCTs conducted in regions of 
mild to moderate iodine deficiency reported childhood development 
or growth or pregnancy outcomes. Effects of iodine supplementation 
on the thyroid function of mothers and their children were 
inconsistent (1). To date, there are no data from randomized 
controlled trials on the effect of maternal iodine supplementation on 
birth outcomes, and no data on long-term outcomes, such as maternal 
goiter, thyroid autoimmunity, or child development.  
 
What measures can be taken to guarantee 
sufficient iodine intake during pregnancy? 
 
Universal salt iodization (USI) is a mass fortification approach that is 
intended to cover the iodine requirements of all individuals in the 
population, placing greater emphasis on ensuring the increased 
needs of pregnant women. WHO/UNICEF/ICCIDD have estimated 
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that the iodine requirement during pregnancy is increased >50% 
compared to non-pregnancy in order to compensate for the increased 
need for thyroid hormones in the mother and fetus (101) and that an 
established USI program with adequate salt iodine levels and good 
population coverage can meet the high iodine requirement of 
pregnant women. In some countries, both dietary intakes of foods 
with high native iodine content and iodine supplements contribute to 
iodine intakes during pregnancy. For example, many Japanese eat 
seaweed and make soup stock from kelp on a daily basis, and in fact 
it is widely believed in the Japanese society that seaweed intake is 
good for pregnancy (102). In the U.S. diet, the common sources of 
iodine are iodized salt, dairy products, breads and seafood (103). 
American Thyroid Association (ATA) recommends that pregnant 
women in North America should supplement their diet with a daily 
oral supplement that contains 150 μg of iodine and also recommends 
that in areas of the world outside of North America, strategies for 
ensuring adequate iodine intake during pregnancy will vary 
according to regional dietary patterns and availability of iodized salt 
(104). In Australia, mandatory use of iodized salt (25-65 mg/kg) by 
bread manufacturers and a daily supplement intake of 150 μg of 
iodine by pregnant women are recommended by the National Health 
and Medical Research Council as the two strategies to achieve 
optimal iodine intakes in this group (105). Using predictive 
modelling, pregnant women in New Zealand were expected to achieve 
adequate iodine intakes when 150 μg of supplemental iodine was 
taken daily, taking into account the contribution of iodized salt in 
bread (106). Salt iodisation has been recognised as the most effective 
and cost-efficient strategy to prevent IDD in China and since 2012, 
China has adopted a new iodized salt standard of 25 or 30 mg/kg 
according to the actual situation of IDD in each province (107). Over 
50 countries on the African continent have salt iodization programs, 
and 70% of all Africans have regular access to iodized salt (108). 
Published data in Germany suggest that during pregnancy more 
than half of the women practice supplementation of iodine (109).  
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Iodine nutrition scenario in India Vis-a-vis global 
prevalence of IDD  
 
The global iodine status has improved markedly during the past 
decade (110, 111), but still 1.88 billion people of the global 
population are estimated to have insufficient iodine intake (110). 
About 41 million newborns a year remain unprotected from the 
enduring consequences of brain damage associated with iodine 
deficiency (112). Fig 3 shows the latest global data on the prevalence 
of iodine deficiency. However, only a limited number of countries 
have completed UIC surveys in pregnant women and women of 
reproductive age at the national or sub-national level and thus, there 
are insufficient data to directly estimate the regional or global 
prevalence of low iodine intake in these important target groups 
(113). Southeast Asia has the largest population with inadequate 
iodine intake globally and 76 million school-aged children in the 
region have low iodine intake. In India, every year 8.1 million 
newborns and 8.9 million pregnant mothers are at risk of IDD due to 
insufficient iodine intake (114). USI remains the single most 
important source of dietary iodine for the Indian population (115). In 
the global prevalence data of IDD, India shows adequate iodine 
nutrition with a subnational UIC of 100-299 µg/L. However, data 
from subnational studies may not reflect regional differences very 
well. A review of available studies from India showed significant 
iodine deficiency in pregnant women (57) suggesting that UI 
monitoring of pregnant women be included as a vital component of 
the National program on control of IDD in India (116). It also 
highlighted the need to conduct national level representative surveys 
to better quantify the iodine nutrition of pregnant women in India 
(116). There are some previous data from the Bangalore region on 
iodine intake. The WHO Global database on iodine deficiency, 2007 
reported that the median UIC in 11-18 y-old children in the 
Bangalore urban district was 185 µg/l (117).  However, there are few 
data on the median UIC of pregnant women from Bangalore region. 
31
 
 
 
Fi
gu
re
 3
: N
at
io
n
 io
di
ne
 s
ta
tu
s 
ba
se
d 
on
 m
ed
ia
n
 U
IC
 in
 s
ch
oo
l-
ag
e 
ch
ild
re
n
. S
ou
rc
e:
 w
w
w
.ig
n
.o
rg
 .
32 
 
Rationale of this thesis  
 
Pregnant women living in areas of mild to moderate iodine deficiency 
and iodine sufficiency may need extra iodine, but we do not know 
exactly the benefits and risks involved in such supplementation. There 
are no randomized controlled trials on iodine supplementation with 
long term follow up that have been conducted in this important group. 
This thesis therefore aimed to fill the important gap that exists in the 
current literature regarding the effect of iodine supplementation 
during pregnancy on birth outcomes, maternal goiter, thyroid 
autoimmunity, infant growth and cognitive development in an RCT. 
The current study is the first multicenter randomized controlled trial 
of iodine supplementation to pregnant women in areas of mild to 
moderate iodine deficiency (India and Thailand)  to see the effects of 
Maternal Iodine supplementation (200 µg) or placebo on Thyroid 
function and Child development (MITCH study). In this thesis, only 
data from the Indian site are presented. We conducted the study at 
the antenatal clinic of the Obstetrics and Gynecology Department of 
St Martha’s Hospital in Bangalore, India in accordance with the 
Declaration of Helsinki. Institutional ethical review boards at St. 
John’s National Academy of Health Sciences, St Martha’s Hospital, 
Bangalore, India and the Wageningen University, The Netherlands 
approved the study. We recruited pregnant women for the study 
between November 2008 to March 2011 and completed the data 
collection in November 2013. We recruited all women presenting to 
the antenatal clinic for potential inclusion in the study if they had a 
positive pregnancy test and were: 
a) ≥18 and ≤40 years old 
b) ≤14 weeks gestational age 
c) Planning to reside in the study area for the duration of the study (3 
years) 
 
Exclusion criteria were:  
a) Chronic diseases including diabetes, heart, kidney and thyroid 
disease, cancer, hypertension, tuberculosis, asthma, epilepsy, 
jaundice 
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b) A positive test for HIV, HbSAg or venereal diseases 
c) TSH value outside the normal range (0.3- 7.5 mIU/l) 
d) Treatment for infertility 
e) Previous repeated spontaneous abortions (4 or more) 
f) Current multiple pregnancy as detected by ultrasound  
g) Currently breastfeeding. 
We randomized the subjects into groups to receive either a daily 
iodine supplement of 200µg iodine (as potassium iodide tablets, 
donated by Merck KGsA, Darmstadt, Germany) until delivery or an 
identical placebo (Merck KGsA, Darmstadt, Germany) until delivery. 
We kept the codes in a sealed envelope with one of the members of 
the Data Safety and Monitoring Board; the codes were broken after 
the data analysis was completed. 
 
We followed pregnant women at each trimester as per their antenatal 
visits at the hospital, obtained information on morbidity, performed 
anthropometry and thyroid gland size measurement and collected 
biological samples. Post-delivery, we followed mother-child pairs at 
72 hrs, 6 weeks, 6 months, 1 and 2 years.  
 
In Chapter 2, we report the results of the randomized controlled trial 
of iodine supplementation in pregnant women to determine whether 
the daily oral administration of iodine (200 µg) to pregnant women 
improves maternal and newborn thyroid function, pregnancy 
outcome, birth weight, infant growth and cognitive performance. We 
also investigate new indicators for assessing iodine status in 
pregnancy and infancy: neonatal TSH and newborn median urinary 
iodine concentration. 
 
In Chapter 3, we report a pilot study which aimed to assess iodine 
intake (based on UIC) and potential determinants of intake, in Indian 
pregnant women and their school aged children who were sharing all 
meals. Our hypotheses were: 1) effective USI can ensure adequate 
iodine intake in pregnant women; 2) but this may lead to more-than-
adequate or excessive iodine intake in their school aged children.   
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In Chapter 4, we aim to understand the pattern and prevalence of 
maternal thyroid dysfunction and its associated risk factors in the 
Indian pregnant population in a cross-sectional study, using the 
screening data of the randomized controlled trial. The aims were to a) 
measure thyroid status in first trimester pregnant women in 
southern India; and b) assess potential determinants of thyroid 
function in this population, including iodine status, thyroid 
autoimmunity, body weight and anemia.  
 
In Chapter 5, we aim to assess the association of maternal 
depression, and thyroid function during pregnancy. We hypothesized 
that thyroid dysfunction would be associated with a higher 
prevalence of depressive symptoms. 
 
In the concluding Chapter 6, we summarise the main findings of this 
thesis, and their implications for public health. We also discuss the 
methodological limitations and suggest directions for future research. 
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Abstract 
 
Background: Children born to pregnant women in severely iodine 
deficient areas clearly benefit from maternal iodine supplementation, 
but there are no data from controlled trials in mildly iodine deficient 
pregnant women that have measured the effect of iodine 
supplementation on infant or child development. 
  
Methods: In a randomized placebo controlled trial we recruited 318 
healthy pregnant women (gestational age ≤14 weeks) in Bangalore, 
India and randomized them to either a daily supplement of 200 µg 
oral iodine or placebo from enrollment until delivery. Women were 
followed through delivery and followed up postnatal with their infants 
at 6 weeks, 1 and 2 year. Early neonatal development was assessed 
using the Neonatal Behavioral Assessment Scale (NBAS) at 6 weeks 
of age; neurocognitive assessment was done using the Bayley Scales 
of Infant Development (BSID III) at 1 and 2 years, and BRIEF-P 
(Behavior Rating Inventory of Executive Function) at 2 years. 
 
Results: Median UIC at the third trimester was significantly higher 
in the intervention group (279 vs. 180 µg/L; p=0.0032). There were 
no significant differences between groups in maternal thyroid 
function tests, thyroid volume, subtypes of thyroid dysfunction, or 
anti-TPO antibodies during gestation and postpartum. There were 
also no significant differences between the infant groups in thyroid 
function, birth outcomes or UIC at any time point. Infants in the 
intervention group scored significantly better on the NBAS 
orientation cluster (8.1 vs. 7.1; p=0.018). There were no group 
differences in the BSID III unadjusted sub scales of cognitive, 
receptive and expressive communication, fine and gross motor 
development at 2 years. The BRIEF-P showed higher problem scores 
of inhibition in the placebo group (median (IQR): 21.0 (19.0, 24.0) as 
compared to the intervention group (median (IQR): 20.0 (18.0, 21.0) 
(p=0.028). 
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Conclusion: Iodine supplementation in iodine sufficient pregnant 
women is safe and does not increase the risk of thyroid 
autoimmunity. Although there were no significant beneficial effects of 
iodine supplementation on thyroid function and birth outcomes, 
neonates whose mothers received iodine supplementation tended to 
have better executive function at 2 years of age. Additional follow-up 
of these children for neurocognitive testing at a later age, when 
development and cognitive testing is more reliable, would provide 
valuable add on information. 
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Introduction 
 
The sharp increase in the requirement for thyroid hormone and 
iodine during pregnancy constitutes a stimulus for both the maternal 
and fetal thyroid (1). By 10 weeks of gestation, the fetal thyroid is 
well-developed and begins concentrating iodine and producing 
thyroid hormone (2). In areas with a sufficient iodine intake, the 
maternal and fetal thyroid machinery adjusts to maintain 
euthyroidism in the mother and fetus (1). In contrast, in areas with 
severe iodine deficiency, goitre and hypothyroidism can occur in 
mother and newborn as a result of the inability of the thyroid gland 
to achieve euthyroidism due to low availability of iodine (3, 4). Mild 
degrees of iodine deficiency during pregnancy have been linked to 
maternal goitre and, in observational studies, to reduced intellectual 
function in children (5, 6). A recent observational study found that 
mild iodine deficiency during pregnancy has long-term adverse 
impacts on childhood neurocognition (7). In a population-based 
iodine sufficient cohort, maternal hypothyroxinemia in early 
pregnancy was associated with cognitive delay in children at 3 years 
of age (8). WHO/UNICEF/ICCIDD have recommended iodine intake 
for pregnant women to be 250 µg/ day in order to compensate for the 
increased need for thyroid hormones in the mother and fetus  which 
can be achieved with  an established salt iodization program (9). 
Expert organizations like the American Thyroid Association (ATA), 
European Thyroid Association (ETA), National Health and Medical 
Research Council (NHMRC) of Australia, The Endocrine Society, Asia 
and Oceania Thyroid Association, and the Latin American Thyroid 
Society recommend that pregnant women should take a daily oral 
supplement of 150 μg of iodine (10-12). However, iodine 
supplementation to pregnant women should be an interim measure 
in areas where universal salt iodization was not effective (13). 
 
There is a wealth of literature showing the association between 
severe iodine nutrition and cognitive capacity in animal and human 
studies however this evidence base is not from the randomized 
controlled trials. Till date, 6RCTs have been conducted in regions of 
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mild to moderate iodine deficiency but none of them reported on 
childhood development or growth, or on long-term pregnancy 
outcomes. The effects of iodine supplementation on the thyroid 
function of mothers and their neonates were inconsistent (14). Thus, 
there are no long-term data from randomized controlled trials on the 
effect of iodine supplementation during pregnancy on birth outcomes 
or infant development in areas of mild deficiency (15). An 
observational study in the UK found associations between mild 
maternal iodine deficiency and impaired cognition in childhood (16). 
Maternal iodine supplementation may not be without risk: excessive 
maternal iodine intake impairs neurodevelopment and cognitive 
function in rat offspring (17) and iodine supplementation during 
pregnancy has been linked to poorer cognitive performance in 
Spanish infants (18, 19).  
 
Clearly, more data are needed on the effects of iodine 
supplementation during pregnancy on infant development especially 
in regions with mild-to-moderate iodine deficiency. Therefore, we 
conducted a randomized controlled trial of iodine supplementation in 
pregnant women from Bangalore, India. The objectives were to 
determine whether the daily oral administration of 200 µg iodine to 
pregnant women in areas of mild-to-moderate iodine deficiency 
improves maternal and newborn thyroid function, pregnancy 
outcome, birth weight, infant growth and cognitive performance.  
 
Methods 
 
Study design and subjects 
 
The MITCH (Maternal Iodine supplementation and its effects on 
Thyroid function and CHild Development) study with the identifier 
NCT00791466 at Clinicaltrials.gov employed a randomized, double 
blind, placebo-controlled design. We conducted the study at the 
antenatal clinic of the Obstetrics and Gynaecology Department of St 
Martha’s Hospital in Bangalore, India. We recruited pregnant women 
for the study between November 2008 and March 2011 and 
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completed the data collection in November 2013. We recruited all 
women presenting to the antenatal clinic for potential inclusion in 
the study if they had a positive pregnancy test and were: a) ≥ 18 and 
≤ 40 years old; b) ≤ 14 weeks gestational age and c) planning to 
reside in the study area for the duration of the study (3 years). 
Exclusion criteria were: a) chronic diseases including diabetes, heart, 
kidney and thyroid disease, cancer, hypertension, tuberculosis, 
asthma, epilepsy, jaundice; b) a positive test for HIV, hepatitis B or 
venereal diseases; c) TSH value outside the normal range (0.3- 7.5 
mIU/l); d) treatment for infertility; e) previous repeated spontaneous 
abortions (4 or more); f) current multiple pregnancy as detected by 
ultrasound; or g) currently breastfeeding. Even though we stipulated 
the use of iodine supplements as exclusion criteria, there were no 
women who were using the only available iodine supplement in the 
market containing 150µg iodine during the recruitment period. At 
recruitment, we obtained data from a subset of pregnant women 
(n=218) on consumption of iodine containing multi-micronutrient 
powders, including quantity and length of time these supplements 
had been consumed.  The pregnant women enrolled in the present 
trial were counselled by the obstetrician to discontinue the use of 
iodine containing multi-micronutrient powder and were prescribed 
another multi-micronutrient powder not containing iodine. 
 
Ethics  
 
We conducted the study in accordance with the Declaration of 
Helsinki. Institutional ethical review boards at St. John’s National 
Academy of Health Sciences, St Martha’s Hospital, Bangalore, India 
and Wageningen University, The Netherlands approved the study. We 
explained the study in detail, in the mother tongue of the 
participating women and one member of their family, and obtained 
written, witnessed informed consent. We prepared the informed 
consent form in English language and back translated the translated 
versions to check with the original form for any mismatch. The study 
participants were free to refrain from the study at any time. We 
reported study related serious adverse events (SAE) within 24 hours 
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to the Data and Safety Monitoring Board (DSMB). In addition, we 
reported periodically, the number of dropouts and SAEs both to the 
DSMB and the IERB of St John’s National Academy of Health 
Sciences. 
 
Recruitment, randomization and enrolment 
 
We present the recruitment details in Fig 1. We enrolled 318 
pregnant women and randomized them into groups of iodine 
intervention, (200µg iodine as potassium iodide (KI) or an identical 
placebo (donated by Merck KGsA, Darmstadt, Germany) using coding 
generated from a table of random numbers by the study statistician. 
The codes were kept in a sealed envelope by one of the members of 
the Data Safety and Monitoring Board and were broken after the data 
analysis was completed. 
 
At recruitment, we carried out routine antenatal tests at the clinic 
where folic acid, iron, calcium supplements and tetanus toxoid 
injection were provided to the subjects as part of standard antenatal 
care.  We handed over a box of 40 tablets (30 for the month and 10 
extra to ensure that the regimen was not missed in case the next 
appointment was not exactly scheduled in 30 days) and a calendar to 
the pregnant women, counselled them on how to use the 
supplements, record the days that the supplements were consumed 
and to bring back the supplement box along with the calendar at 
monthly visits. Subjects received a reminder telephone call a day 
before the scheduled visit. We assessed the compliance with 
supplement use in 3 ways: (a) direct questioning; (b) capsule counting 
and c) measurement of urinary iodine as a marker of compliance with 
the iodine supplement. Compliance was calculated as the percentage 
of tablets consumed out of the total number of tablets expected to be 
consumed until each visit. We followed up women monthly during the 
pregnancy and stopped supplementation at delivery. At baseline and 
at each trimester as per their antenatal visits to the hospital, we 
obtained information on morbidity, measured weight and thyroid 
gland size and collected urine and blood samples. Post-delivery, we 
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followed mother-child pairs at 72 hrs, 6 weeks, 6 months, 1 and 2 
years. 
 
Socio-demography data 
 
At baseline prior to randomization, we obtained socio-demographic 
information on household composition, education, occupation and 
income, on a structured multiple choice questionnaire, as well as 
consanguinity and obstetric history, including parity. We calculated 
gestational age from the reported first day of the last menstrual 
period and confirmed this by using ultrasonography in 65% of 
women. There was a strong positive correlation between the 
gestational age ascertained by the two methods (r=0.858; p<0.001).  
 
Anthropometric measurements  
 
We recorded anthropometric measurements in duplicate using 
standard techniques (20). We recorded maternal weight to the 
nearest 0.1 kg by using a digital weighing scale (Salter’s 9016, 
Tonbridge, Kent, UK) and maternal height to the nearest 0.1 cm by 
using a stadiometer (Biorad, Chennai, India). We calculated BMI as 
weight in kilograms divided by the square of height in metres 
(kg/m2). We obtained birth weight, length and head circumference 
from the hospital records. We measured infant weight to the nearest 
0.01 kg by using an electronic baby and toddler scale (Salter’s 914, 
Tonbridge, Kent, UK). We measured infant length to the nearest 0.1 
cm by using a stadiometer and head circumference by a flexible non-
stretchable measuring table. Low birth weight (LBW) was defined as 
birth weight <2500 g, and small-for-gestational age (SGA) was 
defined as birth weight less than the 10th percentile of gender norms 
for gestational age (20). We calculated Rohrer’s ponderal index, as 
100 times the birth weight (in grams) divided by the cube of the birth 
length (cm3) (20).  
 
Biological specimens 
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We collected a spot casual spot non-fasting urine samples that were 
transported on ice, divided into aliquots and stored at -20⁰ C until 
analysis. We determined UIC by using the Pino modification of the 
Sandell-Kolthoff reaction (21) at the Human Nutrition Laboratory, 
ETH, Zurich, Switzerland. The laboratory participates successfully in 
the CDC EQUIP procedures. At a mean UIC of 68.8 ± 2.3 µg/L 
(acceptable range: 56-73 µg/L), the intra and inter-assay CV was 3.5 
% and 3.3 % respectively. At a mean UIC of 200.7 ± 3.6 µg/L 
(acceptable range: 180-216 µg/L), the intra and inter-assay CV was 
1.3 % and 1.8% respectively. We used the UIC data to classify iodine 
status according to the recommended WHO/UNICEF/ICCIDD criteria 
for pregnancy, lactation and infancy (9). We collected non-fasting 
whole blood samples by venipuncture into plain vacutainers (BD 
diagnostics, Franklin Lakes, New Jersey, USA) that were transported 
on ice and centrifuged to obtain serum. This was stored at -80⁰C 
until analysis by immunoassay of thyroid stimulating hormone 
(TSH), total triiodothyronine (TT3), total thyroxine (TT4), free T3 (fT3), 
free T4 (fT4), thyroglobulin (Tg), and anti-thyroid peroxidise 
antibodies (TPO-Ab). We previously described in detail the 
immunoassay method used to measure the TFT’s, including %CVs, 
reference range, analytical measurement range and analytical 
sensitivity (23). With the exception of TSH and TT4, we used the 
manufacturer’s recommended reference range for TFT’s. For TSH, we 
applied a reference range of 0.1-2.5 mIU/L for the first trimester, 0.2-
3.0 mIU/L for the second trimester and 0.3-3.0 mIU/L for the third 
trimester (10, 24). For TT4, for all 3 trimesters, as per the CDC/ATA 
recommendation, we adjusted the non-pregnant reference range by a 
factor of 1.5 to arrive at a new reference range (87-241.5 nmol/L) (10, 
25). We used these reference ranges for TSH and TT4 to identify   
thyroid dysfunction in pregnancy. Haemoglobin (Hb) was measured 
on an automated Coulter counter (ABX Pentra 60C+, Horriba Ltd, 
Kyoto, Japan). Anaemia was defined as Hb <11.0 g/dL.  
 
We collected cord blood at delivery that was transported on ice and 
centrifuged to obtain serum, which was stored at -80⁰C until analysis 
for TSH. We measured TSH by using a third generation solid phase, 
57 
 
two-site chemiluminescent assay (IMMULITE 1000, Siemens 
Healthcare diagnostics, USA) and applied a reference range as 
supplied by the manufacturer: >37wk, 2.3-13.2 mU/L. We collected 
heel prick sample from the infants at 72 hrs of birth into filter paper 
cards, dried them at room temperature, placed them into airtight 
plastic ziplock bags and stored them at -80⁰C until analysis for TSH. 
We measured TSH and T4 concentrations using an automated time-
resolved fluoroimmunoassay (TSH [DELFIA NeoTSH, PerkinElmer 
Life Sciences, Turku, Finland] and T4 [Delfia Neonatal T4 kit, 
PerkinElmer Life Sciences) respectively (26). We applied age-specific 
reference ranges for TSH and T4 as provided by the Children’s 
Hospital, Zurich, Switzerland: Normal value range TSH: 0-7 d, 0.1-
10.5 mU/L ; 7-21 d, 0.1-5.3 mU/L ; 21-60 d,  0.1-5.0 mU/L ; 60-155 
d, 0.1-4.5 mU/L ; 155-365 d, 0.1-3.7 mU/L ; 1-99 y, 0.1-3.7 mU/L. 
Normal value range T4: 0-7 d, 114-245 nmol/L ; 7-21 d, 123-170 
nmol/L ; 21-60 d, 84-170 nmol/L ; 60-155 d, 80-165 nmol/L;155-
365d, 65-165 nmol/L ; 1-99 y, 65-165nmol/L. 
  
Thyroid gland measurement 
 
We measured thyroid gland volume by using an Aloka SSD-500 
Echocamera (Aloka, Mure, Japan) with a 7.5MHz linear transducer. 
We calculated thyroid volume of each lobe using the formula for a 
prolate ellipsoid where thyroid volume (ml) = 
0.479*length*breadth*depth (cm) and summed the volumes of both 
lobes to obtain total thyroid volume (9). 
 
Neonatal behavioural assessment scale  
 
We used Neonatal Behavioral Assessment Scale (NBAS) to assess the 
impact of maternal iodine supplementation on early neonatal 
development (27). A certified psychologist trained in the 
administration of NBAS followed standard procedures for scoring as 
described by Brazelton and Nugent (27). Scores were reduced to 
seven clusters as follows: habituation, orientation, motor 
performance, range of state, regulation of state, autonomic stability 
58 
 
and abnormal reflexes, as per the data reduction scheme described 
by Brazelton and Nugent (27).  The missing values in a cluster were 
replaced by the individual mean cluster score; cases where >3 items 
were missing in a cluster were not included in the analysis.   
 
Neurocognitive assessment 
 
We administered Bayley’s Scale for Infant Development (BSID III) to 
obtain standard scores for cognitive, language (receptive and 
expressive subtests) and motor (gross and fine subtests) scales (28).  
BSID III uses standardized administration and scoring procedures to 
provide the infant and toddler with situations and tasks that capture 
his or her interest and provide an observable set of behavioural 
responses. The cognitive scale assesses play skills, information 
processing, information processing speed, problem solving, and 
number concepts. The language scale assesses both receptive (ability 
to hear, understand, and respond) and expressive (ability to 
communicate) language skills and is important for identifying critical 
delays. The motor sub-test assesses quality of movement, sensory 
and perceptual motor integration, and basic locomotion milestones. 
Testing was performed by a trained master’s level psychologist 
experienced in child developmental testing.  
 
Assessment of executive functioning 
 
Whereas cognition provides global insight of brain functioning, 
executive functioning represents different structures and functions of 
the brain involved in the cognitive regulation of behaviour (29). 
Executive function is defined as a group of processes, e.g., inhibition, 
working memory, and the ability to plan and organize, that are 
dependent on and influence more basic cognitive abilities, such as 
attention, language, and perception (30). We measured impairment of 
executive functioning in children at 2 years of age by using the 
BRIEF-P (31). The BRIEF-P is a standardized rating scale developed 
to provide a window into behaviours associated with specific domains 
of executive functioning in children aged 2 to 5 y. The BRIEF-P 
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consists of a single rating form, completed by parents or other 
caregivers, with 63 items in 5 scales: inhibition (to stop own 
behaviour), shifting (to make a transition and change focus from one 
mind set to another), emotional control (to modulate emotional 
responses), working memory (to hold information in mind for the 
purpose of completing a task), and planning/organization (to manage 
current and future-oriented task demands within the situational 
context). The scales can be combined into the global executive 
composite (GEC) but in our cohort of children, items on working 
memory were not applicable at 2 years of age hence GEC could not 
be computed. We present only the raw scores on the items of 
inhibition, shift, emotional control and planning/organization. 
Higher scores indicate more problems with executive functioning.  
 
Data analysis  
 
All study forms were checked for inconsistencies and the data were 
double entered into a structured query language database by two 
data entry operators. Discrepancies or mismatches in the data entry 
were corrected by a data entry supervisor. The matched data was 
locked, held by the study statistician and made available for 
analysis. Statistical analyses were carried out with SPSS (version18, 
SPSS, Chicago, IL, USA).  
 
Primary outcome measures were maternal thyroid function. 
Secondary outcome measures were birth outcome, infant thyroid 
function, infant cognitive and motor development and maternal and 
infant urinary iodine. We estimated the sample size on an anticipated 
decrease in the prevalence of elevated newborn TSH (>10 mU/L at 
postnatal days 2-4) with iodine supplementation. The calculation 
indicated a sample size of 250 pregnant women (randomized into two 
groups of 125 women) would be needed to have 80% power to detect 
a decrease of 8% (from an anticipated incidence of 10% in the control 
to 2% with supplementation) in the proportion of elevated newborn 
TSH values with a significance level of 0.05 (two tailed). Before the 
study began, we anticipated a 10% loss to follow-up and thus the 
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sample size considered was 275; however as the study was 
progressing the loss to follow-up was identified to be ˜25% and 
therefore 318 pregnant women were recruited. 
 
We report normally distributed data as arithmetic means ± SD, non-
normally distributed data as medians (quartiles) and categorical data 
as numbers (%). We examined normal distribution of the data using 
Q-Q plots and Kolmogrov-Smirnov test. All the thyroid function 
parameters except total T4 were not normally distributed and were 
log-transformed except fT3 which was square transformed, and the 
transformed data were used for further statistical analysis. The 
normal distribution of the transformed data was verified. We 
compared basic socio-demographic variables and all thyroid function 
parameters at all three trimesters between the treatment groups 
(intervention vs placebo) using t-test for normally distributed data, 
Mann-Whitney U test for non-normally distributed data and chi-
square test for categorical data. Mixed linear analyses were 
performed for each maternal thyroid function parameter to examine 
the effect of the intervention on change in these measures during 
pregnancy across the three trimesters. These were intention to treat 
analyses. Initially, we created a simple model which only considered 
treatment group. In the next step, we considered the gestational age 
at entry into the study as an important covariate since the mean 
gestational age at entry was early, at 10 weeks (range 5.0-14.6 
weeks) and it is known that the earlier supplementation starts, the 
better. We created a variable “duration of treatment” (Gestational age 
at trimester 1, 2, or 3 minus gestational age at trimester 1) to 
quantify the duration (in weeks) the subjects were in the study at the 
time of each blood draw for thyroid function test. This model 
considered “duration of treatment”  as a covariate and the difference 
in slope of thyroid function parameters with “duration of treatment” 
between the intervention groups was considered as a measure of 
efficacy of the intervention obtained by the interaction with treatment 
group, henceforth referred to as “interaction term” which is guiding 
the interpretation of the study outcomes. Further, we considered 
percentage compliance percentage compliance based on pill counts 
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as a covariate in addition to the factors in the second model to adjust 
for the effect of compliance to intervention/placebo. Compliance to 
intervention was significantly associated with most thyroid function 
parameters, but did not modify the interaction between duration of 
treatment and treatment group. All these models included additional 
covariates of BMI, parity, baseline gestational age and maternal age. 
These possible confounders were identified in separate bivariate 
analyses with the thyroid function parameters.  We repeated these 
analyses in a per-protocol population for thyroid function tests. The 
per-protocol population was defined as those subjects who were part 
of the study throughout their pregnancy with their thyroid hormones 
and antibodies and thyroid gland volume measured. The intervention 
group was considered as fixed effects and subject as random effect in 
all the models. The appropriateness of the models was examined 
using residual plots. Sensitivity analyses were performed by 
excluding outliers. However results from the original analyses did not 
change and therefore the analyses including outliers are presented. 
At delivery, we assessed the difference in TFT measures, UICs, 
neonatal characteristics and developmental data between the two 
groups using linear regression analysis with treatment group as 
independent variable, adjusted for possible confounding effects of 
maternal characteristics, such as gestational age at delivery, gender, 
parity, and maternal height. At postnatal maternal time points (6 
weeks, 6 months, 1 and 2 year), we assessed the difference in TFT 
measures by mixed linear model analysis and present the p values 
for the treatment group. We compared all children’s thyroid function 
parameters, anthropometry data and neurocognitive assessment data 
between codes using t-test for normally distributed data, and Mann-
Whitney U test for non-normally distributed data. Statistical 
significance was considered at p < 0.05 for all analyses. 
  
Results 
 
There were no statistically significant differences in age, gestational 
age, education, occupation, monthly household income, height, 
weight or BMI between those who declined participation and those 
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who agreed to participate in the study (data not shown). Figure 1 is a 
flow diagram of recruitment, enrolment and follow-up of pregnant 
women in the RCT. There was a 21% dropout each in the 
intervention and placebo group from the study entry to second 
trimester. This dropout rate increased to 26.1 and 24.8% at the third 
trimester, 27.3 and 28.0% until delivery, 30.4% (n=112) and 31.2% 
(n=108) at delivery and 72 hrs in the intervention and placebo group 
respectively thus 30.4% and 31.2% dropout at 6 weeks. At 6 months, 
1 year and 2 year, the dropout rate increased to 31.7%, 35.2%, 
40.9% and 36.3%, 39.4% and 44.6% in the intervention and placebo 
group respectively. Thus, there was an overall 43% dropout in the 
number of participants who were available for assessments at 2 
years (n=95 and n=87 in the intervention and placebo group 
respectively) 
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The baseline characteristics of 318 pregnant women recruited in the 
study are in Table 1. There were no significant differences between 
the two groups in any of the baseline characteristics. The gestational 
age at recruitment was 10.4±2.5 weeks (range 5.0-14.6 weeks) and 
the prevalence of anemia was 19% (Hb <11 g/dL). 
 
Thirty four percent of pregnant women were consuming multi-
micronutrient powders containing iodine in the range of 73-294 
µg/100 g. But the mean (range) iodine intake from these powders 
was low (5-10g/day).  The iodine content in these powders ranged 
from 73-294 µg/100 g. In the intervention group, the mean (range) 
iodine intake was: 12.4 (3.6-41.7) µg/day for mean (range) duration 
of 9.5 (0-180) months. This was not statistically significantly different 
in the placebo group; the mean (range) iodine intake was: 11.5 (3.5-
29.8) µg/day for a mean (range) duration of 11.3 (0-180) months. The 
median (IQR) UIC values between pregnant women using multi-
micronutrient powders containing iodine (n=70) was 180.5 (92.1, 
303.8) vs 216.5 (110.9, 388.1) in non-users (n=140) at study entry 
and did not differ significantly (p=0.102). 
65 
 
Table1: Baseline demographic, anthropometric and biochemical 
characteristics of Indian pregnant women given 200 µg iodine daily or 
placebo1 
Parameters n Intervention n Placebo p 4 
Age, years1 161 24.8 ± 4.1 157 24.6 ± 4.1 0.751 
Gestational age, weeks1 161 10.5 ± 2.4 157 10.2 ± 2.5 0.376 
Total monthly household 
income, INR2 
161  12000  
(7125, 
20000) 
157 12000 
 (8000, 
24500) 
0.943 
Level of education3 160  155  0.459 
    No formal education  -  1 (0.6)  
     Finished high school  72 (45.0)  60 (38.7)  
     Post high school  35 (21.9)  43 (27.7)  
     University degree & above  53 (33.2)  51 (32.9)  
Consanguinity3 160  155  0.665 
      Yes  23 (14.4)  25 (16.1)  
      No  137 (85.6)  130 (83.9)  
Parity3         
       0  105 (69.1)  99 (65.1) 0.726 
       1  45 (29.6)  50 (32.9)  
       2  2 (1.3)  3 (2.0)  
History of abortion3 152  152  0.450 
       0  118 (77.6)  126 (82.9)  
       ≥1  34 (22.3)  26 (17.1)  
Use of I supplements3 112  106  0.887 
       Yes  38 (33.9)  35 (33.0)  
       No  74 (66.1)  71 (67.0)  
Weight, kg1 160 52.2 ± 9.0 156 53.8 ± 9.2 0.125 
Height,cm1 160 153.8 ± 5.8 154 154.4 ± 5.6 0.354 
BMI, kg/m2 1 160 22.1 ± 3.9 154 22.6 ± 3.9 0.302 
Haemoglobin, g/dL 1 156 11.9 ± 1.4 154 11.9 ± 1.4 0.887 
Anemia 156 30 (19.2) 154 29 (18.8) 0.929 
1 Data are mean ± S.D., 2 median (Quartile 1, Quartile 3) and  3 n (%), 4 p values are from t-test 
for normally distributed data, Mann-Whitney U-test for non-normally distributed data, and chi-
square test for categorical data. 
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Table 2 presents the urinary iodine concentration values and their 
distribution between the two groups at first, second and third 
trimester by intention-to-treat analysis. We present p values for 
treatment group, duration of treatment and interaction of treatment 
group with duration of treatment.  The median (range) UIC of all the 
women in first trimester was 187.5 (8.1-1152.2) µg/L and was not 
significantly different between the intervention and placebo groups 
(p=0.603). In the intervention group, UIC increased by 18.8% and 
35.5% in the second and third trimester of pregnancy while in the 
placebo group, there was no significant change in UIC at the second 
or third trimester (Figure 2). The median UIC at the second and third 
trimester was significantly higher in the intervention group (p=0.048 
and 0.003, respectively). In a mixed linear model analysis, the overall 
UIC tended to be 3.2% higher in the intervention group (p=0.750), 
while there was no significant effect of duration of treatment 
(p=0.892) and a borderline significant effect of the interaction 
between duration of supplementation and treatment group (Table 4). 
The results from the per-protocol analysis (Supplementary Table 1) 
were comparable to the intention-to-treat analysis. 
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The thyroid function and thyroid volume of the two groups at 
baseline, second and third trimesters is shown in Table 3, analysed 
by intention-to-treat analysis. We present p values for treatment 
group, duration of treatment and interaction of treatment group with 
duration of treatment.   The thyroid function parameters were not 
significantly different between the intervention and placebo groups 
except baseline TSH (p=0.015) and fT4 (p=0.021). In a mixed linear 
model analysis, the overall TSH was 5.7% lower in the intervention 
group but not significant (p=0.159). There was a significant 0.5% 
increase in TSH for every week in the study (p<0.001) in both groups. 
However this increase was not different between the groups 
(pinteraction=0.986). The percentage of women with elevated TSH levels 
decreased over pregnancy in both the groups. At baseline, fT4 was 
significantly higher in the intervention group and was comparable 
between the groups in the second and third trimesters. In a mixed 
linear model analysis, fT4 and TT4 were 3% higher in the 
intervention group (p=0.006 and p=0.049 respectively). Overall, fT4 
decreased from baseline by 0.34% for every week in the study but 
there was no significant difference in this decline between the groups 
(pinteraction=0.070). (pinteraction =0.070). The percentage of women with 
low fT4 concentrations increased 5 and 8 fold in the second and third 
trimester from baseline in the intervention group. A similar trend was 
also seen in the placebo group. However, prevalence of low titres of 
TT4 was quite low for TT4 (0.8-2.9%) in the second and third 
trimester for both the groups. FT3 and TT3 increased significantly 
every week (0.3%,p=0.011); 1.32%, p<0.001) respectively during 
pregnancy but there were no significant differences between groups 
and interaction effect. While a 5 fold increase in the higher TT3 
reference group from baseline was observed in both the groups at the 
second and third trimester, fT3 did not show similar change. 
Thyroglobulin was 10.6% lower in the intervention group after 
treatment though not significant (p=0.367). There was a significant 
0.6% increase in thyroglobulin for every week in the study (p=0.009) 
however this increase was not different between the groups 
(pinteraction=0.739). TT3/TT4 ratio and FT3/TT3 ratio increased 
significantly each week (0.01%, p<0.001); 1.1%, p<0.001) respectively 
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during pregnancy but there was no significant difference between the 
treatment group and time from start*group interaction. The thyroid 
volume of the pregnant women increased systematically through the 
second and third trimester in the intervention group (5.0 vs 5.2 vs 
5.8) and placebo group (5.0 vs 5.3 vs 5.6) There was a significant 
0.5% increase in the thyroid gland volume for every week in the 
study (p<0.001) without treatment or interaction effects. In the per-
protocol analysis (Supplementary Table 2), all the results were 
comparable to the intention-to-treat analysis except that TSH and 
fT4 were not significantly different between the two groups at 
baseline. 
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Fig 3 presents the prevalence of thyroid dysfunction in the two 
groups across the antenatal and postnatal time points. There were no 
cases of overt hyperthyroidism during pregnancy and at 1 and 2 
years after delivery. Some cases were reported at 6 wks: 3 (3.2%) vs 2 
(2.4%) and 6 months: 3 (3.9%) vs 1 (1.3%) in the intervention and 
placebo group respectively. In the intervention group, the prevalence 
of subclinical hyperthyroidism was 2.6%, in the first trimester, 
absent in the second and third trimester, 4.3% at 6 wks, 5.3% at 6 
months and then absent in year 1 and 2. In the placebo group, the 
prevalence of subclinical hyperthyroidism was 1.3% in the first 
trimester, 0.8% in the second trimester, absent in the third trimester 
and 6 weeks, 3.9% at 6 months and then absent in year 1 and 2. The 
prevalence of overt hypothyroidism was 1.93 vs 2.65 % at baseline, 
1.8 vs 0% at second trimester, absent in the third trimester and 6 
wks, 3.9 vs 3.9% at 6 months, 1.4 vs 1.6% at 1 year and absent at 2 
year in the intervention and placebo group respectively. The 
prevalence of subclinical hypothyroidism was 7.7 vs 9.9% in the first 
trimester, 4.4 vs 7.6% in the second trimester, 4.8 vs 8.7% in the 
third trimester, absent at 6 wks, 10.5 vs 2.6% at 6 months, 7.0 vs 
4.8% at 1 year and 10.3 vs 12.8% at 2 year in the intervention and 
placebo group respectively. In the intervention and placebo group 
respectively, the prevalence of isolated hypothyroxinemia was 0 vs 
3.3% in the first trimester, 0.9 vs 0.8% in the second trimester, 2.9 
vs 1.9% in the third trimester, 8.5 vs 17.1% at 6 wks, 1.3 vs 9.1 % at 
6 months, 15.5 vs 11.1% at 1 year and 2.6 vs 2.6% at 2 year. During 
pregnancy, there was no significant difference between groups in 
prevalence of overt or subclinical hypothyroidism or isolated 
hypothyroxinemia. There were no differences when a summary 
variable of these three conditions was created and compared among 
groups. 
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Table 4 presents the continuous and categorical data of thyroid 
function, thyroid volume and UICs of  women at postnatal time 
points 6 weeks, 6 months, 1 and 2 year, by the two groups. There 
were no significant differences in thyroid function measures between 
the two groups except TT3 and TT3/TT4 ratio which showed a 6.5% 
and 0.09% difference in the intervention  group with respect to 
placebo group (p=0.017 both). In both the groups, TSH levels 
decreased at 6 wks and thereafter remained at the levels that were 
achieved by the end of pregnancy. TT4, TT3 fT3, fT3/fT4 ratio were 
lower in the postpartum period compared to their pregnancy levels in 
both the groups of women while fT4 levels decreased in the second 
and third trimester but returned to first trimester levels in the 
postpartum period in both the groups. Tg and TT3/TT4 ratio 
remained more or less in the same range of values throughout 
pregnancy and postpartum period in both the groups. In both the 
groups, thyroid volume at 6 wks was same as the third trimester 
gland size and then it continued to increase at 6 months, 1 and 2 
year. In both the groups, UIC was sharply lower from the pregnancy 
levels but it was still >100 µg/L indicating iodine sufficiency.  
 
Fig 4 shows the percentage of normal and high TPO-Antibody (TPO-
Ab) titres in the women at antenatal and postnatal time points. The 
prevalence of high ATPO-Ab titres was 12.7 vs 12.3% in the first 
trimester, 12.1 vs 8.3% in the second trimester, 13.2 vs 9.7 % in the 
third trimester, 8.5 vs 17.1% at 6 wks, 16.7 vs 10.3% at 6 months, 
11.3 vs 12.1% at 1 year and 10.3 vs 17.9% at 2 year in the 
intervention and placebo group respectively. In a generalised 
estimated equation analysis, there were no statistically significant 
differences in the prevalence of high ATPO-Ab titres between the 
intervention and placebo group (p=0.851 for treatment group, 
p=0.394 for duration of treatment, p=0.192 for interaction effect). 
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The neonatal characteristics, thyroid function, thyroid volume, UIC 
and NBAS score in newborns in the treated and placebo groups are 
shown in Table 5. There was no difference in the length of gestation 
between the intervention and placebo groups (38.6 vs 38.7 wks). The 
placebo group had a higher percentage of female to male (48 vs 65) 
when compared to the intervention group (56 vs 52) but this 
difference in gender was not significant between the two groups 
(p=0.163). Infant birth weight in the placebo group was 174 g higher 
compared to intervention group but this difference was not 
statistically significant when birth weight was adjusted for 
gestational age at delivery, gender, parity and maternal height. 
Between intervention and placebo group, the prevalence of low birth 
weight (22.8 vs 17.4%), small-for-gestational-age (35.4 vs 24.8%) and 
pre-term (8.0 vs 8.6%) were not significantly different. The transient 
neonatal hypothyroxinemia (neonatal TSH>5 mIU/L) observed in 
both the groups at delivery (73.4 vs 76.7) resolved at 72 hrs post 
delivery with no cases of neonatal TSH >5 mIU/L. T4 levels decreased 
from delivery to 72 hrs post delivery in both the groups.  The 
percentage of infants with UIC <100 µg/L was also not different 
between the two groups. There was no difference in any of the 
domains of the Neonatal behavioural assessment scale at 1 week 
postpartum but at 6 weeks, infants in the intervention group scored 
significantly higher in the orientation cluster (8.1 vs 7.1) (p=0.018). 
 
The thyroid function and anthropometry of children at ages 6 weeks, 
6 months, 1 and 2 year are shown in Table 6. There was no 
difference in the measures of thyroid function (TSH, T4, UIC) or 
anthropometry (weight, height, head circumference) in both the 
groups of children at any of the time point.  
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Table 7 presents the raw scores of Bayleys scales of infant 
development (BSID-III) assessed in children at 1 and 2 years of age. 
Between the two groups of children, there was no difference in the 
unadjusted sub scales of cognitive, receptive and expressive 
communication, fine and gross motor development at 2 years. At 1 
year, unadjusted expressive communication was statistically 
significantly different between the two groups. Table 8 presents the 
raw scores of executive function as assessed by Brief P in both the 
groups of children at 2 years of age. The unadjusted scale on 
inhibition showed lower problem scores of inhibition in the children 
of mothers who received iodine during pregnancy (median (IQR): 20.0 
(18.0, 21.0) compared to those in the placebo group, (median (IQR): 
21.0 (19.0, 24.0) and this difference was statistically significant 
(p=0.028).
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Discussion 
  
This study has two distinctions: this is the first study to measure 
child development at two years as an outcome of iodine 
supplementation during pregnancy in a randomised controlled trial. 
The second distinction, though not anticipated, is that the pregnant 
women were iodine sufficient, not mildly iodine deficient, likely due to 
recent improvements in the coverage and quality of iodized salt in the 
area. This was confirmed by maternal UIC >150 µg/L throughout 
pregnancy, UIC >100 µg/L in the postpartum period and a less than 
3% frequency of neonatal TSH concentrations >5mU/L on samples 
collected 3–4 days after birth (32).  
 
Iodine supplementation brought about an 18.8% and 35.5% increase 
in the UIC in the second and third trimester of pregnancy in the 
intervention group. In this study, the significant difference in UIC 
values was observed in the third trimester between the intervention 
and placebo group (p=0.003). There was a difference of 35 and 99 
µg/L UIC  between the two groups at second and third trimester 
respectively while this difference should have been ~147 µg/L 
between the intervention and treatment groups considering >80% 
compliance with supplement use (200 µg iodine)  and 92% dietary 
iodine bioavailability. It could be that the renal handling of UI 
excretion is efficiently targeted at providing iodine until the fetal 
thyroid matures around second trimester. So irrespective of 
additional supplementation, this mechanism is efficient in pregnant 
women with sufficient intra-thyroidal stores at the beginning of 
pregnancy. There are conflicting reports of gestational changes in UI 
excretion; mean UIC did not change with progression of pregnancy in 
France (33), Sweden and Sudan (34), whereas data from the United 
Kingdom (35), Spain (36), and Hong Kong (37)  showed an increasing 
level of UIC with advancing gestational age. In cross-sectional studies 
assessing iodine supplement use (140-150 µg/dose) and thyroid 
function, median UICs were 111 Vs 61 µg/L in UK (38); 60 Vs 35 
µg/L at term in Denmark (39) in women taking iodine supplement 
and women not taking a supplement respectively. Results from 
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randomised trials of iodine supplementation (n=35-120; 50-230 µg 
iodine/day from 11/14/17/18 wk to term) in mild-to-moderately 
iodine deficient pregnant women showed significantly higher median 
UI in the intervention group compared to controls (1, 40-43). In a 
prospective, randomized, open-label trial, Antonangeli et al. (44) 
supplemented mildly iodine-deficient pregnant women (n=67; median 
UI 74 µg/g cr) with 50 µg or 200 µg iodine/day from 18-26 wk to 29-
33 wk. Median UI was significantly higher in the 200 µg group than in 
the 50 µg group (230 vs. 128 µg/g cr). Our results compare with those 
from Japan where overall median UICs throughout pregnancy and in 
the postpartum period were 224.0 and 135.0μg/L, respectively, 
suggesting sufficient iodine nutrition (45). In Ireland, UI excretion in 
the immediate antenatal and early postpartum periods showed a 
precipitous fall in median values from 93 µg/L antenatally to 36 µg/L 
at delivery subsequently rising to 49 µg/L and 63 µg/L at days 3 and 
10 postpartum respectively (46). In a longitudinal observational 
study conducted in Slovenia, an iodine sufficient area, UIC was 
significantly higher during pregnancy than after delivery (P=0.044) 
(47). The fact that the maternal UIC levels at the end of pregnancy 
drops considerably at 6 weeks postpartum indicates normalization of 
thyroid hormone production and renal function for UI excretion, and 
also reflects iodine losses into breast milk in lactating women (45). It 
is also interesting to note that the maternal UIC levels reached back 
to those of pregnancy values from 6 months onwards in both the 
groups indicating sufficient iodine nutrition. 
 
In this RCT in both the groups of women, TT4 levels were higher 
during pregnancy than in the postpartum period. In a longitudinal 
study done in 20 pregnant women from a borderline iodine deficient 
area, TT4 levels were increased during pregnancy when compared to 
postpartum levels (48). In a cross-sectional study of healthy, iodine-
sufficient Swedish pregnant women across trimesters and 
postpartum, T4 concentrations were both higher during pregnancy 
than in the postpartum period. T4 levels remained stable throughout 
pregnancy (49). Results from randomised trials of iodine 
supplementation (n=54,108; 200, 230 µg iodine/day from 11/17 wk 
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to term) in mild-to-moderately iodine deficient pregnant women 
showed no significant effect of intervention on T4 (41, 42). The 
results from this study showed that in both the groups of women, fT4 
levels decreased in the second and third trimester but returned to 
first trimester levels in the postpartum period. Even though there 
was a borderline significant change in the interaction term, this was 
not clinically significant (with a 0.009% difference between the slopes 
of the two groups). It has been reported that the highest levels of fT4 
occur in the first trimester, and gradually decrease over the 
remainder of the pregnancy (49-52). A gradual decrease of the fT4 
level during pregnancy, with its lowest level in the third trimester, 
has been reported in iodine-sufficient areas (34, 51, 53, 54). A study 
carried out in Japan showed that 3 to 4 days after delivery the values 
of both free thyroid hormones were already significantly higher than 
in the third trimester of pregnancy (53). In a cross-sectional study in 
Denmark, iodine supplement use (150 µg/day) showed significantly 
higher fT4 compared to the non-supplement group at term (39). 
Results from randomised trials of iodine supplementation (n=66,54; 
150, 200 µg iodine/day from 11/17 wk to term) in mild-to-moderately 
iodine deficient pregnant women showed no significant differences in 
maternal fT4 between groups (40, 42). In a prospective, randomized, 
open-label trial, Antonangeli et al. (44) supplemented MID pregnant 
women (n=67; median UI 74 µg/g cr) with 50 µg or 200 µg iodine/day 
from 18-26 wk to 29-33 wk. There were no differences in maternal fT4 
between groups.  
 
In our study, TSH increased in both groups of women from first 
trimester through pregnancy, decreased at 6 wks postpartum and 
then increased again until 2 years after delivery; TT3 levels were 
higher during pregnancy than in the postpartum period ; fT3 levels 
were lower in the postpartum period compared to their pregnancy 
levels; fT3/fT4 ratio were lower in the postpartum period compared to 
their pregnancy levels; Tg and TT3/TT4 ratio remained more or less 
in the same range of values throughout pregnancy and postpartum 
period. Our findings suggest that the changes in maternal thyroid 
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hormone levels during pregnancy reflect physiological changes and 
occur in pregnant women irrespective of their iodine nutrition.  
 
One of the concerns about iodine intake in pregnancy and 
postpartum has been the risk of exacerbating thyroid autoimmunity 
(55). In this study, the prevalence of elevated TPO-Ab titers was 
similar in the intervention and placebo groups at baseline (12.7 vs 
12.3%). In the intervention group, the prevalence did not change 
during the second (12.1%) and third trimesters (13.2%) until the 
postpartum period; 6 wks (12.4%), 6 months (16.7%), 1 year (11.3%), 
2 year (10.3%). The placebo group showed a decrease in prevalence 
at subsequent trimesters (8.3 and 9.7%) with an increase in the 
postpartum period; 6 wks (14.1%), 6 months (10.3%), 1 year (12.1%), 
2 year (17.9%). In previous maternal iodine supplementation studies 
in areas of mild-to-moderate iodine deficiency, supplementation did 
not induce or worsen postpartum thyroiditis (40) or induce 
autoimmunity (41). From this longitudinal study, we have shown 
that iodine supplementation even in iodine sufficient pregnant 
women is safe and does not increase the risk of thyroid 
autoimmunity. 
 
There was no difference in any of the clusters of the NBAS at 1 week 
postpartum but at 6 weeks, infants in the intervention group scored 
significantly higher in the orientation cluster (8.1 vs 7.1) (p=0.018). 
Our results are the first from an iodine intervention trial but similar 
to an earlier case-control study where infants of women with 
hypothyroxinemia at 12 weeks had significantly lower scores on 
NBAS orientation index compared with controls (56). We also found 
that in the cognitive assessment at 1 year unadjusted expressive 
communication was statistically significantly different between the 
two groups with children born to mothers who received placebo 
performing better on BSID-III. However, this difference might be a 
transient effect since it did not sustain at 2 yrs of age. On the BRIEF-
P at 2 years, inhibition scores were significantly higher in the 
children of mothers in the placebo group compared to those whose 
mothers received iodine during pregnancy, indicative of executive 
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dysfunction. In a population-based cohort that examined the 
association between maternal urinary iodine during early pregnancy 
and executive functioning in children at 4 y of age, it was found that 
the children of mothers with low urinary iodine showed higher scores 
on the problem scales of inhibition (β =0.05 (95% CI: 0.01, 0.10), P = 
0.03) and working memory (β = 0.07 (95% CI: 0.02, 0.12), P = 0.003) 
(63). Mildly-deficient maternal iodine intake during pregnancy may 
have different effects in the mother and fetus. It has been suggested 
that their response varies, with the mother more likely to maintain 
euthyroidism while the fetus may become hypothyroid (57). This 
might explain why we found modest impairments in newborn infant 
development despite the lack of a measurable intervention effect on 
maternal thyroid function. Increasingly, studies are using measures 
of executive function as they have been linked to future development 
of disorders of childhood psychopathology such as attention deficit 
and hyperactivity disorder. Future studies are needed to show if 
these children develop later differences in cognitive development. 
 
In this RCT, in both the groups of women, thyroid volume increased 
systematically through the pregnancy and postpartum period with a 
similar pattern observed also for TSH. At 2 year postpartum, thyroid 
volume had increased by 34% and 38% from baseline in the 
intervention and placebo group respectively. Our study suggests that 
the goitrogenic effect of pregnancy may be mediated via increased 
TSH secretion and that the thyroid volume increase during 
pregnancy is primarily the result of increased vasculature of the 
gland, independent of the iodine supply. A longitudinal observational 
study done in 20 pregnant women from a borderline iodine deficient 
area also showed a goitrogenic effect of pregnancy which was 
unexplained by alterations in thyroid function variables (48). In that 
study, thyroid volume increased during pregnancy but not in the 
postpartum period while TSH level was unaltered during pregnancy 
when compared with postpartum levels, although TSH levels at 2 
years showed a 33% increase from the baseline level at 18 weeks of 
pregnancy (48). Berghout and Wiersinga (50) reviewed that in 
countries affected by mild or moderate iodine deficiency (Ireland, 
95 
 
Germany, Belgium, Italy, Denmark), thyroid volume increases 15-31% 
during pregnancy, while in iodine-sufficient countries (Finland, USA, 
the Netherlands), there is little or no increase in thyroid volume during 
pregnancy (50). Results from randomised trials of iodine 
supplementation (n=35-120; 50-230 µg iodine/day from 
11/14/17/18 wk to term) in mild-to-moderately iodine deficient 
pregnant women have shown varied results. There was no significant 
effect of intervention on maternal thyroid volume (41, 44), treated 
women had smaller thyroid volumes compared to controls (1), 
maternal thyroid volume increased 16% in the treated group vs. 30% 
in controls (42), thyroid volume did not change in the treated group 
while in the controls, there was a 16% increase in thyroid volume 
(43).  
 
In this study, median cord blood TSH, median dried blood spot TSH 
and T4, and prevalence of TSH >5mIU/L and UIC <100 µg/l was not 
different between neonates in both the groups. Earlier RCT’s of iodine 
supplementation (n= 54-120; 100-230 µg iodine/day from 11/14/17 
wk to term) conducted in mild-to-moderately iodine deficient 
pregnant women, reported no effect of intervention on newborn TSH 
(41), maternal or cord T3, FT4, and T3/T4 ratio (1), maternal or cord 
T4, T3, and FT4 (42). Newborns of the treated group had significantly 
higher UI, smaller thyroid volumes (1) and lower Tg concentrations 
compared to controls (1, 42). Our findings suggest that maternal 
iodine supplementation in iodine sufficient regions does not result 
impact significantly on neonatal thyroid function.  
 
In this RCT, maternal iodine supplementation did not seem to affect 
infant birth weight. Between newborns born to mothers who received 
200 µg iodine daily and placebo during pregnancy, the prevalence of 
low birth weight (22.8 vs 17.4%), small-for-gestational-age (35.4 vs 
24.8%) and pre-term (8.0 vs 8.6%) was comparable and not 
statistically significant between the two groups. Iodine repletion of 
pregnant women improved head circumference in a severely iodine-
deficient area of western China (82) while significantly increased 
placental and birth weights were reported in a region of endemic 
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goiter area in Algeria (58). In a prospective cohort study nested in a 
Bangladeshi population-based randomized supplementation trial in 
pregnant women, maternal iodine status at an average gestational 
age  of 8 weeks, was positively associated with weight, length, and 
head circumference in male newborns up to ~1 mg/L maternal UIC. 
But in this study, ~60% of these measurements were done mostly 
within 72 hr of birth and therefore may not truly reflect the 
association with birth weight (59). An earlier study on Spanish 
infants looking at associations of thyroid function with birth weight 
or SGA suggested that iodine status during pregnancy may be related 
to prenatal growth (36) but to date there is no conclusive evidence for 
this. 
 
Measurement of FT4 by isotope dilution tandem mass spectrometry 
provides accurate and reliable results during pregnancy, but these 
assays are not broadly available. In contrast, automated 
immunoassays are currently the most widely used systems for 
measuring fT4, but they are variously biased by several factors, 
which are responsible for significant method-dependent variations in 
FT4 measurement in pregnancy (60). A recent review did not 
recommend using fT4 as a screening tool since there are considerable 
method-dependent variations in free T4 assessment during 
pregnancy (61). According to CDC/ATA recommendation, FT4 
estimate methods are sensitive to abnormal binding-protein states 
such as pregnancy and there is no absolute FT4 value that will define 
hypothyroxinemia across methods. While TT4 changes in pregnancy 
are predictable and not method-specific, TT4 <100 nmol/L was 
indicative of hypothyroxinemia in pregnancy (25). We therefore used 
these recommendations and adjusted the non-pregnant reference 
range by a factor of 1.5 to derive at a new reference range (87-241.5 
nmol/L), the lower limit of which fell close to 100 nmol/L  (CDC/ATA 
recommendation)(10, 25) . This was useful in interpreting the data on 
fT4 and TT4. In this iodine sufficient pregnant population, 
irrespective of iodine supplementation, fT4 decreased and TT4 
increased during pregnancy. While the prevalence of low titres of 
these hormones was quite low for TT4 (0.8-2.9%), this prevalence 
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was quite high for fT4 (26.3-40.4%) in the second and third trimester 
respectively. Currently, using TSH along with fT4 is considered to be 
the best screening measure for women at risk of thyroid dysfunction 
during pregnancy. Considering serum TSH may be a less sensitive 
measure of mild thyroid hormone deficiency in early pregnancy, use 
of TT4 and not fT4 might improve clinical screening performance for 
thyroid disorders in pregnancy.   
 
The overall dropout rate was 30.4% and 31.2% at delivery and 72 hrs 
in the intervention and placebo group respectively, which was close 
to the anticipated dropout rate of ~25% and the number of women 
(n=125) that were required in each group and thus the statistical 
power of the study appeared to be adequate. However, we had only 
64 neonatal TSH from blood spots at delivery (cord blood) each in the 
intervention and placebo group which increased to 92 and 93 
respectively at 72 hrs. But since there were no differences in the 
prevalence of elevated neonatal TSH at delivery and 72 hrs (which 
was the basis of our sample size calculation) we are confident that 
addition of more numbers to the existing data would have not made 
any difference in the study findings. Moreover, throughout the study, 
women who dropped out were equally divided between the two 
groups for various reasons: adverse events, women/family not willing 
to continue using the supplements, moved out of the study area, re-
pregnant. Thus we feel that the exposure itself was not the reason for 
the dropout rate and hence the findings of the study are inferential. 
 
In conclusion, our findings indicate that the changes in maternal 
thyroid hormone levels during pregnancy reflected physiological 
changes and occurred irrespective of iodine supplementation. 
However, additional iodine supplemented to iodine sufficient 
pregnant women is safe and does not increase thyroid autoimmunity, 
which is reassuring. Though there were no significant effects of 
iodine supplementation on neonatal and maternal thyroid function 
and birth outcomes, there were modest effects on neurocognitive 
development of children as assessed by executive function of children 
at 2 years. However, there are concerns over reliability of 
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neurocognitive assessments in children less than 4 yrs of age and 
thus follow-up of these children would provide further insights. 
Although salt iodization is likely to be a more effective and equitable 
strategy to increase iodine intakes in populations, iodine 
supplementation to pregnant women should be considered as an 
important interim measure of ensuring optimal iodine nutrition until 
universal salt iodization reaches all strata of the population.  
 
Acknowledgements: We thank the pregnant women, their children 
and families for participation in the study. We are thankful to the 
doctors, nurses and technical staff at St Martha’s Hospital and St 
John’s Medical College and Hospital for their support. We also 
acknowledge Dr Sumithra Muthayya for her contribution to the 
study and the research team at St John’s Research Institute; Ms  
Madhumitha J., Ms Menega Mary, Ms Usha Rani, Ms Ramya H.P., 
Ms Vimala Rani, Ms Mumtaj Begum, Ms Manjula M., Ms Arathi Rao, 
Ms. Ramya P.S., Ms Poornima R., Ms Ramya, Ms Shilpa K., Ms. 
Manjula, Ms Bindiya, Ms Chetana J.K, Mr Nanjappa and Mr Arul R 
for technical support. We thank Dr Chetana Basavaraj, Dr Gautam 
Pranesh, Uma S. Unni, Christophe Zeder, Sara Stinca, Ozel Birge for 
conducting the thyroid function and UIC measurements. We also 
thank Dr. Hendriek Boshuizen for her advice on statistical analysis. 
Iodine and placebo tablets were donated in kind by MERCK KGaA, 
Darmstadt, Germany. 
Financial support: This work was supported by the Nestlé 
Foundation, Lausanne, Switzerland. The Nestlé Foundation had no 
role in the design, analysis or writing of this article.  
 
Conflicts of interest: None. 
  
Ethics of human subject participation: The study was conducted in 
accordance with the guidelines laid down in the Declaration of 
Helsinki and all procedures involving pregnant women and their 
children were approved by the institutional ethical review boards at 
St John’s National Academy of Health Sciences and St Martha’s 
Hospital, Bangalore, India. The study was explained in detail to the 
99 
 
participating women and written informed consent from each 
participant was obtained at recruitment. 
 
References 
 
1. Glinoer D., De Nayer P., Delange F., Lemone M., Toppet V., Spehl M., 
Grün J.P., Kinthaert J., B. L 1995 A randomized trial for the 
treatment of mild iodine deficiency during pregnancy: maternal and 
neonatal effects. J Clin Endocrinol Metab 80(1):258-69. 
2. Shepard T.H. 1967 Onset of function in the human fetal thyroid: 
biochemical and radioautographic studies from organ culture. J Clin 
Endocrinol Metab 27(7):945-958. 
3. Thilly C.H., Delange F., Lagasse R., et al. 1978 Fetal hypothyroidism 
and maternal thyroid status in severe endemic goiter. J Clin 
Endocrinol Metab 47:354-360. . 
4. Silva J.E., Silva S. 1981 Interrelationships among serum thyroxine, 
triiodothyronine, reverse triiodothyronine, and thyroid-stimulating 
hormone in iodine-deficient pregnant women and their offspring: 
effects of iodine supplementation. . J Clin Endocrinol Metab 52:671-
677. 
5. Becker D.V., Braverman L.E., Delange F., et al. 2006 Iodine 
supplementation for pregnancy and lactation -United States and 
Canada: recommendations of the American Thyroid Association. 
Thyroid 16: 949-951. 
6. Dunn J.T., Delange F. 2001 Damaged reproduction: the most 
important consequence of iodine deficiency. . J Clin Endocrinol 
Metab 86: 2360- 2363. 
7. Hynes K.L., Otahal P., Hay I., Burgess J.R. 2013 Mild iodine 
deficiency during pregnancy is associated with reduced educational 
outcomes in the offspring: 9-year follow-up of the gestational iodine 
cohort. J Clin Endocrinol Metab 98(5):1954-62. doi: 
10.1210/jc.2012-4249. Epub 2013 Apr 30. 
8. Henrichs J., Bongers-Schokking J.J., Schenk J.J., Ghassabian A., 
Schmidt H.G., Visser T.J., Hooijkaas H., de Muinck Keizer-Schrama 
S.M., Hofman A., Jaddoe V.V., al. e 2010 Maternal thyroid function 
100 
 
during early pregnancy and cognitive functioning in early childhood: 
the Generation R Study. J Clin Endocrinol Metab 95:4227-34. 
9. WHO/UNICEF/ICCIDD 2007 Assessment of iodine deficiency 
disorders and monitoring their elimination: a guide for programme 
managers. 3rd ed, World Health Organization, Geneva. 
10.Stagnaro-Green A., Abalovich  M., Alexander  E., Azizi  F., Mestman  
J., Negro  R., Nixon  A., Pearce  E.N., Soldin  O.P., Sullivan  S., 
Wiersinga  W. 2011 The American Thyroid Association Taskforce on 
Thyroid Disease During Pregnancy and Postpartum. Guidelines of 
the American Thyroid Association for the diagnosis and management 
of thyroid disease during pregnancy and postpartum. Thyroid 
21:1081-1125. 
11.Charlton K.E., Yeatman H., Brock E. 2013 Iodized baking salt 
improves iodine intakes in Australian pregnant women, but they still 
need iodine supplements to achieve sufficient intakes. Prev Med 57, 
26-30. 
12.De Groot L., Abalovich M., Alexander E.K., Amino N., Barbour L., 
Cobin R.H., Eastman C.J., Lazarus J.H., Luton D., Mandel S.J., 
Mestman J., Rovet J., Sullivan S. 2012 Management of thyroid 
dysfunction during pregnancy and postpartum: an Endocrine Society 
clinical practice guideline. J Clin Endocrinol Metab Aug;97(8):2543-
65. doi: 10.1210/jc.2011-2803. 
13.Sadou H., Seyfoulaye A., Alma M.M., Daouda H. 2014 Inadequate 
status of iodine nutrition among pregnant women residing in three 
districts of Niamey, the Niger Republic's capital. Maternal & Child 
Nutrition 10(4): 650-656. 
14.Zhou S.J., Anderson A.J., Gibson R.A., Makrides M. 2013 Effect of 
iodine supplementation in pregnancy on child development and other 
clinical outcomes: a systematic review of randomized controlled 
trials. Am J Clin Nutr 98:1241-54. 
15.Zimmermann M.B. 2007 The adverse effects of mild-to-moderate 
iodine deficiency during pregnancy and childhood: a review. Thyroid 
17, 829-835 (erratum in: Thyroid 2008 18, 97). 
16.Bath S.C., Steer C.D., Golding J., Emmett P., Rayman M.P. 2013 
Effect of inadequate iodine status in UK pregnant women on 
cognitive outcomes in their children: results from the Avon 
101 
 
Longitudinal Study of Parents and Children (ALSPAC). Lancet Jul 
27;382(9889):331-7.doi:10.1016/S0140-6736(13)60436-5. Epub 
2013 May 22. 
17.Zhang L., Teng W., Liu Y., Li J., Mao J., Fan C., Wang H., Zhang H., 
Shan Z. 2012 Effect of maternal excessive iodine intake on 
neurodevelopment and cognitive function in rat offspring. BMC 
Neurosci Oct 8;13:121. doi: 10.1186/1471-2202-13-121. 
18.Rebagliato M., Murcia M., Espada M., et al. 2010 Iodine intake and 
maternal thyroid function during pregnancy. Epidemiology 21, 62-
69. 
19.Murcia M., Rebagliato M., In˜ iguez C., Lopez-Espinosa M.J., 
Estarlich M., Plaza B., Barona-Vilar C., Espada M., Vioque J., 
Ballester F. 2011 Effect of Iodine Supplementation during Pregnancy 
on Infant Neurodevelopment at 1 Year of Age. . Am J Epidemiol 
173(7):804-812. 
20.WHO Expert Committee. Physical status: The use and interpretation 
of  anthropometry Geneva: World Health Organization 1995. p47. 
WHO Technical Report Series 894. 
21.Pino S., Fang S.L., Braverman L.E. 1996 Ammonium persulfate: a 
safe alternative oxidizing agent for measuring urinary iodine. Clin 
Chem 42:239-243. 
22.Pino S., Fang S.L., Braverman L.E. 1996 Ammonium persulfate: a 
safe alternative oxidizing agent for measuring urinary iodine. Clin 
Chem 42:239-243. 
23.Jaiswal N., Melse-Boonstra A., Thomas T., Basavaraj C., Sharma 
S.K., Srinivasan K., Zimmermann M.B. 2014 High Prevalence of 
Maternal Hypothyroidism Despit Adequate Iodine Status in Indian 
Pregnant Women in the First Trimester. Thyroid 24(9):1419-1429. 
24.Mannisto T., Surcel H.M., Ruokonen A., Vaarasmaki M., Pouta  A., 
Bloigu  A., Jarvelin M.R., Hartikainen  A.L., Suvanto  E. 2011 Early 
pregnancy reference intervals of thyroid hormone concentrations in a 
thyroid antibody-negative pregnant population. . Thyroid 21:291-
298. 
25.Mandel S.J., Spencer C.A., Hollowell J.G. 2005 Are detection and 
treatment of thyroid insufficiency in pregnancy feasible? . Thyroid 
15; 1: 44-53. 
102 
 
26.Torresani T.E., Scherz R. 1986 Thyroid screening of neonates 
without use of radioactivity: evaluation of time-resolved 
fluoroimmunoassay of thyrotropin. Clin Chem 32: 1013-16. 
27.Brazelton T.B., Nugent J.K. 1995 Neonatal Behavioral Assessment 
Scale, 3rd edition. Mac Keith Press, London. 
28.Bayley N. 2006 Bayley Scales of Infant and Toddler Development.3rd 
ed. San Antonio, TX: Harcourt Assessment. 
29.Alvarez J.A., Emory E. 2006 Executive function and the frontal 
lobes: a metaanalytic review. Neuropsychol Rev 16:17-42. 
30.Gioia G.A., Isquith P.K., Guy S.C., Kenworthy L. 2000 Behavior 
rating inventory of executive function. Child Neuropsychol 6:235-8. 
31.Gioia G.A., Espy K.A., Isquith P.K. The Behavior Rating Inventory of 
Executive Function-Preschool version (BRIEF-P). Odessa (FL): 
Psychological Assessment Resources; 2003. 
32.World Health Organisation., United Nations Children’s Fund., 
International council for the control of iodine deficiency disorders. 
1994 Indicators for assessing iodine deficiency disorders and their 
control through salt iodization. WHO/NUT/946 edition World Health 
Organisation, Geneve, Switzerland. 
33.Caron P., Hoff M., Bazzi S., Dufor A., Faure G., Ghandour I., Lauzu 
P., Lucas Y., Maraval D., Mignot F., Re´ssigeac P., Vertongen F., 
Grange´ V. 1997 Urinary iodine excretion during normal pregnancy 
in healthy women living in the southwest of France: correlation with 
maternal thyroid parameters. . Thyroid 7:749-754  
34.Elnagar B., Eltom A., Wide L., Gebre-Medhin M., Karlsson F.A. 1998 
Iodine status, thyroid function and pregnancy: study of Swedish and 
Sudanese women. . Eur J Clin Nutr 52(5):351-5. 
35.Smyth P.P. 1999 Variation in iodine handling during normal 
pregnancy. Thyroid 9:637-642. 
36.Alvarez-Pedrerol M., Guxens M., Mendez M., Canet Y., Martorell R., 
Espada M., Plana E., Rebagliato M., Sunyer J. 2009 Iodine levels and 
thyroid hormones in healthy pregnant women and birth weight of 
their offspring. Eur J Endocrinol 160:423-9. 
37.Kung A.W., Lao T.T., Chau M.T., Tam S.C., Low L.C.K. 2000 
Goitrogenesis during pregnancy and neonatal hypothyroxinaemia in 
a borderline iodine sufficient area. Clin Endocrinol (Oxf) 53:725-731. 
103 
 
38.Bath S.C., Walter A., Taylor A., Wright J., Rayman M.P. 2014 Iodine 
deficiency in pregnant women living in the South East of the UK: the 
influence of diet and nutritional supplements on iodine status. Br J 
Nutr 111(9):1622-31. doi: 10.1017/S0007114513004030. . 
39.Nohr S.B., Laurberg P. 2000 Opposite variations in maternal and 
neonatal thyroid function induced by iodine supplementation during 
pregnancy. J Clin Endocrinol Metab 85:623-7. . 
40.Nohr S.B., Jorgensen A., Pedersen K.M., Laurberg P. 2000 
Postpartum thyroid dysfunction in pregnant thyroid peroxidase 
antibody-positive women living in an area with mild to moderate 
iodine deficiency: is iodine supplementation safe? J Clin Endocrinol 
Metab 85:3191-8. 
41.Liesenkötter K.P., Göpel W., Bogner U., Stach B., Grüters A. 1996 
Earliest prevention of endemic goiter by iodine supplementation 
during pregnancy. Eur J Endocrinol 134:443-448. 
42.Pedersen K.M., Laurberg P., Iversen E., Knudsen P.R., Gregersen 
H.E., Rasmussen O.S., et al. 1993 Amelioration of some pregnancy-
associated variations in thyroid function by iodine supplementation. . 
J Clin Endocrinol Metab 77(4):1078-83. 
43.Romano R., Jannini E.A., Pepe M., Grimaldi A., Olivieri M., Spennati 
P., Cappa F., D'Armiento M. 1991 The effects of iodoprophylaxis on 
thyroid size during pregnancy. Am J Obstet Gynecol 164:482-485. 
44.Antonangeli L., Maccherini D., Cavaliere R., Di Giulio C., Reinhardt 
B., Pinchera A., et al. 2002 Comparison of two different doses of 
iodide in prevention of gestational goiter in marginal iodine 
deficiency: a longitudinal study. . Eur J Endocrinol 147(1): 29-34. 
45.Fuse Y., Ohashi T., Yamaguchi S., Yamaguchi M., Shishiba Y., Irie 
M. 2011 Iodine status of pregnant women and postpartum Japanese 
women: effect of iodine intake on maternal and neonatal thyroid 
function in an iodine-sufficient area. J Clin Endocrinol Metab 96(12): 
3846-3854. 
46.Smyth P.P., Smith D.F., Sheehan S., Higgins M., Burns R., O'Herlihy 
C. 2007 Short-term changes in maternal and neonatal urinary iodine 
excretion. Thyroid Mar;17(3):219-22. 
47.Fister P., Gaberscek S., Zaletel K., Krhin B., Hojker S., Gersak K. 
2011 Thyroid function in the third trimester of pregnancy and after 
104 
 
delivery in an area of adequate iodine intake. Int J Gynaecol Obstet 
112(1):52-5. doi: 10.1016/j.ijgo.2010.07.029. . 
48.Rasmussen N.G., Hornnes P.J., Hegedüs L. 1989 
Ultrasonographically determined thyroid size in pregnancy and 
postpartum: the goitrogenic effect of pregnancy. . Am J Obstet 
Gynecol 160(5 Pt 1):1216-20. 
49.Soldin O.P., Tractenberg R.E., Hollowell J.G., Jonklaas J.G., Janicic 
N., Soldin S.J. 2004 Trimester specific changes in maternal thyroid 
hormone, thyrotropin and Thyroglobulin concentrations during 
gestation: trends and associations across trimesters in iodine 
sufficiency. Thyroid 14(12):1084-90. 
50.Berghout A., Wiersinga W.M. 1998 Thyroid size and thyroid function 
during pregnancy: an analysis. . Eur J Endocrinol 138(5):536-42. 
51.Marwaha R.K., Chopra S., Gopalakrishnan S., Sharma B., Kanwar 
R.S., Sastry A., et al. 2008 Establishment of reference range for 
thyroid hormones in normal pregnant Indian women. . BJOG 
115(5):602-6. 
52.Berghout A., Endert E., Ross A., Hogerzeil H.V., Smits J., Wiersinga 
W. 1994 Thyroid function and thyroid size in normal pregnant 
women living in an iodine-replete area. Clin Endocrinol 41(3):375-9. 
53.Kurioka H., Takahashi K., Miyazaki K. 2005 Maternal thyroid 
function during pregnancy and in puerperal period. Endocr J 
52(5):587-91. 
54.Stricker R., Echenard M., Eberhart R., Chevailler M.C., Perez V., 
Quinn F.A., et al. 2007 Evaluation of maternal thyroid function 
during pregnancy: the importance of using gestational age-specific 
reference intervals. Eur J Endocrinol 157(4): 509-14. 
55.Laurberg P., Cerqueira C., Ovesen L., Rasmussen L.B., Perrild H., 
Andersen S., Pedersen I.B., Carle A. 2010 Iodine intake as a 
determinant of thyroid disorders in populations. . Best Pract Res Clin 
Endocrinol Metab 24:13-27. 
56.Kooistra L., Crawford S., van Baar A.L., Brouwers E.P., Pop V.J. 
2006 Neonatal effects of maternal hypothyroxinemia during early 
pregnancy. Pediatrics 117: 161-167. 
105 
 
57.de Escobar G.M., Obregon M.J., del Rey F.E. 2007 Iodine deficiency 
and brain development in the first half of pregnancy. Public Health 
Nutr 10:12A:1554-70. 
58.Chaouki M.L., Benmiloud M. 1994 Prevention of iodine deficiency 
disorders by oral administration of lipiodol during pregnancy. Eur J 
Endocrinol 130:547-51. 
59.Rydbeck F., Rahman A., Grandér M., Ekström E.C., Vahter M., 
Kippler M. 2014 Maternal urinary iodine concentration up to 1.0 
mg/L is positively associated with birth weight, length, and 
headcircumference of male offspring. . J Nutr Sep;144(9):1438-44. 
doi: 10.3945/jn.114.193029. 
60.Moleti M., Trimarchi F., Vermiglio F. 2011 Doubts and concerns 
about isolated maternal hypothyroxinemia. . Journal of Thyroid 
Research 2011: 463029. 
61.Ghassabian A., Henrichs J., Tiemeier H. 2014 Impact of mild thyroid 
hormone deficiency in pregnancy on cognitive function in children: 
lessons from the Generation R Study. . Best Pract Res Clin 
Endocrinol Metab 28(2):221-32. doi: 10.1016/j.beem.2013.04.008. 
 
 
 
 
 
 
106 
 
107 
 
Chapter 3 
 
The iodized salt programme in 
Bangalore, India provides 
adequate iodine intakes in 
pregnant women and more-than-
adequate iodine intakes in their 
children 
 
Nidhi Jaiswal, Alida Melse-Boonstra, Surjeet Kaur 
Sharma, Krishnamachari Srinivasan, Michael B 
Zimmermann.  
 
 
 
 
 
 
 
 
 
Public Health Nutr 2014; Apr 24:1-11. doi: 
10.1017/S136898001400055X 
108 
 
Abstract  
Objective: To compare the iodine status of pregnant women and 
their children who were sharing all meals in Bangalore, India.  
 
Design: A cross-sectional study evaluating demographic 
characteristics, household salt iodine concentration and salt usage 
patterns, urinary iodine concentrations (UIC) in women and children, 
and maternal thyroid volume (ultrasound). 
 
Setting: Antenatal clinic of an urban tertiary-care hospital, which 
serves a low-income population. 
 
Subjects: Healthy pregnant women in all trimesters, aged 18–35 
years, who had healthy children aged 3–15 years. 
 
Results: Median (range) iodine concentrations of household 
powdered and crystal salt were 55·9 (17·2–65·9) ppm and 18·9 (2·2–
68·2) ppm, respectively. The contribution of iodine-containing 
supplements and multi-micronutrient powders to iodine intake in the 
families was negligible. Adequately iodized salt, together with small 
amounts of iodine in local foods, were providing adequate iodine 
during pregnancy: (i) the overall median (range) UIC in women was 
172 (5–1024) μg/l; (ii) the median UIC was >150 μg/l in all 
trimesters; and (iii) thyroid size was not significantly different across 
trimesters. At the same time, the median (range) UIC in children was 
220 (10–782) μg/l, indicating more-than-adequate iodine intake at 
this age. Median UIC was significantly higher in children than in 
their mothers (P =0·008). 
 
Conclusions: In this selected urban population of southern India, 
the iodized salt programme provides adequate iodine to women 
throughout pregnancy, at the expense of higher iodine intake in their 
children. Thus we suggest that the current cut-off for median UIC in 
children indicating more-than-adequate intake, recommended by the 
WHO/UNICEF/International Council for the Control of Iodine 
Deficiency Disorders may, need to be reconsidered. 
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Introduction  
 
Universal salt iodization (USI) is a mass fortification approach that is 
intended to cover the iodine requirements of all individuals in the 
population; it is estimated that 128 countries have established 
iodized salt programmes (1). As USI programmes mature in many 
countries, greater emphasis is being placed on ensuring that USI 
meets the increased needs of pregnant women because of the risk of 
irreversible fetal brain damage due to iodine deficiency (2, 3). Another 
focus of mature programmes is the need for careful monitoring to 
avoid not only iodine deficiency but also iodine excess(1). Median 
urinary iodine concentration (UIC) in school-aged children (SAC) and 
household access to adequately iodized salt based on national 
standards are routinely used as the primary indicator of the impact 
of USI programmes. However, the iodine requirement of SAC is 
disproportionately lower than that of pregnant women, which leaves 
only a narrow intake range to meet the needs of pregnant women 
without leading to more-than-adequate intake in children according 
to the current UIC cut-off of 200μg/l(4). The 
WHO/UNICEF/International Council for the Control of Iodine 
Deficiency Disorders (ICCIDD) have estimated that the iodine 
requirement during pregnancy is increased by >50% compared with 
non-pregnancy in order to compensate for the increased need for 
thyroid hormones in the mother and fetus (4). The 
WHO/UNICEF/ICCIDD have also stated that an established USI 
programme with adequate salt iodine levels and good population 
coverage can meet the high iodine requirement of pregnant women. 
However, there are concerns that this may be possible only at the 
expense of more-than-adequate and excessive intakes, reflected by 
UIC in the range of 200–299 μg/l and >300 μg/l, respectively, in 
SAC.  
 
There are several reasons for this concern. The daily requirement for 
iodine during pregnancy is estimated to be 250 μg, more than twice 
the 120 μg requirement, for instance, in SAC (4). In populations 
consuming iodized salt, iodine intake during pregnancy increases 
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due to higher energy intake, but does not fully compensate for the 
higher demand for iodine. The daily energy requirement of a pregnant 
woman is 10 460 kJ/d (2500 kcal/d) in the second and third 
trimester (+1255 kJ/d (+300 kcal/d) compared with a non-pregnant 
woman), as compared with the daily energy requirement of 8368–10 
460 kJ/d (2000–2500 kcal) for SAC (5). Thus, the difference in energy 
requirement in pregnant women is only 0–25% compared with SAC, 
while the difference in iodine requirement is >100 %. The relatively 
small increase in food intake during pregnancy is therefore unlikely 
per se to provide the additional iodine requirement unless iodine-rich 
foods are preferentially selected.  
 
Adequately iodized salt at the household level is defined by WHO as 
salt containing 15–40 mg iodine/ kg(4,6), and many USI programme 
managers, aware of the irreversible effects of iodine deficiency on 
fetal development, feel justified in setting salt iodization levels near 
the upper end of the recommended range in order to ensure adequate 
iodine intake during pregnancy. However, only a limited number of 
countries have completed UIC surveys in pregnant women and 
women of reproductive age on the national or sub-national level, and 
thus there are insufficient data to directly estimate the regional or 
global prevalence of low iodine intake in these important target 
groups(7). Indian salt legislation stipulates that the iodine content in 
salt at consumption level should be at least 15 ppm(8) and USI 
remains the single most important source of dietary iodine for the 
Indian population(9). 
 
There has been a remarkable improvement in the consumption of 
adequately iodized salt in India, with the national coverage reaching 
51% in 2005–2006 and 71% in 2009(10,11). Access to iodized salt was 
higher in urban  (83·2%) than rural households (66·1%)(12); however, 
nearly 20% of households were found to be consuming inadequately 
iodized salt and 9% were using salt that was not iodized(11). A recent 
review recommended the mandatory use of adequately iodized salt in 
the mid-day meal programme for SAC in order to reach the last 30% 
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of households that are likely to be least accessible and most socio-
economically disadvantaged (13). 
 
Studies have assessed concurrent iodine intakes in SAC and 
pregnant women, and reported that USI provides adequate iodine to 
pregnant women only when iodine intakes for children are more than 
adequate (median UIC >200 μg/l) (14,15). However, these studies did 
not assess pregnant women and children from the same household 
sharing all meals together, which limits comparisons between the 
groups. Therefore, the aim of the present study was to assess iodine 
intake (based on UIC), and potential determinants of intake, in 
Indian pregnant women and their children who are sharing all meals. 
Our hypotheses were: (i) effective USI can ensure adequate iodine 
intake in pregnant women; but (ii) this may lead to more-than-
adequate or excessive iodine intake in their children. 
 
Methods 
 
The present study was carried out in southern India in Bangalore, 
one of the districts in the Indian state of Karnataka. Bangalore is 
India’s third most populous city with 9·6 million inhabitants and the 
fifth-most populous urban agglomeration (16,17). The average literacy 
rate in Karnataka is 75 %, being 69% and 88% in rural and urban 
Karnataka, respectively (18). The average literacy rate of Bangalore 
district is 88% (16) and the city is among the top ten preferred 
entrepreneurial locations in the world (19). The study site was the 
antenatal clinic (morning and evening) of the Obstetrics and 
Gynecology Department of St Martha’s Hospital, which serves 
Bangalore’s less-affluent population. The morning antenatal clinic 
operates between 08.30 and 12:30 hours and the evening antenatal 
clinic operates between 16.00 and 18.00 hours. We aimed to recruit 
200 pairs of pregnant women and their children who were sharing all 
meals in the same household. Our inclusion criteria were healthy 
pregnant women across all trimesters, aged 18–35 years, who had 
healthy children, aged 3–15 years. It is a common practice in India 
for a working mother to leave her children at their grandparents’ 
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home during the day. In such a scenario, sharing of meals from a 
common household basket does not hold. We thus excluded from the 
study such mother–child pairs. In addition, the Government of India 
runs a Mid-Day Meal Programme, one of the largest school lunch 
programmes in the world (20). This flagship programme for 
achievement of universalization of elementary education is being 
implemented in partnership with the State Government (21). The 
programme sources double-fortified salt from the Tamil Nadu Salt 
Corporation. The double fortified salt premix produces a salt with 50 
ppm iodine (as KI) and 1000 ppm Fe at production level (22). For the 
purpose of the current study, we ensured that the children we 
enrolled were not participating in this programme. Thus, the 
schoolchildren in the present study were those who were carrying 
food from home, which is a common practice in Indian settings, and 
thus sharing all meals including lunch with their mothers. We 
excluded women with a multiple pregnancy and those who were still 
breast-feeding. Data were collected from May 2008 to September 
2011. 
 
Information was obtained by a structured questionnaire and 
included: (i) age of the mother and her child; (ii) sex of the child; (iii) 
parity as per the antenatal record; (iv) number of members (adults 
and children) in the household; (v) education and occupation of the 
pregnant woman and her husband; (vi) monthly income of the 
household; (vii) household usage of iodized or noniodized salt 
including brand and type of salt; (viii) cooking practices using salt; 
(ix) average household consumption of salt; (x) use and frequency of 
seafood consumption; and (xi) knowledge of iodine and opinion on 
salt type preferred with its reason, this information was collected on 
a subset of the sample. Data on iodine intake from supplements and 
multi-micronutrient powders available in the market were collected 
from a subset of pregnant women and their children. This subset was 
a convenience sample. Crude average per capita consumption of 
powdered and crystal salt was estimated by dividing the reported 
monthly consumption of salt (using single recall) by the number of 
members in the household. 
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Pregnant women were classified into three trimesters according to 
their gestational age. This was based on their reported first day of the 
last menstrual period but, where available, first-trimester ultrasound 
scan was used. Body weight and height were recorded using 
standard anthropometric techniques (23). Weight was recorded to the 
nearest 0·1 kg using a digital weighing scale (Salters 9016, 
Tonbridge, UK). Height was recorded to the nearest 0·1 cm using a 
locally made stadiometer (Biorad, Chennai, India). 
 
A single spot urine sample, obtained throughout the day, was 
collected from all mothers and children within a week of each other. 
Samples were transported on ice, divided into aliquots and stored at 
− 20ºC until analysis. UIC was determined using the Pino 
modification of the Sandell–Kolthoff reaction (24) with external 
reference standards (C. Zeder, ETH Zurich, Switzerland). The intra-
assay CV at a mean UIC of 74, 162 and 282 μg/l (n 21 each) was 11, 
9 and 13 %, respectively. The iodine nutrition status in pregnant 
women and their children was evaluated according to the 
recommended WHO/UNICEF/ICCIDD criteria (4). Salt samples of all 
the types used by the household were collected in clean plastic 
containers and stored at − 80°C until analysis. Composite samples 
from each recognized commercial brand were analysed for iodine 
content by using iodometric titration; those from an unknown source 
were analysed only qualitatively (iodine presence: yes/no) using a 
test kit (MBI Chemicals, Chennai, India). Twenty-two duplicate 
titrations of brand specific composite samples (made by mixing 10 g 
of salt from five different households and sampling 2 × 10 g of this 
homogenized mixture for analysis) were done. It would have required 
fifty-seven more duplicate titrations to also analyse the samples from 
unknown brands individually, which was not possible within the 
resources available for this project. 
 
Thyroid gland volume of the pregnant women was measured using 
an Aloka SSD-500 Echocamera (Aloka, Mure, Japan) with a 7·5MHz 
linear transducer and ultrasound coupling gel. The thyroid volume of 
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each lobe was calculated using the formula for a prolate ellipsoid (4), 
where Thyroid volume (ml) = 0·479×length (cm)×breadth (cm)×depth 
(cm). The thyroid volume was calculated as the sum of the volumes of 
both lobes and did not include the isthmus. 
 
Statistical analyses were performed using the statistical software 
package SPSS version 14·0 and Microsoft® Excel (MS Office 2003). 
Weight-for-age Z-scores (WAZ), heightfor-age Z-scores (HAZ) and 
BMI-for-age Z-scores (BAZ) were computed from data on height, 
weight, age and gender using the WHO Anthro and AnthroPlus 
software. Data are presented as mean and standard deviation when 
normally distributed. For non-normal distributions, data are 
presented as median (range) or median (25th, 75th percentile). Mann–
Whitney and Kruskal–Wallis tests were used for comparisons and P 
values <0·05 were considered significant. Proportions were compared 
using χ2 tests. Spearman correlations were performed for 
associations. 
 
Results 
 
We recruited 226 pregnant women and their children for the study, 
and 194 complete sets of data for mother–child pairs were obtained. 
Maternal indicators are shown in Table 1; 78·3% (n 177) of the study 
women attended the outpatient clinic in the morning while 21·7% (n 
49) attended the evening clinic. Although the UIC of pregnant women 
from the morning clinic was higher than for pregnant women from 
the evening clinic (187 v. 128 μg/l), this difference was not 
statistically significant. Data on intake of iodine-containing 
supplements and multi-micronutrient powders were collected from a 
subset of pregnant women and their children (n 105). Of these, 
50·5% (n 53) of the pregnant women and 46·7% (n 49) of the children 
were consuming iodine-containing multi-micronutrient powders, 
averaging 18·5 and 15·9 μg/d, respectively. There was no significant 
difference in median UIC between mothers or children consuming 
iodine containing multi-micronutrient powders as compared with 
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those not consuming them (192 v. 163 μg/l in mothers and 228 v. 
218 μg/l in children, respectively). 
 
Table 1: Maternal indicators among the pregnant women aged 18–35 
years, Bangalore, India, May 2008 to September 2011 
Parameter n % 
Level of Education of subject  
     No formal education 
     Finished high school (10th Grade) 
     Post high school  
     University degree & above 
 
4 
98 
58 
66 
 
1.8 
43.4 
25.7 
29.2 
Level of Education of subject’s husband  
     No formal education 
     Finished high school (10th Grade) 
     Post high school  
     University degree & above 
 
2 
102 
53 
69 
 
0.9 
45.1 
23.5 
30.5 
Occupation of subject  
     Unemployed 
     Unskilled worker 
     Skilled worker 
     Others (secretarial job, teacher, shop 
owner, business) 
 
203 
2 
1 
20 
 
89.8 
0.9 
0.4 
8.8 
Occupation of subject’s husband  
     Unemployed 
     Unskilled worker 
     Skilled worker 
     Others (secretarial job, teacher, shop 
owner, business) 
 
1 
11 
49 
165 
 
0.4 
4.9 
21.7 
72.9 
Parity  
     0 
     1 
     ≥2 
 
10 
163 
52 
 
4.4 
72.4 
23.1 
Trimester of pregnancy  
     1                                                                                        
     2 
     3 
 
33
79 
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14.6
35.0 
50.4 
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Opinion on salt preference  
     Powder salt 
     Crystal salt 
     Other 
 
108 
46 
21 
 
61.7 
26.3 
12 
Reason for salt type preference  
     Taste 
     Tradition 
     Quantity 
     Health 
     Others 
 
41 
36 
39 
32 
27 
 
23.4 
20.6 
22.3 
18.3 
15.5 
Household seafood consumption per week    
     Never 61 27.0 
     < 1 time 124 54.9 
     1-2 times 35 15.5 
     >2 times 6 2.7 
Cooking practices with salt  
     Salt added during cooking 
     Salt added at the end of cooking 
 
210 
16 
 
92.9 
7.1 
Knowledge of iodine  
     Yes 
     No 
 
53 
120 
Median  
 
30.6 
69.4 
25th,75th 
percentile    
Total monthly household income (INR)  10000 (6500, 20000) 
 
We collected samples of all available salt types from the study 
households. Some households were using both powdered and crystal 
salt. In total, 275 salt samples were obtained, and 86% of the 
powdered salt samples (n 164) and 71% of the crystal salt samples (n 
106) were from a known brand; 79% (n 216) of the salt samples were 
analysed for their iodine content by titration. The median (range) 
iodine concentration of household powdered and crystal salt was 
55·9 (17·2–65·9) ppm and 18·9 (2·2–68·2) ppm, respectively. All of the 
remaining powdered salt samples (n 23) tested positive for iodine 
content by the kit method, whereas 75% of the remaining crystal salt 
samples (n 31) were iodized as determined by the kit method. Overall, 
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inadequately iodized crystal salt (<15 ppm) was found in 3·1% (n 8) of 
the households, but in each case except one with crystal salt iodine 
content of 12·7 ppm and no powdered salt use, the households had 
adequately iodized powdered salt. In the households that used both 
types of salts, crystal salt contributed 57% to the monthly salt usage. 
Regarding salt preference, 62% (n 108) of the pregnant women 
preferred powdered salt, 26% (n 46) preferred crystal salt, and 12% (n 
21) preferred both types of salts. There was a significant difference in 
the median UIC of pregnant women and children among these three 
groups of preferred salt use: powdered salt v. crystal salt v. both 
types of salt (P=0·006; 188 v. 133 v. 96μg/l in mothers and 248 v. 
151 v. 218 μg/l in children, respectively). Figure 1 shows the UIC of 
pregnant mothers and their children by usage of powdered and 
crystal salt and the salt iodine content (<45 ppm and >45 ppm). 
There was no statistically significant difference in the median UIC of 
pregnant mothers and their children between the salt iodine content 
categories among the salt type groups. The estimated average daily 
consumption of salt per capita based on dietary recall was 13 (SD 
6·8) g/d; calculated from the median iodine content in the salt 
samples, the estimated median (range) per capita iodine intake from 
salt was ≈301 (0–2283) μg/d. 
 
 
11
8 
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Maternal gestational age, anthropometrics, thyroid volume and UIC 
by trimester are shown in Table 2. Gestational age calculated from 
the date of the last menstrual period correlated highly with that from 
the uterine ultrasound scan (r=0·99, P = 0·001). Mean thyroid volume 
and median UIC did not differ significantly among trimesters. There 
was no correlation between the median UIC and thyroid volume in 
these pregnant women. The median (range) UIC in the pregnant 
women was 172 (5–1024) μg/l and indicates iodine sufficiency; the 
distribution of UIC is shown in Fig. 2(a). Overall, the estimated 
median (range) daily iodine intake as calculated from UIC in 
pregnant women was ≈278 (0–1670) μg/d assuming a daily urine 
volume of 1·5 litres and 92% dietary iodine bioavailability (5). 
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Age, anthropometrics and UIC of the children (preschoolers and SAC) 
are shown in Table 3; 45·2% of them were boys. The median (range) 
UIC in the children was 220 (10–782) μg/l, significantly higher than 
the median UIC in their mothers (P=0·008) and indicating more-than 
adequate iodine intake in this group. The distribution of UIC among 
children is shown in Fig. 2(b). Using the formula of the US Institute 
of Medicine (5) to estimate iodine intakes from UIC and body weight 
in children, a median UIC of 220 μg/l in 6–15-year-old children (n 
52) with a mean age of 7·8 years and a body weight of 24·2 kg would 
correspond to a median iodine intake of ≈140 (range 9–413) μg/d. As 
shown in Fig. 3, there was a weak but significant positive correlation 
between the UIC of the children and that of their pregnant mothers 
(r=0·160; P=0·03). By trimester, this correlation was significant only 
in the first trimester (r=0·423; P=0·035), not in the second (r=0·162; 
P=0·21) or the third (r=0·063; P=0·54). 
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Discussion 
 
The current cross-sectional study is the first to report iodine intakes 
in pregnant women and their children sharing a common household 
food basket and all meals. Based on median UIC, pregnant women 
were iodine sufficient but children had more-than-adequate iodine 
intake. A recent review concluded that when the median UIC in SAC 
or non-pregnant women indicated iodine intake was adequate or 
above requirements in a region, about half the time pregnant women 
in that same region had inadequate iodine intake (15). Multiple studies 
have reported that when SAC have adequate iodine status (median 
UIC=100–199 μg/l), pregnant women are deficient (median UIC <150 
μg/l), and that iodine sufficiency in pregnancy is attained only when 
the SAC have more-than-adequate (median UIC=200–299 μg/l) 
iodine status (14,15, 25–28). In an earlier Thai study using similar 
methodology (25) but in families where not all meals were consumed 
within the household, despite a median UIC of 200 μg/l in SAC, 
iodine intakes in pregnant women were inadequate, with a median 
UIC of only 108 μg/l. In Tasmania, iodine status of pregnant women 
before and after iodine fortification of bread was compared with 
concurrent data for schoolchildren; the data showed pregnant 
women to be iodine deficient after supplementation, while children 
were sufficient (29). Recent studies from Belgium (30) and China (31) also 
suggest that median UIC in SAC may not be a good proxy of iodine 
status in the entire population. In our data, there was a modest 
positive correlation between UIC in pregnant mothers and their 
children, and this correlation was strongest in the first trimester, 
consistent with an earlier study from Thailand (25). In a survey in 
Kyrgyzstan where children and pregnant women did not live together 
but were from the same settlements with access to the same salt 
supplies, their median UIC values were also positively correlated 
(r=0·63; P<0·001) (26). 
 
Our findings form a valuable contribution to the discussion on 
whether salt iodization programmes can adequately cover the iodine 
requirements of all population groups including that of pregnant 
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women. In our study population, the salt iodization programme was 
adequately covering the iodine requirement of pregnant women. A 
systematic review of iodine nutrition status in Indian pregnant 
women found that median UIC were in the range of 95–178 μg/l with 
60–95% of pregnant women consuming adequately iodized salt (32). A 
recent study in rural and urban settings in the Maharashtra region 
of India reported median UIC of 203 and 211 μg/l at 17 and 34 
weeks of pregnancy, suggesting adequate dietary provision at both 
gestational stages studied and implying that iodine deficiency was 
unlikely to be a frequent problem in that population(33). However, 
studies from rural India, especially in tribal populations, report 
significant iodine deficiency in pregnant women and areas where only 
19% of salt is adequately iodized (34,35). Thus, our results should not 
be generalized to less-affluent, rural areas of India where adequately 
iodized salt is not available and where pregnant women are likely to 
still have inadequate iodine intakes. Because there are wide 
variations in iodized salt quality and coverage across India, 
additional population-based studies in other regions of India are 
needed to confirm these findings. 
 
There are some previous data from the Bangalore region on iodine 
intake. The WHO Global database on iodine deficiency 2007 reported 
that the median UIC in 11–18-year-old children in the Bangalore 
urban district was 185 μg/l(36). The National Family Health Survey 
(NFHS-3) for the state of Karnataka, India (2005–2006) found 66·5 
and 27·6% of households in urban and rural areas, respectively, were 
using salt iodized at >15 ppm (10). The 2009 Coverage Evaluation 
Survey conducted by UNICEF reported that the use of non-iodized 
salt seemed more common in the state of Karnataka compared with 
other states, with 40·1, 23·9 and 35·9% of the households using non-
iodized salt (0 ppm), inadequately iodized salt (<15 ppm) and 
adequately iodized salt (≥15 ppm), respectively (12). The Iodized Salt 
Coverage Study in 2010 found only a marginal improvement from 
NFHS-3 in the consumption of adequately iodized salt in rural 
Karnataka (35·4%) and attributed this to the continued preference for 
crystal salt that tends to be less well iodized(37), which is confirmed by 
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our study. Currently, in Karnataka, iodized crystal salt is distributed 
through the public distribution system at 3·00 Indian rupees/kg (38) 
and 64·2% of the pregnant women in our study preferred powdered 
to crystal salt; this likely explains why non-iodized crystal salt was 
present in only 4% of households (but in each case, adequately 
iodized powdered salt was present) and the median UIC in pregnant 
women indicated sufficient intake. However, two-thirds of households 
(64·3%) were using both types of salt and in these households crystal 
salt contributed 57% of the monthly salt usage. Therefore, it is 
important that crystal salt, along with powdered salt, continues to be 
adequately iodized. 
 
A better understanding of the iodine sources, planned and un-
planned, is crucial for the design and monitoring of national iodine 
nutrition programmes (1). Accounting for iodized salt intake obtained 
from processed foods is becoming increasingly important, as well as 
iodine containing products such as iodine supplements, multi 
micronutrient supplements, home fortification products such as 
micronutrient powders, ready-to-use supplementary foods and, in 
some specific cases, iodine in the natural environment(1). In our 
study, the contribution of iodine containing supplements and multi-
micronutrient powders to iodine intakes was negligible; the only 
significant source of iodine was household salt, and the mean per 
capita consumption of household salt was estimated to be high, at 13 
(SD 6·8) g/d. This was a crude estimate derived by dividing the 
monthly consumption of salt by the number of members in the 
household that included both adults and children. Although our data 
provide only a rough estimate of actual salt consumption, it is in 
general agreement with the mean per capita salt intake of 11·3 (SD 
5·1) g/d calculated using 3 d weighed food records in a recent study 
in Bangalore(39). The estimated daily iodine intake in pregnant women 
and 6–15-year-old children (n 52) in the present study was ≈278 and 
140 μg/d, respectively (5). While we did not collect dietary data for 
iodine intakes in the present study, recent 24 h dietary recall intake 
data from a comparable group of pregnant women in this area found 
that these women consume a traditional South Indian meal with 
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dairy products but no bread and a minimum amount of processed 
foods (N Jaiswal, unpublished data). Thus, iodized salt is most likely 
the most important source of iodine and a secondary source could be 
dairy products in these households. However, it is important that 
native dietary sources of iodine and processed foods be identified and 
accounted for iodine intake in populations. The findings of the 
current study can likely be generalized to other households in 
Bangalore. The lunch meal the children shared with their pregnant 
mothers in the present study would be similar to that provided in the 
noon meal programme in Karnataka. The suggested menu for the 
meals in this programme are meals of rice and lentils, semolina with 
vegetables and rice, and lentils with vegetables, all cooked with 
double fortified salt containing Fe and 50 ppm iodine(40). The median 
iodine concentration of powdered salt in our study was 55 ppm. 
 
Although iodine intake in our study appeared mainly due to iodized 
salt, in other countries, both dietary intake of foods with high native 
iodine content and iodine supplements contribute to iodine intakes 
during pregnancy. For example, many Japanese eat seaweed and 
make soup stock from kelp on a daily basis; and in fact it is widely 
believed in Japanese society that seaweed intake is good for 
pregnancy (41). In the US diet, the common sources of iodine are 
iodized salt, dairy products, breads and seafood (42). To achieve a total 
of 250 μg iodine ingestion daily in North America, the American 
Thyroid Association recommends that pregnant women should 
supplement their diet with a daily oral supplement that contains 150 
μg iodine (43). However, iodine intake in the USA continues to fall and 
pregnant women are iodine deficient; despite recommendations for 
iodine supplementation by experts, iodine supplements are used by 
only 22% of US pregnant women (44). The American Thyroid 
Association also recommends that in areas of the world outside North 
America, strategies for ensuring adequate iodine intake during 
pregnancy will vary according to regional dietary patterns and 
availability of iodized salt (43). In the UK, a recent study called for 
iodine deficiency in pregnant women to be treated as an important 
public health issue, particularly considering there is no national salt 
129 
 
iodization programme and dietary guidelines from the UK 
government are outdated (45). In Australia, mandatory use of iodized 
salt (25–65 mg/kg) by bread manufacturers and a daily supplement 
intake of 150 μg iodine by pregnant women are recommended by the 
National Health and Medical Research Council as the two strategies 
to achieve optimal iodine intakes in this group (46). Using predictive 
modelling, pregnant women in New Zealand were expected to achieve 
adequate but not excessive iodine intakes when 150 μg of 
supplemental iodine was taken daily, taking into account the 
contribution of iodized salt in bread (47). However, disparities in 
supplement use by New Zealand pregnant women highlight the need 
for further efforts towards USI, such as the mandatory fortification of 
additional processed foods with iodized salt (48). 
 
A limitation of our study is the use of a single spot urine sample 
collected from pregnant mothers and their children within a week of 
each other. Considering that UIC in spot samples varies substantially 
between days and seasons (49–51), as a consequence of a circadian 
rhythm of iodine excretion (52) and due to differences in fluid 
intake(53), it would have been preferable to obtain samples at the 
same time. Although we did not attempt to estimate the proportion of 
our population with high and low intakes of iodine, a sub-sample 
collection would have removed the within-person variance thus 
permitting a correction to the population distribution. In a 
population with a median UIC in the sufficient range, this correction 
of the tails would lead to a decrease in the proportion at either 
extreme of the distribution(54). However in the present study, we 
found a good significant correlation (r=0·432; P=0·035) between the 
UIC values of the children and their pregnant mothers in their first 
trimester. 
 
We are aware of no published data that show iodine intakes by SAC 
in the more-than-adequate range indicated by a median UIC of 200–
299 μg/l have adverse effects. On the contrary, a recent study 
including data from twelve countries and more than 2500 children 
concluded that chronic iodine intakes from iodized salt resulting in 
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more-than-adequate UIC values do not cause thyroid dysfunction in 
6–12-year-old children (55). That study recommended that the more-
than-adequate iodine intake range (200–299 μg/l) should be 
reconsidered and merged with the adequate iodine intake range 
resulting in a widened range of 100–299 μg/l indicating sufficient 
intake in children (55). Earlier, it had been shown that UIC up to 500 
μg/l is not associated with thyroid volume in a large international 
sample of 6–12-year-old children with iodine intakes ranging from 
adequate to excessive (56). Most people who are iodine sufficient are 
remarkably tolerant to high dietary intakes of iodine, and intakes up 
to 1100 μg/d are tolerated well by healthy adults (5). There are 
concerns that more-than-adequate iodine intake could increase 
thyroid autoimmunity in adults (57) but findings are equivocal. 
Therefore, considering the available evidence, we feel the iodine 
intake level of the children in the current study is very likely to be 
safe. 
 
 It could be argued that the current Indian salt legislation with a cut-
off value for adequacy at 15 ppm needs a revision in the current 
scenario to incorporate a range with an upper limit for salt iodization, 
as is done in many national programme standards. According to 
WHO/UNICEF/ ICCIDD, an adequate iodine level in household salt 
is defined as salt containing 15–40 mg iodine/kg (4,6). We found a 
median (range) iodine concentration of 55·0 (17·2–65·9) μg/g in 
powdered salt and 18·9 (2·2–68·2) μg/g in crystal salt in the present 
study. Studies from Rajasthan, India and China showed that optimal 
iodine status of both children and pregnant women was attained 
when the salt iodine content was approximately 30 mg/kg (58,59). In 
the Rajasthan study, it was proposed that the iodization of household 
salt should be increased from the current level in order to provide 
optimal iodine intakes in the population (58). In a recent cross-
sectional study from Shanghai, China where the median salt iodine 
concentration was 29·5 mg/kg and 91·5% of households were using 
adequately iodized salt, pregnant women were still iodine deficient 
while the general population had adequate iodine nutrition (31). In 
Kyrgyzstan, pregnant women had adequate iodine intakes only in 
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those households where salt iodine content was ≥25 mg/kg (26). In 
these studies, salt was the main source of iodine intake in the diet. 
In populations where a substantial proportion of the total iodine 
intake comes from milk, UIC in SAC may overestimate the iodine 
status of the general adult population because milk consumption 
usually is higher in children (7). However, in most countries where 
salt is the primary source of iodine in the diet, the differences 
between children and adults is smaller and the median UIC in SAC 
may be used to represent iodine status of the population at large (60). 
 
Conclusion 
 
In conclusion, our data indicate that in this selected urban 
population of southern India, salt iodization (including iodization of 
crystal salt) ensures adequate iodine intake in pregnant women, 
although iodine intake in their children is in the more-than-adequate 
range according to current cut-off criteria. Although the study 
suggests that a well functioning iodized salt programme can provide 
adequate iodine to pregnant women, continuous monitoring of this 
critical target group is required and in populations where iodized salt 
is either not available or not adequately iodized, iodine 
supplementation during pregnancy should be considered. In 
addition, evaluation of the current recommendation to use median 
UIC in SAC as a proxy for the iodine status in the general population 
and population groups most vulnerable to iodine deficiency, such as 
young children and pregnant women, was recently recognized as a 
research priority (61). We suggest that the current 
WHO/UNICEF/ICCIDD cut-off for median UIC in children indicating 
more-than-adequate intake may need to be reconsidered to allow the 
iodized salt programme to cover the increased needs of pregnant 
women. 
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Abstract 
  
Background: Iodine requirements are increased during pregnancy to 
maintain maternal and fetal euthyroidism. There have been recent 
improvements in iodized salt coverage in India but whether iodized 
salt is sufficient to sustain iodine requirements during pregnancy 
remains uncertain. Our aims were to measure thyroid status in first 
trimester pregnant women in southern India and assess potential 
determinants of thyroid function, including iodine status, thyroid 
autoimmunity, dietary patterns, body weight and anemia. 
 
Methods:  Cross-sectional study among 334 pregnant women ≤14 
weeks of gestation, in Bangalore, India. We measured 
anthropometrics, urinary iodine concentration (UIC), maternal 
thyroid volume (by ultrasound) and thyroid function. We applied a 
thyrotropin (TSH) upper limit of 2.5 mIU/L to classify thyroid 
insufficiency. Using a questionnaire, we obtained socio-demographic 
and dietary data, obstetric history, and use of iodised salt and iodine 
supplements.  
 
Results: Among the women, the mean (standard deviation) 
gestational age was 10.3 (2.5) weeks, 67% were nulliparous, 21% 
were vegetarian, 19% were anemic and 23% were overweight or 
obese. Iodized salt was used by 98% of women, and they were iodine 
sufficient: median UIC (range) was 184.2 (8.1-1152) µg/L and all had 
a normal thyroid volume. However, 18% of the women had thyroid 
insufficiency: 3.7% had overt hypothyroidism (83% with positive 
TPO-Ab), 9.2% had subclinical hypothyroidism and 5.2% had 
hypothyroxinemia. Women consuming vegetarian diets did not have 
significantly lower iodine intakes or higher risk of hypothyroidism 
than those consuming mixed diets, but overweight/obesity and 
anemia predicted thyroid insufficiency. 
 
Conclusion: In this urban population of southern India, pregnant 
women have adequate iodine status in the first trimester. Despite 
this, many have thyroid insufficiency, and the prevalence of overt 
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hypothyroidism is more than fivefold higher than reported in other 
iodine sufficient populations of pregnant women. 
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Introduction 
 
Iodine requirements during pregnancy sharply increase to maintain 
maternal and fetal euthyroidism (1). In the first trimester, the mother 
requires additional iodine to produce and transfer thyroid hormone 
across the placenta while the fetal thyroid matures. In the second 
half of pregnancy, the fetus begins producing thyroid hormone, 
which requires additional iodine transfer from the maternal 
circulation (2). Worldwide, iodine deficiency during pregnancy is a 
leading cause of maternal thyroid insufficiency, which can 
irreversibly impair fetal brain development, and the first trimester is 
a particularly vulnerable period (1). Thus, in iodine deficient 
populations, prevention of hypothyroidism and cretinism is most 
effective when iodine is supplied to women before or very early after 
conception (3).  
 
The World Health Organization states that an established universal 
salt iodization program with adequate salt iodine levels and good 
population coverage can meet the increased iodine requirement of 
pregnant women (4). However, maternal iodine insufficiency is 
prevalent even in countries with established programs (5-9). India, 
because of its large population, high birth rate and iodine deficient 
soils, has until recently had a large number of infants potentially 
exposed to in utero iodine deficiency (10). However, household 
coverage of iodized salt has increased, and it is now estimated that 
>70% of households in India have access to iodized salt (10). 
Nevertheless, recent studies highlight the presence of iodine 
insufficiency among Indian women (11). 
 
In areas of iodine sufficiency, the prevalence of overt and subclinical 
hypothyroidism during pregnancy is 0.2-0.4% and 3-5% respectively, 
but varies by trimester of pregnancy and the diagnostic criteria 
(particularly the thyrotropin [TSH] upper limit) used for classification 
(12). More than 90% of thyroid disorders in pregnancy are thought to 
be of autoimmune etiology (13), and chronic autoimmune thyroiditis 
is the main cause of hypothyroidism during pregnancy in iodine 
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sufficient regions (14). Two additional variables that may affect the 
maternal thyroid axis and contribute to thyroid insufficiency during 
pregnancy are iron deficiency anemia (15) and overweight/obesity (7, 
16-19), and both are common among women in urban areas of India 
(20-22). Better understanding of the pattern and prevalence of 
maternal thyroid dysfunction and associated risk factors could 
improve screening and treatment in the Indian population. Improved 
detection of maternal hypothyroidism may be particularly valuable in 
the first trimester, because thyroid function should be normalized as 
quickly as possible early in gestation (12).  
 
Therefore, the aims of this cross-sectional study were to: a) to 
measure thyroid status in first trimester pregnant women in 
southern India; and b) to assess potential determinants of thyroid 
function in this population, including iodine status, thyroid 
autoimmunity, body weight, and anemia.  
 
Subjects and methods  
 
This cross-sectional study consisted of a cohort of pregnant women 
who were screened for the Maternal Iodine supplementation and its 
effects on Thyroid function and CHild development (MITCH) study 
(Clinicaltrials.gov with the identifier NCT00791466). The parent 
study investigates the effects of oral iodine supplementation during 
pregnancy on pregnancy outcome, infant growth and offspring 
cognitive development. The study was conducted at the antenatal 
clinic of the Obstetrics and Gynecology Department of St. Martha’s 
Hospital in Bangalore, India. Pregnant women were recruited 
between December 2008 and March 2011. We conducted the study 
in accordance with the Declaration of Helsinki. Institutional ethical 
review boards at St. John’s National Academy of Health Sciences, St 
Martha’s Hospital, Bangalore, India and Wageningen University, The 
Netherlands approved the study. We explained the study in detail to 
the participating women and one member of their family, and 
obtained written, witnessed informed consent. 
 
145 
 
Study population 
 
We screened all women presenting to the antenatal clinic for 
potential inclusion in the study if they had a positive pregnancy test 
and were: a) ≥ 18 and ≤ 40 years old; and b) ≤ 14 weeks gestational 
age. Exclusion criteria were: a) chronic diseases, including diabetes, 
heart, kidney and thyroid disease, cancer, hypertension, 
tuberculosis, asthma, epilepsy, jaundice; b) a positive test for HIV, 
HbSAg or venereal diseases; c) treatment for infertility; d) previous 
repeated spontaneous abortions ( four or more); e) current multiple 
pregnancy as detected by ultrasound; and e) currently breastfeeding. 
Of the 1058 pregnant women who presented at the antenatal clinic at 
the start of their pregnancy during the study period, 1015 women 
were contacted for the study; 43 women were not contacted because, 
based on their hospital record, they did not meet the inclusion 
criteria.  Of the 1015 women contacted, 344 women were not eligible 
for the study because they did not meet the inclusion criteria. Of the 
remaining 671 pregnant women who were considered eligible, 337 
declined to participate in the study. A total of 334 pregnant women 
were eligible and consented for their participation in this study. 
There were no statistically significant differences in age, gestational 
age, education, occupation, monthly household income, height, 
weight or body mass index (BMI) between those who declined 
participation and those who agreed to participate in the study (data 
not shown).  
 
Socio-demographic and anthropometric data 
 
We used a structured multiple-choice questionnaire to obtain 
sociodemographic information on household composition, education, 
occupation, and income, as well as consanguinity and obstetric 
history, including parity. We did not collect information on family 
history of thyroid disease. We calculated gestational age from 
reported first day of the last menstrual period and confirmed this by 
using ultrasonography in 63% of the women. We recorded 
anthropometric measurements in duplicate using standard 
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techniques (23). We recorded weight to the nearest 0.1 kg by using a 
digital weighing scale (Salter’s 9016, Tonbridge, Kent, UK), and 
height to the nearest 0.1 cm by using a stadiometer (Biorad, 
Chennai, India). We calculated BMI as weight in kilograms divided by 
the square of height in metres (kg/m2); we defined overweight as BMI 
of 25.0-29.9 kg/m2 and obesity as ≥30 kg/m2 (23).  
 
Data on diet, salt and iodine supplement use 
 
By using a self reported written questionnaire, we obtained data on 
dietary habits including: a) whether the subject was a vegan, a lacto-
ovo vegetarian or nonvegetarian; b) household usage of iodized or 
noniodized salt, including brand and type of salt; c) cooking practices 
using salt; d) use and frequency of seafood and egg consumption; 
and e) knowledge of iodine nutrition and reason for iodized salt 
consumption, data on  consumption of nutritional supplements 
containing iodine or iodine containing multi-micronutrient powders, 
including quantity and length of time these supplements had been 
consumed, these data were collected from a subset of pregnant 
women. This subset was a convenience sample. 
 
Laboratory analysis 
 
We collected a casual spot nonfasting urine sample that was 
transported on ice, divided into aliquots, and stored at -20⁰C until 
analysis. We determined UIC by using the modification of Pino et al. 
the Sandell-Kolthoff reaction (24) with external reference standards 
(C. Zeder, ETH Zurich, Switzerland). At a mean UIC of 82.6 µg/L, the 
intra and inter-assay CV was 9.5% and 7.6% respectively, and at a 
mean UIC of 206.4 µg/L, the intra and inter-assay CV was 3.2% and 
5.3% respectively. We collected a nonfasting whole blood sample by 
venipuncture into plain vacutainers (BD diagnostics, Franklin Lakes, 
NJ) that was transported on ice and centrifuged to obtain serum, 
which was stored frozen at -80⁰C until analysis for TSH, total 
triiodothyronine (TT3), total thyroxine (TT4), free T3 (fT3), free T4 
(fT4), thyroglobulin (Tg), thyroid binding globulin (TBG), anti-thyroid 
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peroxidise antibodies (TPO-Ab) and anti-Tg antibodies (Tg-Ab). With 
the exception of TSH, for which trimester-specific ranges are 
available, we used the manufacturer’s recommended reference range 
for thyroid function tests. We measured TSH by using a third 
generation solid phase, two-site chemiluminescent assay (IMMULITE 
1000, Siemens Healthcare Diagnostics, Llanberis, Gwynedd, United 
Kingdom) and applied a reference range of 0.1-2.5 mIU/L  for the 
first trimester (25, 26). The percent CVs at a TSH of 0.44 and 4.75 
were 3.86% and 7.16% respectively. The analytical measurement 
range of the TSH assay was up to 75 mIU/L and its analytical 
sensitivity was 0.004 mIU/L. We measured TT4, fT4, TT3, fT3, Tg, 
Tg-Ab, TPO-Ab and TBG by using immunoassays (IMMULITE 1000). 
The reference range for TT4 was 4.5-12.5 µg/dL, 58-161 nmol/L, the 
precent CVs at 4.3 and 11.5µg/dL were 6.5% and 7.6% respectively; 
the analytical measurement range was 1-24 µg/dL; and analytical 
sensitivity was 0.4 g/dL. The reference range for TT3 was 70-204 
ng/dL, 1.1-3.1 nmol/L; the percent CVs at a TT3 of 61.7 and 
192.5ng/dL were 9.0% and 7.26% respectively; the analytical 
measurement range was 40-600 ng/dL and analytical sensitivity was 
35ng/dL. The reference range for TBG was 15-34 µg/mL, 0.3-0.6 
µmol/L, the percent CV at a TBG of 15.09 was 7.58%; the analytical 
measurement range was 3.5-80 µg/mL; and analytical sensitivity was 
1.1µg/mL. The reference range for fT4 was 0.89-1.76 ng/dL, 11.5-
22.7 pmol/L; the percent CVs at a fT4 of 0.95 and 2.5 ng/dL were 
5.14% and 4.91% respectively; the analytical measurement range 
was 0.3-6.0 ng/dL; and the analytical sensitivity was 0.13 ng/dL. 
The reference range for fT3 was 2.6-4.8 pg/mL, 4.0-7.4 pmol/L; the 
percent CVs at a fT3 of 2.39 and 5.92 pg/mL were 4.24% and 4.13% 
respectively; the analytical measurement range was 1-40 pg/mL; and 
the analytical sensitivity was 1 pg/mL. The reference range for Tg 
was 1.7-55.6 ng/mL; the percent CV at a Tg of 9.69 ng/mL was 
3.64%; the analytical measurement range was up to 300 ng/mL; and 
the analytical sensitivity was 0.2 ng/mL. The reference range for Tg-
Ab was 0-40 IU/mL, the percent CV at 25.21 IU/mL was 5.29%; the 
analytical measurement range was 20-3000 IU/mL; and the 
analytical sensitivity was 10 IU/mL. We applied a cut off value for 
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TPO-Ab of <35 IU/mL; the percent CV at 50.35 IU/mL was 6.97%; 
the analytical measurement range was 10-1000 IU/mL; and the 
analytical sensitivity was 7 IU/mL. Haemoglobin (Hb) was measured 
on an automated Coulter counter (ABX Pentra 60C+, Horriba Ltd, 
Kyoto, Japan). Anaemia was defined as Hb < 11.0 g/dL. 
 
Thyroid gland measurement 
 
We measured thyroid gland volume by using an Aloka SSD-500 
Echocamera (Aloka, Mure, Japan) with a 7.5MHz linear transducer. 
We calculated thyroid volume of each lobe using the formula for a 
prolate ellipsoid where thyroid volume (ml) = 0.479 ×length× breadth 
×depth (cm), and summed the volumes of both lobes to obtain total 
thyroid volume (4). 
 
Statistical analysis 
 
All the thyroid function parameters except total T4 were non-
normally distributed, and these were log-transformed before analysis. 
We confirmed the normality of the log-transformed data using the 
Kolmogrov-Smirnov test. We report normally distributed data as 
arithmetic means ± standard deviation (SD), non-normally 
distributed data as medians (quartiles) and categorical data as 
numbers (%). We examined correlations among thyroid hormones by 
using Pearson’s correlation, the association of thyroid function 
parameters with maternal characteristics using linear regression 
analysis, and present the R2 for each characteristic in the univariate 
analysis. All characteristics with p < 0.20 in the univariate analyses 
were considered in multiple variable model to adjust for possible 
confounding effects of maternal characteristics and the results 
presented with R2 for multivariate model. The regression coefficient 
from the linear regression analysis of log transformed data was 
interpreted as percent change for one unit increase in independent 
variable (27). The percentage change for TT4 was calculated by 
dividing the regression coefficient by the reference group mean and 
multiplied by 100. Regression of TSH, fT4, TT4, and Tg considered 
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maternal age, gestational age (<10 wks vs. >10 wks), haemoglobin, 
BMI (normal vs. underweight, overweight, obese), consanguinity, 
parity (0 vs. ≥1), maternal education, maternal employment, food 
habits (vegetarian vs. non-vegetarian, lacto-ovo-vegetarian), reason 
for salt use (health vs. taste, tradition, quantity, others), seafood 
intake, egg intake, use of iodine containing multi-micronutrient 
powders and presence of Tg-Ab and TPO-Ab above the cut off values. 
Statistical analyses were carried out with SPSS v 18.0 (SPSS, Inc., 
Chicago, IL).  
 
Results 
 
The demographic, anthropometric and dietary characteristics of the 
women are shown in Table 1. Mean gestational age was 10.3 weeks 
and two-thirds of the women were nulliparous. Notably, 23% were 
overweight or obese, 18.3% were anemic (Hb <11.0 g/dL), 20.7% 
were vegetarian, and 56.1% and 36.9% of the women were not 
consuming seafood and eggs respectively. Although nearly all were 
using iodized salt at home, only about half were aware of iodine in 
their diet, and only 10% specifically chose iodised salt for health 
reasons. One third of women were consuming multi-micronutrient 
powders (5-10g/day) containing iodine in the range of 73-294 µg/100 
g. But the mean (range) iodine intake from these powders was low: 
12.4 (4-59) µg/day for a mean (range) duration of 10 (0-180) months.  
 
Thyroid parameters and UICs in the women are shown in Table 2. 
The median UIC (range) was 184.2 (8.1-1152) µg/L and none of the 
women had an elevated thyroid volume or an elevated thyroglobulin; 
all of these indicators suggest iodine sufficiency (28). The distribution 
of UIC is shown in Figure 1.  
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Table 1: Demographic, anthropometric and dietary characteristics of 
first trimester pregnant women in Bangalore, India 
Parameters Values 
Age, years (n= 334)1 
 
 
 
24.7 ± 4.2  
 Gestational age, weeks (n=334)1 10.3 ± 2.5  
Total monthly household income, INR (n=318)1 14000 (8000, 
24625) 
 Level of Education (n=331)1  
    No formal education 1 (0.3) 
    Finished high school (10th grade) 136 (41.1) 
    Post high school 85 (25.7) 
    University degree and above 109 (32.9) 
Level of husband’s education (n=330)1  
    No formal education 5 (1.5) 
    Finished high school (10th grade) 138 (41.8) 
    Post high school 96 (29.1) 
    University degree and above 91 (27.6) 
Occupation (n=330)1  
    Unemployed 272 (82.4) 
    Unskilled worker 2 (0.6) 
    Skilled worker 11 (3.3) 
    Others (secretarial jobs, teachers, shop owners) 
business, shop owner 
45 (13.6) 
Husband’s occupation (n=327)1  
    Unemployed 0 
    Unskilled worker 26 (7.9) 
    Skilled worker 86 (26.3) 
    Others (secretarial jobs, teachers, shop owners) 
business, shop owner 
215 (65.7) 
Consanguinity (n = 331)1  
     Yes 51 (15.4)        
     No                                                                                                    280 (84.6)
Parity (n=319)2  
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      0 213 (66.8) 
     ≥ 1 106 (33.2) 
History of Abortion (n=319) 2  
      0 255 (79.9) 
     ≥ 1 64 (20.1) 
Haemoglobin, g/dL (n=322) 11.9 ± 1.4  
     Weight, kg (n=331)3 52.8 ± 9.1  
     Height, cm (n=329)3 154.1 ± 5.6  
     BMI, kg/m2 (n=329)3 
 
22.3 ± 3.9  
BMI category  (n=329)3  
     Underweight  50 (15.2) 
     Normal 204 (62.0) 
     Overweight  60 (18.2) 
     Obese  15 (4.6) 
Food habits (n = 323)4  
     Vegetarian 57 (17.6)            
     Lacto-ovo-vegetarian                                                                                                    10 (3.1)
     Non-vegetarian 256 (79.3) 
Salt used (n=272) 4  
      Iodised powder salt 
 
64 (23.5) 
      Iodised crystal salt 2 (0.7) 
      Both (iodised powder and crystal salt) 
 
203 (74.6) 
      Loose crystal and iodised powder salt 3 (1.1) 
Reason for salt choice (n=275) 4  
      Taste 110 (40.0) 
      Tradition 71 (25.8) 
      Quantity 48 (17.5) 
      Health 28 (10.2) 
      Others 18 (6.5) 
Knowledge of iodine (n=273) 4  
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      Yes 125 (45.8) 
      No 148 (54.2) 
Salt use practice (n = 277) 4  
      Salt added during cooking 237 (85.6)            
      Salt added at the end of cooking                                                                                                    40 (14.4)
Frequency of seafood consumption per week 
(n=320) 4  
 
      Never 180 (56.3)     
      <1                                                                                                    93 (29.1) 
      >1 47 (14.7) 
Frequency of egg consumption per week (n =289) 4   
      Never 118 (40.8)     
      <5                                                                                                   112 (38.8) 
      >5 59 (20.4) 
Use of nutritional iodine supplements (n = 231) 4  
      Yes 78 (33.8)      
      No                                                                                                    153 (66.2)
Data are mean ± SD, median with quartiles in parantheses, and numbers with 
percentages in parantheses 
Socio-demography1, obstetrics history2, anthropometry 3, dietary characteristics 4 
Parity was defined as the number of times a woman has given birth to a fetus with a 
gestational age of 24 weeks or more, regardless of whether the child was born alive or 
was stillborn. Abortion was defined as termination of pregnancy, whether spontaneous 
or induced 
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Table 2: Thyroid parameters and urinary iodine concentrations in 
first trimester pregnant women in Bangalore, India 
Parameters n Median (range) 
Thyrotropin (TSH), mIU/L 334 1.2 (0.02-32.8)  
Total thyroxine (TT4), nmol/L 322 146.1 (55.9-242)  
Free T4, pmol/L 325 14.3 (8.9-78.5)  
Total triiodothyronine (TT3), nmol/L 313 2.2 (0.6-4.0)  
Free T3, pmol/L 316 5.7 (0.5-47.5)  
Thyroglobulin, µg/L 318 6.6 (0.1-87.1)  
Thyroxine binding globulin, µmol/L 313 0.7 (0.1-1.5)  
Thyroid gland volume, ml 332 5.0 (1.5-10.6)  
Urinary iodine concentration, µg/l 321 184.2 (8.1-1152)  
Thyroid dysfunction1  Percent (%) 
Overt hyperthyroidism 1 0.3 
Subclinical Hyperthyroidism 6 1.8 
Overt hypothyroidism 12 3.7 
Subclinical Hypothyroidism 30 9.2 
Hypothyroxinemia 17 5.2 
1overt hyperthyroidism, low TSH + high free T4; subclinical hyperthyroidism, low TSH 
+ normal free T4; overt hypothyroidism, high TSH+ low free T4; subclinical 
hypothyroidism, high TSH+ normal free T4; isolated hypothyroxinemia, normal TSH + 
low free T.                                      
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The prevalence of thyroid function tests outside reference ranges are 
shown in Figure 2.  Only seven (2.1%) women were hyperthyroid, six 
of whom had subclinical hyperthyroidism. In contrast, 42 (12.9%) 
were hypothyroid, 30 of whom had subclinical hypothyroidism; and 
17 (5.2%) had isolated hypothyroxinemia with normal serum TSH. 
Thirty-two (9.7%) and 46(14.0%) of the women had elevated TPO-Abs 
and Tg-Abs, respectively. 
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Table 3 shows the comparisons of characteristics of women with 
thyroid hypofunction (hypothyroidism or hypothyroxinemia) to those 
who were euthyroid. In women with thyroid hypofunction, 
hemoglobin was lower (p=0.005), and there was a significantly 
increased prevalence of TPO-Ab (34.5% vs. 9.2%) and Tg-Ab (22.4% 
vs. 6.5%; p=<0.001) compared to euthyroid women. Hemoglobin 
levels did not differ between pregnant women with overt and 
subclinical hypothyroidism (p=0.825). The prevalence of elevated 
TPO-Ab was 12.5%, 26.7% and 83.3% in women with 
hypothyroxinaemia, subclinical hypothyroidism, and overt 
hypothyroidism respectively, and the median UICs in these three 
subgroups were 146.8, 166.1 and 195.9 µg/L respectively. 
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Table 4 presents the significant univariate and multivariate 
regression models with TSH, fT4, TT4 and Tg as dependent variables. 
Vegetarianism was not associated with any of the thyroid function 
tests.  In the multivariate regression, presence of elevated TPO-Ab 
was associated with higher TSH (β= 0.238; p=0.006), and lower fT4 
(β= -0.094; p=0.032) and lower Tg (β= -0.96; p=<0.001). Use of iodine 
supplements was associated with lower Tg (β= -0.286; p=0.028) and 
higher fT4 (β= 0.055; p=0.045). Overweight and obesity were 
associated with lower fT4 (β= -0.08; p=0.018) and TT4 (β= -20.9; 
p=0.023) respectively, with fT4 and TT4 concentrations 8.2% and 
14.2 % lower in overweight/obese women compared to normal weight 
women. As fewer data were available for iodine supplement use 
(n=231) and salt use reason (n=275), the multiple variable linear 
regression analyses were repeated excluding these two variables in 
order to examine the associations in the complete sample 
(Supplementary Table S1). All the previously noted associations 
remained significant and additionally, Hb was associated with lower 
TSH (β= -0.041; p=0.010) and higher fT4 (β = 0.015; p=0.011).  In 
addition, obesity was associated with lower fT4 (β= -0.090; p= 0.028), 
with fT4 concentrations 9.4% lower in obese women compared to 
normal weight women. In addition, a sensitivity analysis was 
performed for fT4 by removing one outlier and the significant 
associations remained the same. 
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Discussion 
 
The major findings of this study are that first trimester pregnant 
women in Bangalore have sufficient iodine status, as indicated by an 
adequate median UIC and normal thyroid volumes and serum Tg 
concentrations. But despite this b) nearly one in five women had 
thyroid insufficiency and in these women, more than one-third had  
had signs of autoimmune thyroiditis, and there was a high 
prevalence of overt hypothyroidism (3.7%), with 83% of these women 
having positive TPO-Ab. A potential explanation for the high 
prevalence of hypothyroidism in our sample could be thyroidal 
disruptors, from environmental or dietary sources (29). We have no 
data on potential exposure to environmental thyroid disruptors, such 
as perchlorate, in our sample. Dietary goitrogens have been 
described in selected plant foods of Indian origin (30), and include 
thiocyanates (metabolites of cyagenic glucosides present in plant 
foods such as cabbage, cauliflower, bamboo shoot, cassava, mustard, 
turnip and radish) and isoflavones. The consumption of isoflavones 
(found in soy products, peas, bean, nuts, grain products, coffee and 
tea) is high in some Asian populations (31). A study looking for 
associations between isoflavone intake and thyroid function and 
autoimmunity in menopausal Indian women reported a modest 
reduction in serum fT3 levels (32). A limitation of the present study is 
that we did not collect data on intake of goitrogenic foods, although 
we did collect single 24 hour dietary recall data and frequency of 
consumption of seafood and eggs in the pregnant population. 
However, it is unlikely that the quantity and frequency of 
consumption of these potentially goitrogenic foods in the rice-based 
diet of south India would be high enough to produce hypothyroidism. 
 
The prevalence of overt hypothyroidism in our study population is 
more than fivefold higher than reported from other iodine-sufficient 
women early in pregnancy (12). The prevalence of thyroid 
insufficiency in iodine-sufficient women in pregnancy varies and is in 
large part dependent on gestational age and the definition of the 
upper reference limit for TSH used. We used the widely accepted 
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criteria of the American Thyroid Association, that is, a TSH upper 
limit of 2.5 mIU/L in the first trimester (25). In women in the United 
Kingdom and Italy <15 weeks’ gestation (using a TSH upper limit of 
3.65 mIU/L in the United Kingdom and 3.5 mIU/L in Italy), the 
overall prevalence of subclinical and overt hypothyroidism was 2.3% 
and 0.25%, respectively (33). In women in the Czech Republic at 9-12 
weeks’ gestation, using a TSH upper limit of 3.67 mIU/L, the 
respective prevalences were 3.9% and 0.4 (34), and in U.S. women at 
<20 weeks of gestation, using a TSH upper limit of between 2.74 and 
5.09 mIU/L,  the respective prevalences were 2.3% and 0.2%  (35). A 
recent retrospective study of U.S. women in all three trimesters, 
using the same TSH reference range in the first trimester that we 
used in this study (2.5 mIU/L), reported much higher prevalences of 
subclinical hypothyroidism (15.1%) but a low prevalence (<0.5%) of 
overt hypothyroidism (36). A recent study from China found a 27.8% 
prevalence of subclinical hypothyroidism using the diagnostic criteria 
of TSH >2.5 mIU/L and 4.0% using the laboratory TSH reference 
interval of 0.14–4.87 mIU/L (37). A recent study from the 
Netherlands suggested there may be ethnic differences in reference 
ranges to diagnose thyroid disease (38). However, if we apply a TSH 
upper limit of 3.5mIU/L in our population to draw better comparison 
with studies from the available literature, the prevalence of 
subclinical hypothyroidism drops to 3.1%, but the prevalence of overt 
hypothyroidism remains the same at 3.7%, more than fivefold higher 
than reported in other iodine-sufficient populations of pregnant 
women. 
 
In a cross-sectional study among healthy pregnant women without a 
family history of thyroid illness conducted in northern India in 2008, 
the prevalence of overt and subclinical hypothyroidism was 1.3% and 
14.2% respectively, using a TSH reference range of 0.27–4.2 mIU/L) 
(39). In another study among pregnant women from northern India, 
the prevalence of overt and subclinical hypothyroidism was 4.6% and 
6.5% respectively, using a TSH reference range of 0.5–5.5 mIU/L 
(40). In iodine-sufficient areas, the main cause of hypothyroidism 
during pregnancy is chronic autoimmune thyroiditis (14) and this 
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also appears to be the primary cause in our study population. In 
women early in pregnancy in Europe and the United States, positive 
TPO-Ab are present in 10% of women with hypothyroxinemia, 30-
60% with subclinical hypothyroidism, and 70-90% with overt 
hypothyroidism (41). These prevalences are similar to the ones in our 
subjects: TPO-Ab was elevated in 12.5%, 26.7% and 83.3% of women 
with hypothyroxinemia, subclinical hypothyroidism and overt 
hypothyroidism respectively. Advancing parity may increase risk for 
thyroid autoimmunity (42) but in our data, the prevalence of TPO-Ab 
did not differ significantly between nulliparous and multiparous 
pregnant women.  
 
Worldwide, iodine deficiency is a common cause of maternal thyroid 
insufficiency (1). Moderate to severe iodine deficiency can result in 
both maternal and fetal hypothyroxinemia (43, 44). In less severely 
affected areas, isolated maternal hypothyroxinemia is more common 
(12). A review of iodine status in Indian pregnant women reported a 
range of median UICs of 95-178 µg/l, with 60-95% consuming 
adequately iodized salt (11). In a recent cross-sectional study from 
the Bangalore region, we found a median UIC of 172 µg/L in 
pregnant women consuming adequate amounts of iodized salt (45). 
In large populations of pregnant women, although the overall median 
UIC may indicate adequate iodine status, subgroups with different 
dietary patterns may remain at risk of low intakes. For example, 
among pregnant women in Maharashtra, the median UIC was 203 
and 211 µg/L at 17 and 34 weeks of gestation, but a subgroup of 
women were hypothyroxinemic and borderline iodine deficient with a 
median UIC of only 147 µg/L (46). However, in our study, the 
subgroup of women with thyroid insufficiency had a sufficient 
median UIC that was not significantly different from women who 
were euthyroid. In addition, women consuming vegetarian diets did 
not have lower iodine intakes than those consuming mixed diets, nor 
did those consuming less fish (the food group richest in native 
iodine). Thus, it appears that poor iodine intake in a subgroup of 
pregnant women is not the cause of the high prevalence of thyroid 
dysfunction in our sample.  
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Other potential contributing factors to thyroid insufficiency in our 
women were the high prevalence of anemia (19%) and 
overweight/obesity (23%). Hemoglobin was significantly lower in 
women with thyroid insufficiency than in euthyroid women (Table 3), 
and a lower hemoglobin was associated with higher TSH and lower 
fT4 (Table 4). Iron deficiency may impair thyroid function during 
pregnancy because thyroid peroxidase is an iron-dependent enzyme 
(47). Previous studies in children have shown that iron deficiency 
impairs correction of thyroid dysfunction during iodine repletion, and 
in Swiss pregnant women in the second and third trimester, the 
relative risk of hypothyroxinaemia was more than sevenfold higher in 
women who were anemic (15).  A limitation of our study was that we 
did not measure other markers of iron status besides hemoglobin.  
 
In the multiple regression analysis, overweight and obesity were 
significant predictors of a lower fT4 and TT4 (Table 4). Adiposity may 
increase the risk for thyroid insufficiency, and overweight adults tend 
to have higher TSH and lower fT4 concentrations than normal weight 
adults (48). Previous studies have reported an inverse relationship 
between fT4 concentrations and maternal weight and BMI during 
early pregnancy (17-19). One study found that high maternal BMI at 
mid-gestation positively correlated with the fT3/fT4 ratio (16). In 
mildly iodine-deficient pregnant Thai women, those who were 
overweight had a 3.6-fold higher risk of hypothyroxinemia in the first 
trimester compared to normal weight women (7). As India 
modernizes, overweight and obesity prevalence among adult women 
is increasing (22). If higher BMI is a risk factor for thyroid 
insufficiency in pregnant women, this may become increasingly 
important in India. 
 
Currently, screening of maternal thyroid function is not routinely 
performed during antenatal care at hospitals in Bangalore. Our data 
suggest screening should be considered in this setting. The high 
prevalence of thyroid insufficiency in pregnant women in Bangalore 
may have important health consequences. Overt maternal 
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hypothyroidism increases the risk for multiple adverse pregnancy 
outcomes, including preeclampsia, spontaneous abortion, and 
postpartum haemorrhage, as well as premature birth and low birth 
weight (49, 50). Many of these complications have also been 
associated with subclinical hypothyroidism at lower rates (51), but 
not all studies have found adverse impacts (18). Mild hypothyroidism 
may also adversely affect cognitive development of the offspring, but 
not all studies agree (12). The largest controlled trial showed no 
benefit of treatment of mild maternal hypothyroidism on offspring IQ 
at 3.5 years of age (33). In summary, evidence is stronger that 
detection and treatment of overt and subclinical hypothyroidism will 
benefit obstetric outcomes rather than offspring cognitive 
development.  
 
Almost all the salt (both powder and crystal) used in the households 
of the pregnant women in our study was iodized, illustrating the wide 
coverage of the Indian iodised salt program in this region. Household 
coverage of adequately iodized salt in India has increased remarkably 
over the past decade, with the national coverage reaching 51% in 
2005–2006 and 71% in 2009 (10). But there is better coverage of 
adequately iodized salt in urban areas and higher socioeconomic 
groups (10). Our subjects were urban women from low-to-middle-
income families, and the very high coverage and adequate iodine 
status reported here might not be generalizable to other areas of 
India. Use of iodized salt during the reproductive years leading up to 
pregnancy improves maternal thyroid economy during gestation and 
reduces the risk of maternal thyroid insufficiency because it 
contributes to normal intrathyroidal iodine stores (52). In countries 
with salt iodization programs, if pregnant women restrict their 
dietary salt intake, they have an increased risk of becoming 
hypothyroxinemic (53), indicating the importance of iodised salt as a 
dietary source of iodine. Among our women, fewer than one in five 
chose iodized salt for health reasons, and almost 50% had no 
knowledge of iodine nutrition. The low awareness of the health 
benefits of iodized salt in our study are consistent with findings from 
a recent survey in Karnataka (the Indian State where this study was 
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done) that found awareness of the health benefits of iodized salt 
played a minimal role in salt purchase choice (54). These findings 
argue that although the program of salt iodization is currently 
effective, in order to increase consumer awareness and maintain 
demand for iodized salt in Bangalore, public health strategies such 
as a consumer education campaign would be valuable for program 
sustainability. 
 
In conclusion, in this population of urban first trimester pregnant 
Indian women, the prevalence of overt hypothyroidism is surprisingly 
high. But iodine intakes appear to be adequate, and there are 
apparently no subgroups of the population with low iodine intake 
that predict thyroid insufficiency. The most common factor 
underlying the high prevalence of thyroid insufficiency is 
autoimmune thyroiditis. Both a low hemoglobin and higher BMI 
predict an increased risk. These findings contribute to a better 
understanding of the pattern and prevalence of maternal thyroid 
dysfunction and associated risk factors in the Indian population that 
could improve screening and treatment of gestational thyroid 
insufficiency. 
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Abstract 
 
Purpose: Thyroid dysfunction and depression are common in 
pregnancy. However, the role of thyroid dysfunction in depression 
during pregnancy is less well understood. 
 
Aim: The aim of the present study was to examine the relationship of 
thyroid function with depression in pregnancy across trimesters. 
 
Method: Subjects were 318 pregnant women who were randomized 
into two groups: a) iodine intervention (200μg oral iodine per day) or 
b) an identical placebo in a randomized, double blind, placebo-
controlled trial. Thyroid hormones and antibodies, and depression 
using the Kessler's scale for psychological distress, were assessed at 
each of the three trimesters of pregnancy. Mann Whitney U tests and 
logistic regression were performed to examine associations between 
iodine supplementation, indicators of thyroid function and 
depression. 
 
Results: There was no significant difference in depressive symptoms 
between the iodine intervention and placebo groups. In the first 
trimester, women with depressive symptoms had significantly lower 
serum TSH compared to women without depressive symptoms. 
Pregnant women with prenatal depressive symptoms had a 
significantly higher number of medical symptoms. 
  
Conclusion: In early pregnancy, serum TSH is lower in women with 
depressive symptoms compared to women without depressive 
symptoms. Medical symptoms were associated with antenatal 
depressive symptoms 
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Introduction 
 
Depression in pregnancy is common. Studies from different parts of 
the world have shown that the prevalence rate of depression ranges 
from 4.4% (Lee et al. 2004) to 48.4% (Shah et al. 2011). Several 
recent reviews suggest a higher prevalence of depression during 
pregnancy in women from developing countries compared to 
pregnant women from the West (Lee et al. 2004; Shah et al. 2011).  
While in the past the focus has been on post partum depression 
(Kitamura et al.1996), more recently there has been a considerable 
research interest in antenatal depression and its causal factors and 
outcomes (Highet Gemmill and Milgrom 2011). Depression in 
pregnancy has been found to be associated with several factors. 
These include biological/nutritional (Leung and Kaplan 2009), 
psychosocial (Bowen and Mujaharine 2006) and socio-demographic 
variables (Bowen et al. 2009). In addition, several studies have 
highlighted the adverse effects of depression during pregnancy on 
birth outcomes and child health including early development (Straub 
et al. 2012; Weinstock 2005).  
 
The association between mood disorders and thyroid dysfunction is 
well recognized. The prevalence of mood disorders is higher in 
patients with thyroid dysfunction (Zainal et al. 2010); thyroid status 
predicts treatment response in major depression, and augmentation 
with thyroid hormone has therapeutic efficacy in treatment-resistant 
depression (Cooper-Kazaz and Lerer 2008). Both overactive and 
underactive thyroid have been found to be related to mood 
alterations (Hage and Azar 2012, Kirkegaard and Faber 1998). It is 
also noted that there is a higher prevalence of anti-thyroid antibodies 
in patients diagnosed with depression when compared to the general 
population (Hage and Azar 2012). Thyroid dysfunction is common 
during pregnancy and worldwide iodine insufficiency is a leading 
cause of maternal thyroid insufficiency (Zimmerman 2009). In iodine 
sufficient areas autoimmune thyroiditis is the most common cause of 
maternal hypothyroidism (De Groot et al. 2012). Few studies have 
examined the association between thyroid function in the antenatal 
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period and depression. Pederson et al. (2007) found that antenatal 
thyroid dysfunction, in terms of lower fT4, led to a higher likelihood 
of postnatal depressive symptoms.  Lambrinoudaki et al. (2010) 
found that lower levels of serum FT3 and FT4 during the antenatal 
period are associated with mood disturbances in the first week after 
delivery. Bunevicius et al. (2009) found that women who were 
depressed in late pregnancy had higher fT4 concentration and higher 
prevalence of subclinical hyperthyroidism. 
 
In a cross-sectional study of pregnant women who were screened for 
this intervention trial, there was a high prevalence of hypothyroidism 
with nearly one in five women having thyroid insufficiency in the first 
trimester and among them over one-third had autoimmune 
thyroiditis (Jaiswal et al. 2014).Thus, the aim of the present study 
was to longitudinally examine the relationship between thyroid 
hormones and depression in this cohort of urban South Indian 
pregnant women. We hypothesized that thyroid dysfunction would be 
associated with depression. 
 
Materials and Method 
 
This longitudinal study consisted of a cohort of pregnant women who 
were recruited for the Maternal Iodine Supplementation and its 
Effects on Child Development (MITCH) study (Clinicaltrials.gov with 
the identifier NCT00791466). The intervention study investigated the 
effects of oral iodine supplementation of 200µg/day during 
pregnancy on pregnancy outcome, infant growth and offspring 
cognitive development. The study was conducted at the antenatal 
clinic of the Obstetrics and Gynaecology Department of St Martha’s 
Hospital in Bangalore, India. Pregnant women were recruited 
between December 2008 and March 2011. The study was conducted 
in accordance with the Declaration of Helsinki. Institutional ethical 
review boards at St. John’s National Academy of Health Sciences, St 
Martha’s Hospital, Bangalore, India and Wageningen University, The 
Netherlands approved the study. Study details were explained to the 
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participating women and one member of their family, and written, 
witnessed informed consents were obtained. 
 
Study population 
 
All pregnant women aged between 18 and 40 years, who were ≤ 14 
weeks gestational age presenting to the antenatal clinic were invited 
to participate in the study, and1058 women were screened for 
eligibility to participate in the study. Women with  major chronic 
diseases, those with a positive test for HIV, HbSAg or venereal 
diseases, those  undergoing treatment for infertility, those who had 
previous repeated spontaneous abortions (4 or more), those with  
current multiple pregnancy as detected by ultrasound and those who 
were currently breastfeeding were excluded from the study.  A total of 
318 pregnant women consented to participate.  
 
Socio-demographic data 
 
A structured multiple choice questionnaire was used to obtain socio-
demographic information on education, occupation and income, 
religion and obstetric history, including parity. Gestational age was 
calculated from the reported first day of the last menstrual period 
and confirmed by ultrasonography in 65% of women. 
 
Laboratory analysis 
 
A non-fasting whole blood sample was obtained by venipuncture into 
plain vacutainers (BD diagnostics, Franklin Lakes, New Jersey, USA) 
that was transported on ice and centrifuged to obtain serum, which 
was stored at -80⁰C until analysis for thyroid stimulating hormone 
(TSH), total triiodothyronine (TT3), total thyroxine (TT4), free T3 (fT3), 
free T4 (fT4), thyroglobulin (Tg), thyroid binding globulin (TBG), anti-
thyroid peroxidase antibodies (TPO-Ab) and anti-Tg antibodies (Tg-
Ab). We previously described in detail the immunoassay method used 
to measure the TFT’s, including %CVs, reference range, analytical 
measurement range and analytical sensitivity (Jaiswal et al.  
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2014).With the exception of TSH for which trimester-specific range is 
available, we used the manufacturer’s recommended reference range 
for TFT’s. For TSH, we applied a reference range of 0.1-2.5 mIU/L for 
the first trimester, 0.2-3.0 mIU/L for the third second trimester and 
0.3-3.0 mIU/L for the third trimester (Stagnaro-Green et al, 2011; 
Mannisto et al, 2011). Assessments were carried out at ≤14 weeks, 
24 weeks and 33 weeks of pregnancy. 
 
Assessment of Maternal depression 
 
Depressive symptoms were assessed on the Kessler’s psychological 
distress scale (K-10). The K-10 has 10 items based on a 4 week recall 
period,  each item has five response categories and is scored from 0 
to 4 (‘0’=’None of the time’, ‘1’= A little of the time’, ‘2’=’Some of the 
time’, ‘3’= ‘Most of the time’, ‘4’= All of the time’) yielding a sum of 
score (range 0-40) (Kessler et al. 2003).  In a study of 194 women in 
their third trimester we found that the K-10 compared well with the 
Edinburgh postnatal depression scale (EPDS) (Cox et al. 1987) in 
detecting prenatal depression and a receiver operating characteristic 
analysis showed K-10 to be a good screening measure of prenatal 
depression in South Indian pregnant women at a cut-off of ≥6 
(sensitivity=100%, specificity=81.3%, and area under the curve=0.95) 
(Fernandes et al. 2011). In addition, K-10 is simpler to score as it has 
uniform response options for all the 10 questions as opposed to 
EPDS, where items have different response options. We have since 
used the K-10 in studies of assessing depression in south Indian 
pregnant women (Lukose et al. 2014). In the present study, maternal 
depression was assessed at three time points, at ≤14 weeks, 24 
weeks and 33 weeks of pregnancy and we used a K -10 score ≥6 to 
define pregnant women with prenatal depressive symptoms.  
 
Medical morbidity 
 
We captured medical morbidity through a questionnaire that had a 
checklist of common medical symptoms associated with pregnancy, 
administered at baseline and subsequently every trimester. The 
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check list of medical symptoms was related to respiratory, 
gastrointestinal, central nervous system and dermatological illnesses 
and the responses were recorded in a binary yes/no format. A 
medical morbidity score was computed by totalling the number of 
medical symptoms endorsed by subjects at baseline and in 
subsequent trimesters. The maximum score was 23. 
 
Statistical analyses 
 
Data are described as number (%) or median (25th, 75th percentile). 
The K-10 scores were compared between the intervention and 
placebo groups using Mann Whitney U test. Subjects with prenatal 
depressive symptoms were compared with those without depressive 
symptoms (K-10 score ≥6, Depression group) in each trimester on 
socio-demographic variables, biochemical indices of thyroid function 
and medical morbidity. Most of the biochemical indices of thyroid 
functions were not normally distributed and hence Mann Whitney U 
Test was used. Categorical data were compared using Chi square 
tests. The variables that showed a statistically significant group 
difference (p<0.1) in these analyses were considered in multiple 
variable logistic regression analysis of the dichotomous variable 
representing presence of antenatal depressive symptoms. The 
adjusted odds ratio (OR) and 95% Confidence interval (95% CI) are 
reported. SPSS version 18 (SPSS Inc. Chicago, Ill.) was used for 
statistical analyses and p<0.05 was considered statistically 
significant. 
 
Results 
 
Socio-demographic characteristics 
 
Mean±SD age of the pregnant women was 24.7±4.1 years. The 
majority of the women were primiparous, had finished high school 
education, belonged to Hindu religion and were unemployed with a 
median (25th, 75th percentile) household income of INR 14,000 (8000, 
25000) (Table 1). Prevalence of pr natal depressive symptoms among 
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pregnant women in the first trimester (10.4 ± 2.5 weeks) was 32% 
(n=102), 15% (n=38) in the second trimester (24.4 ± 1.5 weeks) and 
20% (n=42) in the third trimester (32.9 ± 1.3 weeks). 10 women had 
depressive symptoms (Score: ≥6 on K10 scale) in all three trimesters.  
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Table 1: Socio-demographic characteristics of the sample 
Parameters (N=318) Values 
Age, years 1 
 
 
 
24.7±4.1 
Total monthly household income, INR 2 14000 (8000, 25000) 
 Level of Education 3(n=315)  
    Illiterate  1 (0.3) 
    Primary School  6 (1.9) 
    Middle school  21(6.7) 
    High school  105 (33.3) 
Post high school 78 (24.8) 
    Graduate 90 (28.6) 
    Post Graduate 
 
14(4.4) 
Subject’s occupation 3(n=314)  
    Unemployed 260(82.8) 
     Unskilled worker 1(0.3) 
    Skilled worker 11(3.5) 
    Secretarial staff/primary school teacher 31(9.9) 
    Semi professional 7(2.2) 
    Professional 4(1.3) 
Subject’s religion3(n=315)  
    Hindu 254(80.6) 
    Christian 31(9.8) 
 Islam 30(9.5) 
Parity 3(n=304)  
      0 204(67.1) 
≥ 1 100(32.9) 
Mean ± SD1, Median (25th, 75th percentile) 2, Numbers (%) 3 
 
 
There were no differences in the prevalence of depressive symptoms 
between the iodine intervention group (n=157) (median K-10 score 
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(25th percentile, 75th percentile): 4 (2,6) in first trimester, 3(1,5) in the 
second trimester  and 3(2,5) in the third trimester) and placebo group 
(n=161): 4(2,6) in first trimester, 2(1,4) in the second trimester  and 
3(2,5) in the third trimester) group. Hence both the intervention and 
the control group are considered together for the remaining analyses. 
Socio-demographic characteristics were comparable between women 
with and without prenatal depressive symptoms. 
 
Thyroid functions and depression 
 
The overall prevalence of overt and subclinical hypothyroidism was 
2.2% (n=7) and 8.5% (n=27) respectively, in the first trimester; 0.6% 
(n=2) and 4.4% (n=14) respectively, in the second trimester; 0% and 
4.4% (n=14) respectively, in the third trimester. There were no cases 
of overt hyperthyroidism across all trimesters. The overall prevalence 
of subclinical hyperthyroidism in the sample was 1.9% (n=6), 0.3% 
(n=1) and 0% in the first, second and third trimester respectively. 
Isolated hypothyroxinemia was prevalent in 1.6% (n=5), 0.6% (n=2) 
and 1.6% (n=5) of pregnant women in the first, second and third 
trimester respectively. The prevalence of thyroid function disorders in 
the depression and no depression group in each trimester is 
presented in Figure 1.  
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Median (25th, 75th percentile) TSH was significantly lower in the 
group of pregnant women who had depressive symptoms: 1.01(0.64, 
1.71) compared to pregnant women who had no depression: (1.27 
(0.81, 1.80) in the first trimester (p= 0.030) and the second trimester: 
1.17(0.80, 1.81) vs 1.62(1.16, 2.13) (p=0.014).This was comparable in 
the third trimester. In the third trimester, median (25th, 75th 
percentile) fT4 was lower in the group with depressive symptoms 
compared to those without depressive symptoms: 11.4(10.6, 13.2) vs 
12.3(11.1, 13.4) respectively, p= 0.032) (Table 2). 
 
All the other thyroid function parameters were comparable between 
the groups including the percentage distribution of women with 
thyroid antibodies (TPO-Ab >35 IU/mL): 12.8% (n=27) in no 
depression group and 12% (n=12) in the depression group in the first 
trimester, 11.3% (n=22) in no depression group and 5.3% (n=2) in the 
depression group in the second trimester,10.8% (n=17) in no 
depression group and 9.5% (n=4) in the depression group in the third 
trimester) and Tg-Ab> 40 IU/mL:(8.5% (n=18) in no depression group 
and 8% (n=8) in the depression group in the first trimester, 4.1% 
(n=8) in no depression group and 2.6 % (n=1) in the depression group 
in the second trimester,3.9% (n=6) in no depression group and 2.4% 
(n=1) in the depression group in the third trimester). 
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Pregnant women with prenatal depressive symptoms had a 
significantly higher number of medical symptoms compared to 
women without depressive symptoms across all three trimesters 
(Table 3). The medical symptoms of diarrhoea, nausea, vomiting, 
cough, sore throat, fever, constipation, giddiness, tiredness, 
heartburn and painful urination were more common in depressed 
women, out of which sore throat, giddiness and tiredness were 
reported in all three trimesters.  
 
In all the three trimesters a larger number of medical symptoms were 
associated with depressive symptoms (Table 4). After adjusting for 
this, low TSH was associated with the presence of depressive 
symptoms in first trimester alone (OR=0.70, 95% CI: 0.52 - 0.93) and 
not in the second trimester. The association of low fT4 to depressive 
symptoms in the third trimester was also not associated with 
presence of depressive symptoms after adjusting for number of 
medical symptoms in the logistic regression. 
 
 
Table 3 Difference in medical symptoms between depressed and 
non-depressed groups of pregnant women across three trimesters 
Trimester Group  n No. of medical symptoms 
I Depression   208 6 (5,8) 
 No depression  100 5 (3,6) 
 P value  <0.001 
II Depression   209 4 (3,7) 
 No depression  38 3 (2,5) 
 P value  0.002 
III Depression   171 5 (3,8) 
 No depression   45 3 (2,5) 
 P value  <0.001 
Values are median (25th, 75th percentile); p value from Mann Whitney U test 
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Table 4 Logistic regression analysis of depressive symptoms in three 
trimesters of pregnancy 
Trimester  Factors Odds 
Ratio* 
95% CI 
I TSH 0.70 0.52-0.93 
 Medical symptoms 1.37 1.22-1.53 
II TSH 0.89 0.61-1.29 
 Medical symptoms 1.25 1.08-1.44 
III FT4 0.89 0.75-1.06 
 Medical symptoms 1.38 1.21-1.58 
* Adjusted Odds Ratio in multiple variable logistic regression 
 
Discussion and Conclusion 
In this cohort of pregnant urban south Indian women, we found a 
high prevalence of depressive symptoms with the highest prevalence 
in the first trimester of pregnancy (32%). Among the various 
biochemical indices of thyroid function, lower levels of TSH were 
predictive of prenatal depressive symptoms in the first trimester. 
Medical symptoms reported by pregnant women were independently 
associated with prenatal depression across the three trimesters. 
 
Several studies from South East Asia have noted a high prevalence of 
depressive symptoms during pregnancy (Imran & Haider 2010; 
Gausia et al. 2009). Our findings of a 32% prevalence rate of 
depressive symptoms among pregnant South Indian women are 
consistent with these studies and similar to the reported prevalence 
in one of our earlier studies (Lukose et al. 2014). Such a high 
prevalence of depressive symptoms with its associated disability and 
impairment is a source of considerable burden for pregnant women 
(Karatas et al. 2009; Mariam & Srinivasan 2009). In agreement with 
earlier longitudinal studies of prenatal depression, the prevalence 
rates tend to be lower at later time points in pregnancy (Bunevicius 
et al. 2009; Lee at al. 2007). 
 
Few studies have examined the association between indicators of 
thyroid function and maternal depression during pregnancy. In an 
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early prospective study of depression and thyroid function in 1017 
pregnant women, high titres of TPO-Ab at 12 weeks gestation (OR 
2.1; 95% CI: 1.1-5.8) and at 24 weeks gestation (OR 2.8; 95% CI: 1.9-
7.1) were independently associated with a syndromal diagnosis of 
depression (Pop et al. 2006). The same study also reported that 
pregnant women with decreased TSH in the first trimester had 2.8 
fold greater risk for depression. In a study of 199 pregnant women 
from Lithuania, with a diagnosis of major depression or dysthymia 
found that depressed women had higher fT4 values and a trend 
towards lower levels of TSH, only in the third trimester (Bunevicius et 
al. 2009).  While it is difficult to compare our study with these two 
reports as the participants were pregnant women with diagnosable 
depression as opposed to only having depressive symptoms in our 
study, nevertheless one of the consistent finding is the association 
between lower levels of TSH, indicative of sub-clinical 
hyperthyroidism, with prenatal depression. This association between 
lower TSH and prenatal depressive symptoms in our cohort of women 
is all the more remarkable given the high prevalence of autoimmune 
thyroiditis and sub-clinical hypothyroidism in the screened 
population of pregnant women (Jaiswal et al. 2014). An association 
between sub-clinical hyperthyroidism and depression has been 
reported in the general population (Scholte et al. 1992) and in 
patients with Graves’ disease (Bunevicius & Prange 2006). It is 
important to further explore the association between subclinical 
hyperthyroidism and prenatal depression as subclinical 
hyperthyroidism can have several negative long term health 
outcomes that include osteoporosis and cardiovascular vulnerability 
(Casey et al. 2006). 
 
Findings on the association between thyroid autoimmunity and 
prenatal depression have been inconsistent. The studies that 
examined this have yielded conflicting results. Two studies from the 
Netherlands (Kuipjens et al.2001; Pop et al. 2006) reported an 
association between elevated levels of TPO antibodies and prenatal 
depression independent of thyroid function in early pregnancy. 
However, a study from the UK (Oretti et al.1997) and Lithuania 
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(Bunevicius et al. 2009) did not find an association between thyroid 
immunity and prenatal depression.  
  
Our findings indicate that common medical symptoms such as 
nausea, tiredness, giddiness and abdominal pain were predictive of 
depression across trimesters. Most of the earlier studies found 
severity of medical symptoms as one of the risk factors associated 
with prenatal depression in early pregnancy (Kitamura et al. 1996; 
Reeves et al. 1991). Among the various medical symptoms, nausea 
and vomiting in the first trimester are particularly associated with a 
higher risk of prenatal depression (Chou et al. 2003; Lukose et al. 
2014). Most studies report an association between medical symptoms 
and prenatal depression in early pregnancy, but in the present study 
this association persists across trimesters. While it is difficult to 
ascribe a causal relationship between medical symptoms and 
maternal depressive symptoms, the presence of medical symptoms 
must alert the physician to the possibility of prenatal depression.  
 
To our knowledge, this is the first study in India to examine the 
association between thyroid function and prenatal depression. This 
report is based on a prospective longitudinal design with multiple 
assessments at different time points and adds to the small but 
expanding literature on identifying correlates of prenatal depression. 
However, this study has some limitations. We screened for the 
presence of depressive symptoms but did not assess for the presence 
of syndromal depression. However, several studies have shown that 
sub-clinical depression is associated with considerable disability and 
impairment (Karatas et al. 2009; Mariam & Srinivasan 2009). We did 
not assess the severity of medical symptoms though we found 
medical symptoms to be positively associated with prenatal 
depression across trimesters. 67 (21.1%) women dropped out from 
the study in the second trimester, and 14 (4.4 %) women dropped out 
in the third trimester. However, there was no difference in the 
prevalence of depression in those who continued in the study and 
those who dropped out (data not provided). 
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In conclusion, we found a high prevalence of depressive symptoms 
among urban south Indian pregnant women from a low 
socioeconomic background. There was an association between low 
levels of TSH and prenatal depression in early pregnancy. Medical 
symptoms were associated with prenatal depression. Depression and 
thyroid dysfunction being common in pregnancy and more 
importantly having an influence on birth outcomes and post natal 
child development (Straub et al. 2012; Weinstock 2005), future 
studies with larger sample size are needed. We are currently 
following up the mother-child dyad through 2 years of age with 
periodic assessment of maternal depression, child development and 
thyroid function. This study, in addition, highlights the need for 
systemic screening for prenatal depression during antenatal visits as 
it is an independent risk factor for later development of clinical 
depression (Satyanarayana et al. 2011; Mariam & Srinivasan 2009; 
Davey et al. 2011). 
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Chapter 6 
 
GENERAL DISCUSSION   
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Globally, in 2011, 32 countries and 1.88 billion people remained 
iodine deﬁcient, including 241 million schoolchildren, who had 
insufficient dietary iodine intake (3). A recent review estimated that 
350 million Indians are at risk of iodine deficiency disorders (IDD) as 
they consume salt with inadequate iodine and every year nine million 
pregnant women and eight million newborns are at risk of IDD in 
India. In sub-national IDD surveys (2001-2006) in seven States of 
India, household level consumption of adequately iodized salt (≥15 
ppm) ranged from 18.2-91.9% and median UIE ranged from 76-173.2 
μg/l (1); 91% households had access to iodized salt, 71% consumed 
adequately iodized salt and 9% consumed salt with no iodine; wide 
variations in coverage were seen in urban (83.2%) and rural (66.1%) 
areas and States, with Karnataka being a low coverage state (35.5%) 
(2). 
 
Iodine deficiency has far reaching adverse effects in the general 
population, and particularly during pregnancy as the fetus is entirely 
dependent on the mother for its iodine nutrition. Recent evidence 
suggests that using the median UIC value from a population of 
school children as surrogate for pregnant women may place them at 
risk of iodine deficiency. It is also uncertain if it is beneficial to 
supplement mildly iodine deficient pregnant women with iodine. 
WHO does not recommend supplementation in areas with well-
functioning iodized salt programs while many expert medical groups 
recommend supplementation in areas with mild iodine deficiency. 
The potential adverse effects of mild iodine deficiency during 
pregnancy are unclear, as controlled trials of iodine supplementation 
in mildly iodine deficient pregnant women have not shown that 
supplementation increases concentrations of maternal or newborn 
thyroid hormones (4). In this thesis we aimed to address two 
important questions: 1) whether pregnant women should be 
monitored separately for iodine nutrition and 2) seek clarity on the 
issue that persists in the field of iodine nutrition: whether it is 
beneficial to supplement pregnant women with iodine in mild-to 
moderately iodine deficient and also iodine sufficient areas.  
 
Therefore, we aimed to determine whether daily oral iodine 
supplementation in pregnant women with mild iodine deficiency 
improves cognitive development of their offspring at 2 years. 
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6.1 Main findings  
 
Table 1 summarises the main findings from this thesis.  
 
In the RCT, there were no significant differences between the iodine 
supplemented or control group in maternal thyroid function tests or 
thyroid volume during gestation. The prevalence of all subtypes of 
thyroid dysfunction, or anti-TPO antibodies, did not differ 
significantly during gestation and postpartum. Postpartum, there 
were no significant differences between the maternal and infant 
groups in thyroid function, birth outcomes or UIC. Thus, iodine 
supplementation even in iodine sufficient pregnant women was 
found to be safe without increasing the risk of thyroid autoimmunity. 
Neonates whose mothers received iodine supplementation during 
pregnancy had better orientation scores at 6 weeks of age and lower 
scores of inhibition suggesting better executive function at 2 years of 
age although neurocognitive development on the BSID III were not 
significantly different between groups. Thus, additional follow-up of 
these children for neurocognitive testing at a later age when 
development and cognitive testing is more reliable would provide 
valuable add on information (Chapter 2). 
 
In a cross-sectional study (pilot study) comparing iodine status of 
pregnant women and their 3-15 year old children who were sharing all 
meals in Bangalore, we found that adequately iodized salt, together with 
small amounts of iodine in local foods, were providing adequate iodine 
during pregnancy: a) median UIC in women was 172 µg/L, b) the 
median UIC was >150 µg/L in all trimesters and c) thyroid size was not 
significantly different across trimesters. At the same time, the median 
UIC in children was 220µg/L, indicating ‘more than adequate’ iodine 
intake at this age. Median UIC was significantly higher in children than 
in their mothers (p=0.008). We concluded that in our selected urban 
population of Southern India, the iodized salt program was providing 
adequate iodine to women throughout pregnancy, at the expense of 
higher iodine intake in their children. Thus we suggested that the 
current WHO/UNICEF/ICCIDD cut-off for median UIC in children, 
indicating more-than-adequate iodine intake, may need to be 
reconsidered (Chapter 3).  
 
There have been recent improvements in iodized salt coverage in India 
but whether iodized salt is enough to sustain iodine requirements 
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during pregnancy remains uncertain. In a cross-sectional study among 
334 pregnant women ≤14 weeks of gestation who were screened for the 
RCT, we aimed to measure thyroid status in first trimester pregnant 
women and assess potential determinants of thyroid function, including 
iodine status, thyroid autoimmunity, dietary patterns, body weight and 
anemia. We found that 21% women were vegetarian, 19% were anaemic 
and 23% were overweight or obese. Iodized salt was used by 98% of 
women and they were iodine sufficient: median UIC was 184.2 µg/L and 
all had normal thyroid volume. However, 18% of women had thyroid 
insufficiency: 3.7% had overt hypothyroidism (83% with positive TPO-
Ab), 9.2% had subclinical hypothyroidism and 5.2% had 
hypothyroxinemia. Women consuming vegetarian diets did not have 
significantly lower iodine intakes or higher risk of hypothyroidism than 
those consuming mixed diets, but overweight/obesity and anemia 
predicted thyroid insufficiency. Thus we concluded that in our selected 
urban population of southern India, pregnant women have adequate 
iodine status in the first trimester. Despite this, many had thyroid 
insufficiency, and the prevalence of overt hypothyroidism was >5-fold 
higher than reported in other iodine-sufficient populations of pregnant 
women. We suggested that improved screening and treatment of 
gestational thyroid insufficiency is important in this population (Chapter 
4).  
 
While the relationship between thyroid functions and mood symptoms 
has been extensively studied, the role of thyroid dysfunction in 
depression during pregnancy is less well understood. In a secondary 
analysis of the RCT data, we aimed to examine the relationship of 
thyroid function with depression across three trimesters. We found no 
significant difference in the prevalence of depressive symptoms between 
the iodine intervention vs the placebo group. In the first trimester, 
women with depressive symptoms had significantly lower serum TSH 
compared to women without depressive symptoms. Pregnant women 
with prenatal depressive symptoms had a significantly higher number of 
medical symptoms. Although iodine supplementation did not affect 
maternal depression, we highlighted the need for systemic screening for 
prenatal depression during antenatal visits as it is an independent risk 
factor for later development of clinical depression (chapter 5). 
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6.2 Methodological considerations 
 
In this part of the thesis, we critically reflect on the methodology 
adopted in the pilot study that may affect the interpretation of 
findings. We also highlight the methodological constraints, strengths 
and limitations, internal and external validity of the RCT that make 
the findings robust and generalizable to similar settings. 
 
6.2.1 Pilot study 
 
Since there was no data on the iodine status in pregnant women 
from Southern India, in a pilot study, we aimed to assess the median 
UIC of pregnant women from Bangalore, in a target population, 
which was chosen for our RCT. In addition to this objective, we 
aimed to compare the median UIC of these women to that of their 
children, 3-15 years old, in pairs that were sharing all meals at 
home. Thus, all children participating in the school lunch 
programmes and sharing some meals at their grand parent’s homes 
were excluded. Such comparisons have been made in earlier studies 
but in those studies pregnant women and children were not sharing 
all meals together in the same household which limits comparisons 
between the groups. Our findings from this study showed that 
pregnant women were adequate in iodine nutrition while their 
children were “more than adequate” in their iodine status. We also 
captured information on sources of iodine in this population 
(consumption of seafood and multi-micronutrient powders containing 
iodine, salt sample analysis, average household consumption of salt) 
to arrive at estimated iodine intakes in this population. Thus, we 
think that our study provides definitive evidence for the inadequacy 
of using median UIC in children as a surrogate for iodine nutrition in 
pregnant population. But since our study was hospital based and in 
an urban setting, additional population-based studies in other 
regions of India are needed to confirm these findings. We also cannot 
generalize study results to less-affluent, rural areas of India where 
adequately iodized salt is not available and where pregnant women 
are likely to still have inadequate iodine intakes. 
 
6.2.2 Randomized controlled trial (RCT) 
 
Dropouts 
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There was a 21% dropout each in the intervention and placebo group 
from the study entry to second trimester. This dropout rate increased 
to 26.1 and 24.8% at the third trimester, 27.3 and 28.0% until 
delivery, 30.4% (n=112) and 31.2% (n=108) at delivery and 72 hrs in 
the intervention and placebo group respectively. Thus the overall 
dropout rate was close to the anticipated dropout rate of ~25% and 
the number of women (n=125) that were required in each group and 
thus the statistical power of the study appeared to be adequate. 
However, we had only 64 neonatal TSH from blood spots at delivery 
(cord blood) each in the intervention and placebo group which 
increased to 92 and 93 respectively at 72 hrs. But since there were 
no differences in the prevalence of elevated neonatal TSH at delivery 
and 72 hrs (which was the basis of our sample size calculation) we 
are confident that addition of more numbers to the existing data 
would have not made any difference in the study findings.  
There was an overall 43% dropout in the number of participants who 
were available for assessments at 2 years (n=95 and n=87 in the 
intervention and placebo group respectively). However, throughout 
the study, women who dropped out were equally divided between the 
two groups for various reasons: adverse events, women/family not 
willing to continue using the supplements, moved out of the study 
area, re-pregnant. Thus we feel that the exposure itself was not the 
reason for the dropout rate and hence the findings of the study are 
inferential. 
 
Selection bias 
 
This study being an RCT removes the chances of selection bias 
considerably. However there were significant differences in baseline 
TSH and fT4 which cannot be ignored. So apparently there would be 
some outliers at baseline who moved out of the study later. But these 
were definitely not because of the treatment itself since those who 
moved out of the study for various reasons were equally divided 
between the two groups. 
 
Non-consenters 
 
We collected the information on women excluded/not willing to 
participate in the RCT. There were no statistically significant 
differences in age, gestational age, education, occupation, monthly 
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household income, height, weight or BMI between those who declined 
participation and those who agreed to participate in the study (data 
not shown). Thus we are confident that there was no selection bias in 
our study. 
 
Non response bias- ITT/per protocol 
 
We repeated all analyses in a per-protocol population for thyroid 
function tests. The results from the per-protocol analysis (Chapter 2; 
Supplementary Table 1 and 2) were comparable to the intention-to-
treat analysis and thus we are confident that there was no non-
response bias. 
 
Information or measurement bias 
 
We do not foresee any information bias since the codes were kept in a 
sealed envelope until the data analysis was complete. We broke the 
codes in the presence of the study statistician and a former member 
of the Data Safety Monitoring Board. All through the data collection 
and analyses, the investigators, study statistician and data collection 
personnel were blinded to the treatment codes.  
 
All the study forms were checked for inconsistencies by the study 
supervisor and the data were double entered into a structured query 
language database by 2 data entry operators. Discrepancies or 
mismatches in the data entry were corrected by a data entry 
supervisor. The matched data was locked, held by the study 
statistician and made available for analysis. Hence we do not feel 
there are any reporting errors in the data.  
 
All the instruments used in the study like weighing scale and 
pipettes, were calibrated periodically. We collected all the 
anthropometry readings in duplicate. We collected 3 readings while 
measuring the thyroid gland size and a mean of length, width and 
depth of the right and left lobe was taken to calculate the total 
volume. 
 
The inter-assay and intra-assay coefficients for UIC and TFTs were 
all within the acceptable range. The Bangalore laboratory where the 
biochemical sample analysis was done had College of American 
Pathologists (CAP) accreditation, National Accreditation Board for 
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Testing and Calibration Laboratories (NABL) accreditation and was 
an intercontinental referral lab for Esoterix Inc. Belgium, a LabCorp 
company, USA. The lab had quality control systems in place through 
internal QC process & participation in external Proficiency Testing 
programs; Laboratory Information management system (LIMS) for 
data management, formal documentation for endorsement and 
approvals of Work Artifacts for Clinical study with project code no. 
CLG162/STJ/MITCH/2011. Quality control samples were run before 
each test groups for the assays and the results of the quality control 
samples were reviewed for acceptability. Samples were run only after 
verification that the quality control data is within acceptable limits 
for a given assay. Calibration of assays was performed in accordance 
with the calibration Standard Operating Procedures and Instrument 
operating procedure. The frequency of calibration was in accordance 
with the manufacturer’s recommendations. Since we had an idea 
that the effects of iodine supplementation, if any, would be subtle in 
terms of TFT’s, we analysed all the data for each participant (all 
antenatal time points) in one run and thus eliminated the possibility 
of any inter assay variation that could affect the TFT results. 
  
All the research assistants performing measurements on 
anthropometry, dietary data collection, and administration of 
questionnaires were trained before the start of the study and also 
periodically. For the psychological assessments, proper training and 
certification was done for Neonatal behavioural assessment scale 
(NBAS), Bayley’s Scales of Infant Development (BSID), Kessler’s 
psychological distress scale (K-10), Bradleys’ Home environment and 
Brief-P measurements. 
 
Confounding 
 
We identified possible confounders in bivariate analyses with the 
thyroid function parameters and adjusted for covariates of BMI, 
parity, baseline gestational age and maternal age. We considered the 
gestational age at entry into the study as an important covariate 
since the mean gestational age at entry was early, at 10 weeks (range 
5.0-14.6 weeks) and it is known that the earlier supplementation 
starts, the better. We created a  variable  “time from start” 
(Gestational age at trimester 1, 2, or 3 minus gestational age at 
trimester 1) to quantify the duration (in weeks) the subjects were in 
the study at the time of each blood draw for thyroid function test. 
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This variable “time from start” was considered as a covariate and the 
difference in slope of thyroid function parameters with “time from 
start” between the intervention groups was considered as a measure 
of efficacy of the intervention obtained by the interaction with 
intervention. Further, we considered percentage compliance as a 
covariate in addition to all the factors described above to adjust for 
the effect of compliance to intervention/placebo. Compliance to 
intervention was significantly associated with most thyroid function 
parameters, but did not modify the interaction effect.  
 
Study strengths 
 
One of the major strength of the study was that this was a 
randomized controlled trial with study subjects carefully randomized 
so that there were no differences in the maternal characteristics at 
baseline. However, TSH and fT4 showed significant differences at 
baseline in the intention to treat analysis but not the per protocol 
analysis. But since our data analysis using linear mixed models 
factored in these differences and considered the importance of early 
gestational age at entry into the study, we are confident that our 
study findings are generalizable to similar settings. In addition, the 
contrasting findings between observational studies and randomised 
controlled trials are not uncommon and highlight that typical 
statistical adjustments of potential confounders in observation 
studies are likely to be inadequate to capture the full extent of 
influences of social and environmental factors (5). 
 
Study limitations 
 
Even though not anticipated, the pregnant women in Bangalore site 
were found to be iodine sufficient and not mildly iodine deficient. This 
was most likely due to recent improvements in the coverage and the 
quality of iodized salt in the area. This is an important limitation of 
the study since the intervention was not originally designed to be 
tested in an iodine sufficient population.  But this does add a unique 
aspect to the study: in population-based iodine intervention in a 
mildly-iodine deficient area, because of the usual wide range of iodine 
intakes, there will very likely be a portion of the women at the upper 
end of the distribution who are iodine sufficient. Thus, this study 
provides important information on the potential effects of iodine 
supplementation in this group. Even though we aimed to assess the 
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potential benefits and risks of iodine supplementation in this thesis, 
the question remains whether this trial was ethical to perform in the 
first place. This is because of the widespread recommendation for 
iodine supplements to be taken from preconception through to 
lactation and for all prenatal supplements to contain iodine. 
However, antenatal iodine supplementation was (at the start of the 
study) and continues to be not part of the antenatal prophylaxis 
programme in India. All the studies within this thesis were 
conducted in accordance with the Declaration of Helsinki. 
Institutional ethical review boards at St. John’s National Academy of 
Health Sciences, St Martha’s Hospital, Bangalore, India and the 
Wageningen University, The Netherlands approved the studies. 
 
Other points for discussion 
 
One of the exclusion criteria in our study was TSH > 7.5 IU/mL. 
When we started the study in 2008, there was no consensus on 
trimester specific reference ranges for TSH or the thyroid hormones. 
Although most clinicians recognized the reference range for TSH was 
likely lower in the 1st trimester compared to non-pregnancy and in 
later pregnancy, it was not sure how low it should be. And no one 
was sure of the clinical relevance of this, and how much the values 
may be altered by differences in iodine status. Considering that we 
wanted to see the effects of iodine treatment, we did not want to 
exclude women with marginal thyroid dysfunction, as this may 
be more common in areas of iodine deficiency. Thus, the upper end 
of TSH reference range in our local laboratory for non-pregnant 
adults (0.3-5.5) + 2.0 mU/L was set as cut-off for exclusion from the 
study.  
 
Public Health Importance 
 
Our finding from the intervention study showed that additional 
iodine supplementation to iodine sufficient pregnant women is safe 
and does not increase thyroid autoimmunity. Even though there were 
no significant effects of iodine supplementation on neonatal and 
maternal thyroid function and birth outcomes, there were modest 
effects on the neurocognitive development of young children. This 
was assessed by testing the executive function of children at 2 years 
of age. However, there are concerns over the reliability of 
neurocognitive assessments in children of less than 4 yrs of age and 
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thus a follow-up of these children could provide further insights. 
Although salt iodization is likely to be a more effective and equitable 
strategy to increase iodine intakes in populations, iodine 
supplementation to pregnant women should be considered as an 
important interim measure of ensuring optimal iodine nutrition until 
universal salt iodization reaches all strata of population. It is 
important that the intrathyroidal stores are adequate when women 
enter pregnancy and thus continuous monitoring of iodine status of 
this important target group is recommended.  
 
Our data from the pilot study indicated that salt iodization ensures 
adequate iodine intake in pregnant women, although iodine intake in 
their children is in the more-than-adequate range. But we cautioned 
against our results be generalized to less affluent, rural areas of India 
where adequately iodised salt is not available so that pregnant 
women are likely to still have inadequate iodine intakes. Because 
there are wide variations in iodized salt quality and coverage across 
India, we recommended that additional population-based studies in 
other regions of India be done to confirm our study findings.  
 
Based on our screening data of the iodine intervention study, we 
found the prevalence of overt hypothyroidism surprisingly high in 
first trimester pregnant women from Bangalore, India. We found their 
iodine intakes to be adequate; low hemoglobin and higher BMI 
predicted an increased risk for thyroid insufficiency mainly 
attributed to autoimmune thyroiditis. Our data suggested that 
screening of maternal thyroid function be considered in antenatal 
care at hospitals in Bangalore. We found low awareness of the health 
benefits of iodized salt in our study. Although the program of salt 
iodization is currently effective, public health strategies such as a 
consumer education campaign are critical for program sustainability.  
 
Based on our longitudinal study examining thyroid function and 
depression in pregnancy across trimesters, we found that although 
iodine supplementation did not affect maternal depression, there was 
a need for systemic screening for prenatal depression during 
antenatal visits as it is an independent risk factor for later 
development of clinical depression. 
 
The immediate consequence from our research findings would be 
that countries with successful salt iodization programmes will be 
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motivated to maintain their efforts in ensuring that all groups of 
population especially pregnant women receive adequately iodized salt 
in order to achieve optimal iodine nutrition. This could be ensured by 
including pregnant women in the systematic surveys of nutrition 
monitoring which are conducted at the national/sub-national level. 
The results from our study also provide additional data that would be 
helpful in increasing awareness of the importance of adequate iodine 
nutrition and combating anemia in pregnant women. Finally, 
maintaining an ideal body weight remains at the heart of every public 
health programme considering the double burden of malnutrition 
that is currently witnessed in countries in nutrition transition.  
 
Future Research  
 
In the RCT, neurocognitive development at 2 years of age did not 
differ between children whose mothers received iodine 
supplementation during pregnancy compared to the placebo group. 
However, neonates had better orientation scores at 6 weeks of age in 
the intervention group of children while the scores of inhibition were 
significantly higher in the children of mothers in the placebo group 
compared to those whose mothers received iodine during pregnancy 
indicative of executive dysfunction. However, there are concerns over 
reliability of neurocognitive assessments in children less than 4 yrs 
of age. Thus additional follow-up of these children for neurocognitive 
testing at an age considered satisfactory for assessments would add 
valuable information. Increasingly, studies are using measures of 
executive function as they have been linked to future development of 
disorders of childhood psychopathology such as attention deficit and 
hyperactivity disorder. Future studies are needed to show if these 
children develop later differences in cognitive development. 
 
We found a high prevalence of overt hypothyroidism in our screening 
population; this was despite pregnant women being iodine sufficient. 
Over 90% of thyroid disorders in pregnancy are thought to be of 
autoimmune etiology (7) and chronic autoimmune thyroiditis is the 
main cause of hypothyroidism during pregnancy in iodine-sufficient 
regions (8). Although approximately 70% of the risk for developing 
autoimmune thyroid disease is attributable to genetic background, 
environmental triggers are thought to play a role in the development 
of autoimmune thyroid disease in susceptible individuals. 
Understanding the association of environmental agents with thyroid 
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dysfunction can be utilized to reduce the risk to populations. 
Knowledge of the specific factors that trigger autoimmune thyroid 
disease and their mode of action may also inform risk reduction in 
the individual patient (6).  
 
A potential explanation for the high prevalence of hypothyroidism in 
our sample could be thyroidal disruptors, from environmental or 
dietary sources (9). We have no data on potential exposure to 
environmental thyroid disruptors, such as perchlorate or dietary 
goitrogens (including thiocyanates (metabolites of cyagenic glucosides 
present in plant foods such as cabbage, cauliflower, bamboo shoot, 
cassava, mustard, turnip and radish) and isoflavones). However, it is 
unlikely that the quantity and frequency of consumption of these 
potentially goitrogenic foods in the rice-based diet of south India 
would be high enough to produce hypothyroidism. Also, there was no 
evaluation of maternal smoking in our dataset. However, national 
family health survey data (2005-2006) for the state of Karnataka 
(Bangalore is one of the districts of Karnataka) revealed that less 
than 1% of women in the age group of 15-49 smoked cigarettes and 
cigars/pipes. Therefore we do not think that active cigarette smoking 
could be a potential risk factor for thyroid dysfunction in our 
population. But, a recent report from Bangalore suggests that the 
level of pollution in the city is equivalent to smoking 6 cigarettes per 
day (10). A recent study from Thailand also found that low-
level exposure to perchlorate was positively associated with TSH and 
negatively associated with free T4 in first-trimester pregnant women. 
Thiocyanate exposure was also positively associated with TSH in a 
subgroup of pregnant women with low iodine excretion. Thus future 
research in this area would provide additional information on the 
reasons of high prevalence of hypothyroidism in this population. 
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Adequate iodine nutrition during the in utero thyroid-sensitive periods of 
brain maturation is what determines how well the brain and ultimately 
the cognitive functions develop. Children born to mothers from severely 
iodine deficient areas clearly benefit from maternal iodine 
supplementation but data are equivocal on its effect in areas that are 
mildly iodine deficient and iodine sufficient.  
 
India, because of its large population, high birth rate and iodine deficient 
soils, has until recently had a large number of infants potentially exposed 
to in utero iodine deficiency and recent studies highlight the presence of 
iodine insufficiency among Indian women. Iodine status of school aged 
children (SAC) is often used as a proxy for the iodine nutrition of 
pregnant women at the population level, even though the difference in 
energy requirement in pregnant women is only 0-25% compared to SAC, 
while the difference in iodine requirement is >100%. This means that the 
relatively small increase in food intake during pregnancy is unlikely per 
se to provide the additional iodine requirement unless iodine rich foods 
are preferentially selected which is not the practice currently during 
pregnancy.  
 
WHO recommends that pregnant women in areas where iodized salt 
programs are weak consume 250 µg iodine daily; ATA suggests that the 
strategies to implement this recommendation might differ between 
countries. While iodine supplementation during pregnancy is clearly 
beneficial to pregnant women in severely iodine deficient areas, it was 
unclear whether those in mild-to-moderately iodine deficient or iodine 
sufficient areas should receive supplementation. There are no long-term 
data from controlled trials in mildly iodine deficient pregnant women that 
have measured the effect of iodine supplementation on infant or child 
development. 
 
This thesis therefore aims to fill the important gap that exists in the 
current literature regarding the effect of iodine supplementation during 
pregnancy on birth outcomes, maternal goiter, thyroid autoimmunity, 
infant growth and cognitive development. Data was collected in a 
Randomized Controlled Trial (RCT) carried out in Bangalore, India, on 
pregnant women and their infants from November 2008 to November 
2013, the women receiving a supplement of 200 µg iodine per day from 
November 2008 to March 2011. In addition, potential determinants of 
thyroid function including iodine status, thyroid autoimmunity, maternal 
depression, body weight and anemia were assessed. Prior to the RCT, in 
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a cross-sectional study, we compared the median UIC of these women to 
that of their children, 3-15 years old, in pairs that were sharing all meals 
at home. This study started in May 2008, running in parallel with the 
RCT, and the data collection ended in September 2011.  
 
In the RCT (Chapter 2), we aimed to determine whether the daily oral 
administration of iodine (200 µg) to pregnant women improves maternal 
and newborn thyroid function, pregnancy outcome, birth weight, infant 
growth and cognitive performance. In the intervention and placebo 
groups of women, there were no significant differences in maternal 
thyroid function tests or thyroid volume during gestation. The prevalence 
of all subtypes of thyroid dysfunction, or anti-TPO antibodies, did not 
differ significantly during gestation and postpartum. Postpartum, there 
were no significant differences between the maternal and infant groups in 
thyroid function, birth outcomes or UIC. Neonates whose mothers 
received iodine supplementation during pregnancy had better orientation 
scores at 6 weeks of age and lower scores of inhibition suggesting better 
executive function at 2 years of age although neurocognitive development 
on the BSID III were not significantly different between groups. Thus we 
concluded that iodine supplementation even in iodine sufficient pregnant 
women was safe without increasing the risk of thyroid autoimmunity. We 
also concluded that additional follow-up of these children for 
neurocognitive testing at a later age when developmental and cognitive 
testing is more reliable would provide valuable add on information. 
 
Chapter 3 describes a pilot study that assessed iodine intake (based on 
UIC) and potential determinants of intake, in Indian pregnant women 
and their children who were sharing all meals. This study found a) 
median UIC in pregnant women was 172 µg/L, b) the median UIC was 
>150 µg/L in all trimesters and c) thyroid size was not significantly 
different across trimesters;  the median UIC in children was 220µg/L, 
indicating ‘more than adequate’ iodine intake at this age. Median UIC 
was significantly higher in children than in their mothers (p=0.008). We 
concluded that the iodized salt program was providing adequate iodine to 
women throughout pregnancy, at the expense of higher iodine intake in 
their children, in Bangalore, India suggesting that the current 
WHO/UNICEF/ICCIDD cut-off for median UIC in children indicating 
more-than-adequate intake may need to be reconsidered. 
 
In a cross-sectional study of the pregnant women screened for the RCT 
(Chapter 4), we aimed to understand the pattern and prevalence of 
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maternal thyroid dysfunction and its associated risk factors in the Indian 
pregnant population. We found the prevalence of overt hypothyroidism 
surprisingly high in the first trimester pregnant women whose iodine 
intakes were adequate. Both low hemoglobin and higher BMI predicted 
an increased risk for thyroid insufficiency mainly attributed to 
autoimmune thyroiditis. We thus suggested that screening of maternal 
thyroid function be considered in antenatal care at hospitals in 
Bangalore.   
 
In a secondary analysis of the longitudinal data on pregnant women in 
the RCT (Chapter 5), we aimed to assess the association of maternal 
depression, and thyroid function during pregnancy. We found that there 
were no significant differences in depressive symptoms between the 
iodine intervention and placebo groups. In the first trimester, women 
with depressive symptoms had significantly lower serum TSH compared 
to women without depressive symptoms. Pregnant women with prenatal 
depressive symptoms had a significantly higher number of medical 
symptoms. Although iodine supplementation did not affect maternal 
depression, we highlighted the need for systemic screening for prenatal 
depression during antenatal visits as it is an independent risk factor for 
later development of clinical depression.  
 
In the concluding Chapter 6, we summarise the main findings of this 
thesis, and their implications for public health. We also discuss the 
methodological limitations and suggest directions for future research. 
 
In conclusion, this is the first study to measure child development at two 
years as an outcome of iodine supplementation during pregnancy in a 
randomised controlled trial. Even though not anticipated, the pregnant 
women were found to be iodine sufficient and not mildly iodine deficient. 
This was most likely due to recent improvements in the coverage and the 
quality of iodized salt in the area. The results from this RCT indicate that 
additional iodine supplemented to iodine sufficient pregnant women is 
safe and does not increase thyroid autoimmunity. Even though there 
were no significant effects of iodine supplementation on neonatal and 
maternal thyroid function and birth outcomes, there were modest effects 
on the neurocognitive development of young children. This was assessed 
by testing the executive function of children at 2 years of age. However, 
there are concerns over the reliability of neurocognitive assessments in 
children of less than 4 yrs of age and thus a follow-up of these children 
could provide further insights. Although salt iodization is likely to be a 
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more effective and equitable strategy to increase the iodine intake in a 
population, iodine supplementation to pregnant women should be 
considered as an important interim measure for ensuring optimal iodine 
nutrition until universal salt iodization reaches all strata of the 
population. In addition, pregnant women should be included in the 
systematic surveys of nutrition monitoring which are conducted at the 
national/sub-national level. The results from our study also provide 
additional data that would be helpful in increasing awareness of the 
importance of adequate iodine nutrition and combating anemia in 
pregnant women. Finally, maintaining an ideal body weight remains at 
the heart of every public health programme considering the double 
burden of malnutrition that is currently witnessed in countries in 
nutrition transition.  
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Een juiste jodium voeding gedurende de in utero schildklier-gevoelige 
perioden van hersen maturatie bepaalt hoe goed de hersenen en 
uiteindelijk de cognitieve functies zich ontwikkelen. Kinderen geboren uit 
moeders in gebieden met een ernstig jodium tekort profiteren duidelijk 
van maternale jodium aanvulling, maar gegevens zijn dubbelzinnig over 
effecten voor gebieden met een gering of geen jodium tekort. 
 
Vanwege zijn grote populatie, het hoge geboortecijfer ervan, en de 
ontoereikendheid van jodium in de bodems, heeft India tot recent een 
groot aantal zuigelingen die potentieel in de baarmoeder aan 
jodiumtekort zijn blootgesteld, terwijl recente studies op de aanwezigheid 
van jodium tekort onder Indiase vrouwen wijzen. De status van jodium 
bij kinderen in de schoolleeftijd (SAC) wordt vaak als een proxy gebruikt 
voor de voeding van jodium bij zwangere vrouwen op het 
bevolkingsniveau. Echter, het verschil in hun energie behoefte is slechts 
0-25% ten opzichte van SAC, terwijl het verschil in jodium behoefte 
>100% is. Dit betekent dat de relatief kleine stijging in voedsel opname 
tijdens de zwangerschap waarschijnlijk niet per se om de vereiste extra 
jodium gaat, tenzij jodiumrijk voedsel wordt geselecteerd. In de praktijk 
gebeurt dit op dit moment niet tijdens de zwangerschap. 
 
De WHO beveelt een dagelijkse consumptie van 250 µg jodium aan bij 
zwangere vrouwen in gebieden met programma's met zwak gejodeerd 
zout, en de ATA suggereert dat de strategieën naar de uitvoering van deze 
aanbeveling tussen landen kunnen verschillen. Terwijl de toevoeging van 
jodium tijdens de zwangerschap duidelijk gunstig is in gebieden met een 
ernstig jodium tekort, was het onduidelijk of zwangere vrouwen in 
gebieden met een zwak-tot-matig jodium tekort, en ook in gebieden met 
voldoende jodium, toch een suppletie moeten krijgen. Er bestaan geen 
lange-termijn gegevens uit gecontroleerde proeven van zwangere vrouwen 
met een gering jodium tekort, waarbij het effect van jodium suppletie 
werd gemeten op de ontwikkeling van de zuigeling of  het kind. 
 
Dit proefschrift wil daarom de belangrijke leemte vullen die er in de 
huidige literatuur bestaat over het effect van jodium suppletie tijdens de 
zwangerschap op geboorte resultaten, op struma bij moeders, op 
schildklier autoimmuniteit, op de groei van jonge kinderen en hun 
cognitieve ontwikkeling in een RCT. Van November 2008 tot maart 2011, 
alsook in November 2013 werden bij zwangere vrouwen uit Bangalore, 
India, gegevens verzameld over suppleties van 200 µg jodium per dag. 
Bovendien werden potentiële determinanten van de schildklier functie 
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beoordeeld, zoals jodium status, schildklier autoimmuniteit, maternale 
depressie, lichaamsgewicht en anemie. In een cross-sectionele studie 
voorafgaand aan de RCT, wilden we in paren die alle maaltijden samen 
thuis deelden de mediane UIC waarden van deze vrouwen met die van 
hun kinderen tussen 3-15 jaar vergelijken. Deze studie begon in mei 
2008, parallel aan de RCT, terwijl het verzamelen van de gegevens in 
september 2011 eindigde. 
 
In de RCT (Hoofdstuk 2) willen we bepalen of de dagelijkse orale 
toediening van jodium (200 µg) aan zwangere vrouwen de schildklier 
functie van moeder en pasgeboren kind verbetert, alsook het resultaat 
van de zwangerschap, het geboortegewicht, en de groei en cognitieve 
prestaties van de kleuter. In de interventie en placebo groepen van 
vrouwen bestonden er geen significante verschillen in functie of volume 
van de schildklier van de moeder tijdens de zwangerschap. De prevalentie 
van alle subtypen van schildklier dysfunctie, of anti-TPO antilichamen, 
verschilt niet significant tijdens de zwangerschap en postpartum. Er 
waren geen significante verschillen tussen de groepen van moeders en 
kinderen in schildklier functie, geboorte resultaten, of UIC. Pasgeborenen 
waarvan de moeders jodium suppletie tijdens de zwangerschap 
ontvangen hadden, hadden betere oriëntatie scores wanneer ze 6 weken 
oud waren en lagere scores van remming. Dit suggereert een betere 
uitvoeringsfunctie op 2-jarige leeftijd, hoewel de neuro-cognitieve 
ontwikkeling of de BSID III niet significant tussen de groepen verschillen. 
We concludeerden dus dat jodium suppletie bij zwangere vrouwen, zelfs 
wanneer deze voldoende jodium hadden, veilig was zonder het risico van 
schildklier autoimmuniteit te verhogen. Tevens blijkt dat extra follow-up 
van deze kinderen voor neuro-cognitieve testen op latere leeftijd, wanneer 
ontwikkeling en cognitieve testen meer betrouwbaar is, waardevolle 
toevoegingen aan informatie zou bieden. 
 
Hoofdstuk 3, een pilot-studie, die een op UIC gebaseerde jodium opname 
en potentiële determinanten van opname bepaalt, beschrijft de jodium 
opname voor Indiase zwangere vrouwen en hun kinderen die alle 
maaltijden samen hebben. Deze studie vond dat bij zwangere vrouwen a) 
de mediane UIC waarde 172 µg/L was, b) dat de mediane waarde van 
UIC in alle trimesters >150 µg/L was, en c) dat de grootte van de 
schildklier niet significant anders was over de trimesters. Bij kinderen 
was de mediane UIC waarde 220µg/L, wat voor deze leeftijd op een 'ruim 
voldoende' jodium opname wijst. De mediane UIC waarde was significant 
hoger in kinderen dan die in hun moeders (p = 0,008). Wij concludeerden 
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dat het programma van gejodeerd zout voldoende jodium geeft aan 
vrouwen tijdens de zwangerschap, ten koste van hogere jodium opname 
in hun kinderen. Dit suggereert dat voor Bangalore, India, de huidige 
WHO/UNICEF/ICCIDD scheidslijn voor de mediane UIC waarde voor 
kinderen, die op een meer dan voldoende opname wijst, moet worden 
heroverwogen. 
 
In een cross-sectionele studie van de zwangere vrouwen, gescreend voor 
de RCT (Hoofdstuk 4), wilden we proberen het patroon en de prevalentie 
van maternale schildklier dysfunctie en de bijbehorende risicofactoren in 
de Indiase zwangere bevolking te begrijpen. We vonden de prevalentie van 
opvallende hypothyreoïdie verrassend hoog voor zwangere vrouwen in 
hun eerste trimester, waarvan de jodium opname voldoende is. Zowel een 
laag hemoglobine en een hogere BMI voorspelt een verhoogd risico voor 
schildklier insufficiëntie voornamelijk toegeschreven aan auto-immune 
thyroiditis, zodat wij voorgesteld hebben dat in Bangalore screening van 
maternale schildklier functie in prenatale zorg in de ziekenhuizen moet 
worden overwogen. 
 
In een secundaire analyse van de longitudinale gegevens op zwangere 
vrouwen in de RCT (Hoofdstuk 5), we hebben ons gericht op het bepalen 
van het verband tussen maternale depressie en de schildklier functie 
tijdens de zwangerschap. We vonden geen significante verschillen in 
symptomen van depressie tussen de groepen van jodium interventie en 
placebo. Vrouwen met depressie symptomen hadden een significant 
lagere serum TSH ten opzichte van vrouwen zonder depressie symptomen 
in hun eerste trimester. Zwangere vrouwen met prenatale symptomen 
van depressie hadden een significant groter aantal medische symptomen. 
Hoewel jodium suppletie de maternale depressie niet beïnvloedde, 
hebben we gewezen op de noodzaak voor een systematische screening 
voor prenatale depressie tijdens prenatale bezoeken, aangezien het een 
onafhankelijke risicofactor is voor een latere ontwikkeling van klinische 
depressie. 
 
In het afsluitende Hoofdstuk 6 vatten we de belangrijkste bevindingen 
uit deze thesis samen, en bespreken we ook de methodologische 
beperkingen, alsook de implicaties voor de volksgezondheid en voor 
richtingen van toekomstig onderzoek. 
 
Concluderend, dit is de eerste studie om de ontwikkeling van kinderen in 
hun tweede jaar in een gerandomiseerde gecontroleerde trial te meten als 
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gevolg van jodium suppletie tijdens de zwangerschap. Hoewel niet 
verwacht, bevatten de zwangere vrouwen voldoende jodium en waren niet 
zwak jodium arm, waarschijnlijk als gevolg van de recente verbeteringen 
in de dekking en kwaliteit van gejodeerde zout in het gebied. De 
resultaten van deze RCT blijkt dat aanvullende jodium, gegeven aan 
zwangere vrouwen met voldoende jodium, veilig is en dat schildklier 
autoimmuniteit niet toeneemt. Ook al waren er geen significante effecten 
van jodium suppletie op schildklier functie en geboorte resultaten van 
neonatale en maternale vrouwen, waren er geringe effecten op de neuro-
cognitieve ontwikkeling van kinderen, zoals bepaald door de executieve 
functie van kinderen in hun tweede jaar. Echter, er bestaat bezorgdheid 
over de betrouwbaarheid van neuro-cognitieve evaluaties in kinderen 
jonger dan 4 jaar, zodat een follow-up van deze kinderen betere inzichten 
kan bieden. Hoewel zout jodering een meer effectieve en rechtvaardige 
strategie kan zijn ter vergroting van jodium opname in populaties, moet 
jodium suppletie aan zwangere vrouwen worden beschouwd als een 
belangrijke tussentijdse maatregel voor optimale jodium voeding, totdat 
universele zout jodering alle lagen van de bevolking bereikt. Bovendien 
moeten zwangere vrouwen worden opgenomen in systematische 
overzichten van het monitoren van voeding, uitgevoerd op nationaal en 
sub-nationaal niveau. De resultaten van onze studie bieden ook 
aanvullende gegevens die nuttig zou  kunnen zijn bij het vergroten van 
het bewustzijn over en de bestrijding van bloedarmoede bij zwangere 
vrouwen. Tot slot, behoud van een ideaal lichaamsgewicht blijft de kern 
van elk programma voor volksgezondheid, gegeven de dubbele last van 
ondervoeding die momenteel wordt gezien in landen in nutritionele 
overgang. 
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